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Preface
The Research Analysis and Utilization System (RAUS) is designed to
serve four functions:
Collect and systematically classify the findings of all
intramural and extramural research supported by the
National Institute on Drug Abuse (NIDA);
Evaluate the findings in selected areas of particular
interest and formulate a state-of-the-art review by a
panel of scientific peers;
Disseminate findings to researchers in the field and
to administrators, planners, instructors, and other
interested persons;
Provide a feedback mechanism to NIDA staff and planners
so that the administration and monitoring of the NIDA
research program reflect the very latest knowledge
gleaned from research in the field.
Since the number of research topics that can be intensively reviewed
annually is limited, four subject areas are chosen each year to
undergo a thorough examination. Distinguished scientists are
invited to participate. Each scientist is provided reports from
NIDA-funded research and asked to add information derived from the
literature and his or her own research and to prepare a
comprehensive, state-of-the-art review paper on an assigned topic.
These papers, together with a summary of the discussions which take
place at the review meeting, make up a RAUS Review Report in the
NIDA Research Monograph series.
In recent years a large number of reviews and books have appeared
summarizing research advances in the chemistry, pharmacology,
toxicology, metabolism, and distribution of cannabinoids and their
synthetic analogs. Yet the volume of research on structure-activity
relationships of cannabinoids appears to have decreased. In order
to evaluate NIDA's current research program on cannabinoids, to
rekindle interest in this critical area, and to focus attention on
profitable avenues for future research, NIDA found it timely to
bring together experts on the structure-activity relationships of
cannabinoids for a comprehensive review.
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Many cannabinoid analogs have been designed. Some have served as
excellent probes for understanding the mechanism of action of
cannabinoids and have generated optimism that in the near future
potent therapeutic drugs that lack "cannabimimetic" activity can be
developed. In this monograph, while emphasis is placed on
structure-activity relationships and molecular mechanisms of action
of cannabinoids. chapters added to broaden the subject area will
increase the usefulness of this volume as a reference text for
researchers in the chemistry and biology of the cannabinoids.
Drs. Rao S. Rapaka, Alexandros Makriyannis, and Sumner Burstein
served as the scientific moderators of the RAUS review meeting. The
introduction and the concluding overview chapter, by Drs.
Makriyannis and Rapaka, provide a brief summary of the presentations
and the discussions. Jacqueline P. Ludford, Chief, Research
Analysis Branch, Office of Science, is the RAUS coordinator for NIDA.
vi
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Introduction
Rao S. Rapaka, Ph.D., and Alexandros Makriyannis, Ph.D.
Although a number of reviews on cannabinoids are held each year,
reviews devoted entirely to structure-activity relationships of the
cannabinoids are less frequent. Moreover, in recent years a
slackening of interest appears to have occurred, both among academic
scientists and scientists from drug houses, in undertaking studies
of SAR and development of drugs based on the cannabinoid molecular
skeleton. A number of related areas in the medicinal chemistry of
the cannabinoids, such as development of new drugs, resolution of
cannabimimetic activity from other bioactivities such as
anticonvulsant action, and studies of receptors, require special
attention. In order to evaluate the progress and to revitalize
research in SAR and related medicinal chemistry aspects of
cannabinoids, the National Institute on Drug Abuse felt that the
time had come for a review and a publication on the
structure-activity relationships of the cannabinoids.
The stereochemical requirements for cannablmimetic activity are one
major issue. Dr. Mechoulam discusses the structure-activity
relationships (SAR) with emphasis on stereochemical requirements.
Dr. Mechoulam presents biological data to show that (-) enantiomers
of cannabinoids are more active than the (+) enantiomers. Dr.
Razdan, who was unable to attend the review, contributed an overview
chapter on structure-activity relationshlp in cannabinoids, with
special emphasis on SAR and drug development, and on SAR and the
mechanism of action of cannabinoids. Dr. Arnold Martin discusses
SAR of cannabinoids regarding anticonvulsant activity along with
recent information on pinyl and carnyl analogs, simplified
derivatives lacking the 4-isopropenyl group, and a variety of 1'-1'
dialkylhexyl and 1'-1'-dialkeylheptyl analogs. Comparisons of
anticonvulsant potency of delta-6-tetrahydrocannabinol,
delta-6-THC-1', 1'-dimethylheptyl and related analogs are presented
by Dr. Consroe. In addition, Dr. Consroe presents evidence for
stereoselectivity for anticonvulsant and neurotoxic activities.
Drs. Melvin and Johnson review SAR of tricyclic and nonclassical
bicyclic cannabinoids. Their studies demonstrate that some of the
analogs are potent analgesics and exhibit enantiomeric potency.
More importantly, their studies show that it is possible to achieve
extreme biological potency in structures different from classical
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cannabinoid ring systems. This, in turn, gives the researchers
optimism for further development of new analogs and potent analgesic
compounds. Electrophysiological properties of cannabinoids,
delta-9-THC, 11-hydroxy-delta-9--THC (the principal metabolite of
THC) and cannabidiol are discussed by Dr. Turkanis. His studies
demonstrate that different cannabinoids exhibit markedly different
electrophysiological properties. An interesting presentation on the
molecular parameters that determine the cannabimimetic activity is
given by Dr. Reggio. One of the hypotheses presented by Dr. Reggio
is that the basis of cannabimimetic activity is related to molecular
properties conferred by a lone pair of electrons on the phenolic
oxygen and to the orientation of the carboxyclic ring.
Another major point of focus is the molecular mechanisms of
cannabinoid activity. Several researchers are currently involved in
answering the question of "receptor" versus "membrane." Dr. Billy
Martin has reviewed the area, and outlines the different points of
view. Dr. Nye presents findings on the high affinity cannabinoid
binding sites in the brain and on the isolation of an endogenous
inhibitor of cannabinoid binding. This endogenous compound has been
partlally characterized and the role of this compound is not clear
at this time. Dr. Makriyannis presents evidence to support the
hypothesis that the cannabinoids exert their physiologic effects, at
least in part, by interacting with the phospholipid component of the
membrane. The dynamic and conformational changes in the bilayer
that accompany the incorporation of cannabinoids has been studied
using solid state NMR. Dr. Makriyannis shows that cannabinoid
analogs orient in the membrane in such a manner that the phenolic
hydroxyl group has an important role in determining the geometry of
cannabinoid-membrane interaction. Dr. Burstein gives additional
evidence for cannabinoid action at the membrane level. He also
reports an important discovery that major cannabinoid metabolites
antagonize the stimulatory action of THC by inhibiting a specific
step in prostaglandin synthesis. A different view, which favors a
specific protein site for cannabinoid action, is presented by Dr.
Howlett.
Dr. Karler describes the problems involved in the bioassay of
cannabinoids and points out the dramatic differences in cannabinoid
activity among different species. Drs. Chiang and Rapaka make the
monograph more comprehensive with their chapter on pharmacoklnetics
and disposition of cannabinoids. In addition, Dr. B.N. Dhawan of
the Central Drug Research Institute, Lucknow, has contributed a
chapter on drug abuse in India. This is especially timely as it is
expected that, in the near future, there will be more scientific
research collaboration between the two countries.
By bringlng together the contributions of scientists having
multidisciplinary research backgrounds, this monograph represents an
effort to summarize the existing knowledge on the structure-activity
relationships of cannabinoids and to discuss the implications of
this information for further progress toward NIDA's research
objectives.
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Structure-Activity Relationships
in Cannabinoids: An Overview
Raj K. Razdan, Ph.D.
INTRODUCTION
The most important pharmacologically active member of this family of
compounds is (-) delta-9-THC,6a,10a-trans-tetrahydrocannabinol (THC) which is
the main active constituent of marijuana. Delta-9-THC is an optically active
resinous material which is very lipid soluble and water insoluble, a property
shared by numerous cannabinoids, which makes their pharmacological testing
difficult. Both in man and animals effects produced by ingesting marijuana or
delta-9-THC are unique. The gross effects produced cannot be classified
pharmacologically as being primarily due to a stimulant, sedative, tranquilizer, or
hallucinogen, although they share some properties with each of these. In general,
the effects produced by delta-9-THC are dose dependent. It is not a narcotic
and compared to many drugs, such as the opiates, barbiturates, etc., it does not
produce physical dependence.
Cannabinoids is a term used for the typical C21 group of compounds present in
Cannabis saliva L. and includes their analogs and transformation products. Two
different numbering systems, dibenzopyran and monoterpenoid, are generally
used for naming the cannabinoids, as shown in figure 1.
BACKGROUND
The first systematic study of structure-activity relationships (SAR) in
cannabinoids was reported by Roger Adams in the early 1940s (Adams 1942). It
was based on the characteristic dog ataxia test as developed and quantitated with
estimates of error by Loewe (1947). At about the same period, Todd and others
(Todd 1946; Avison et al. 1949) used the Gayer areflexia test (Gayer 1928) for
suppression of rabbit corneal reflex to determine the potency of various extracts
of cannabis and synthetic cannabinoids. They also reported SAR of cannabinoids
based on this test. Both groups assumed that the activity in these tests was a
quantitative measure of the behavioral or psychotropic activity of marijuana in
man, although no controlled experiments to support this assumption were
reported. Since that time, clinical evaluation of a number of natural and
synthetic cannabinoids has shown that there is good correlation between the
relative potency in the dog ataxia test and the psychoactive component of these
compounds in man. The usefulness of the rabbit areflexia test has, however,
been found to be limited and controversial; and this test is not presently used for
screening cannabinoids (Razdan 1986).
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FIGURE 1. Dibenzopyran and monoterpenoid numbering systems generally used
for naming cannabinoids.
When pure delta-9-THC and other cannabinoids became available in the early
1960s, several other qualitative tests were developed to determine the "cannabis-
like" activity of various compounds, for example, the cataleptic reaction in mice
and the effects on motor activity and gross behavior in mice and rats. It was
only after the first study was reported in 1968 on the effects of cannabinoids in
monkeys (Scheckel et al. 1968) that the monkey behavioral test procedures were
standardized and the SAR of cannabinoids were developed. This was largely due
to the efforts of Grunfeld, Edery, and Mechoulam (Grunfeld and Edery 1969;
Mechoulam et al. 1970; Edery et al. 1971, 1972). This test, which provides good
correlation between potencies of various cannabinoids in monkeys and man,
complements the dog ataxia test. Loewe's procedure for the dog ataxia test has
been further refined and standardized by Martin, Dewey, and Harris (Martin et
al. 1975, 1984a). The SAR based on both of these tests are very similar and
provide a good foundation for the SAR of cannabinoids. However, it should be
emphasized that these SAR are mainly reflective of the behavioral activity, rather
than the other pharmacological properties, of the cannabinoids. From time to
time, attempts have been made to introduce newer models for the bioassay of
cannabinoids. These include the mouse ring immobility assay, the genetically
unique tetrahydrocannabinol-seizure susceptible (THC-SS) rabbit, and
spontaneous activity and body temperature in mice. Recently, the drug
discrimination procedure has been used to study cannabinoids in rats and pigeons
(Razdan 1986).
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SAR IN MAN
On the basis of comparative data, delta-9-THC by smoking is considered to be
2.6 to 3 times more potent, and i.v.-administered delta-9-THC is about 10 times
more potent than delta-9-THC ingested p.o. (Isbell et al. 1967; Hollister and
Gillespie 1973). By either smoking or i.v., the effects of delta-9-THC appear
within seconds or minutes, whereas with p.o. doses, the onset of symptoms is
delayed from 30 minutes to 2 hours. The clinical syndrome, however, is very
similar in all cases. Based on the various cannabinoids which have been
evaluated clinically, the following SAR in man are suggested (Razdan 1986).
1. It appears that a benzopyran ring (figure 2) is a definite requirement for
activity, since the ring-opened compound cannabidiol (CBD) is inactive.
However, the benzopyran by itself does not confer activity, since
cannabichromene is inactive. Moreover, the oxygen in the benzopyran ring can
be substituted by a nitrogen without loss of activity as in levonantradol (figure
3).
2. Attachment of a nonplanar alicyclic ring (i.e., ring C) to the benzopyran ring
in the 3,4-position is important for activity. However, a planar ring attachment
as in cannabinol reduces activity (nearly inactive).
3. In place of a nonplanar ring attachment, a bulky substituent in the 4-position
of the benzopyran ring can also confer activity to the molecule.
4. A variety of substituents can be introduced in the alicyclic ring C without loss
of activity. Thus, the methyl in g-position as present in delta-9-THC is not
essential and can be replaced by a hydroxyl (levonantradol), a hydroxymethyl
(11-hydroxy-delta-9-THC), or a ketone (nabilone) without loss of activity. Even
the presence of two different substituents in the alicyclic ring, such as a methyl
group at 9-position and a double bond in the ring (e.g., delta-9, delta-8, delta-
6a-THCs), or a hydroxyl in an S-position (8-hydroxy-THCs) retains activity. In
the double-bond isomers, the position of the double bond at g-position appears
optimum for activity (delta-9> delta-8> delta-6a-THCs).
5. The alicyclic ring attachment to the benzopyran ring can be substituted by a
heterocyclic ring without loss of activity.
6. In the aromatic ring, esterification of the phenolic group retains activity.
7. The length of the aromatic side chain can be varied without loss of activity,
but a three-carbon chain seems minimal for activity, and branching of the chain
increases potency. Attachment of the side chain to the aromatic ring can also be
via an oxygen atom (i.e., an ether as in levonantradol) without loss of activity.
It is noteworthy that, within the structural constraints present in the THC ring
system, changing the position of the double bond in the alicyclic ring, the length
and branching of the side chain, or producing hydroxy metabolites at the 11- or
8-positions do not alter qualitatively the THC effects but may strongly affect
potency. Changing the double bond from delta-9- to delta-8- or delta-6a-
reduces potency. Decreasing the length of the side chain by two carbons reduces
potency by 75%. Increasing the length of the side chain with branching enhances
potency several fold. Substitution of a hydroxyl group in the 11-position retains
potency, while hydroxylation in the 8-position reduces potency by 80%.
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FIGURE 2. Comparison of the structures of the benzopyran and THC ring
systems.
SAR IN ANIMALS
On the basis of recent data available from animals studies, the following
conclusions are drawn regarding the SAR in cannabinoids. It should be
emphasized that the SAR is developed on the basis of cannabis-like effects in
animals, especially in the monkey and the dog. Some natural and synthetic
cannabinoids are shown in figure 3.
1. Essentially, a benzopyran structure with an aromatic hydroxyl group at C-l
position and an alkyl or alkyl ether group at C-3 position is a requirement for
activity. In general, changing the above substitution pattern leads to a major loss
of potency (Avison et al. 1949; Loev et al. 1973). Although a benzopyran ring is
a definite requirement for activity, the benzopyran by itself does not confer
activity. This is based on the observation that the ring-opened compound CBD
is inactive in both the monkey and the dog and does not generalize to delta-9-
THC in the drug discrimination test in the rat. Similarly, cannabichromene,
which has an intact benzopyran ring, is inactive.
2. The position and the environment around the aromatic hydroxyl group are
very important for activity, viz., (a) the OH at position C-1 is in itself necessary
for activity. Thus, the abnormal compounds where the hydroxyl and the side
chain have been interchanged (i.e., side chain at C-1 and OH at C-3) are all
inactive. Similarly, removal of OH at C-1 eliminates activity. (b) Esterification
of the OH at C-1 retains activity. Etherification of the OH at C-1 eliminates
activity. Replacement of the OH by NH, retains activity, and replacement by
SH eliminates activity. (c) Since C-10 in the alicyclic ring C is in close
proximity to the OH group, a methyl substituent at C-10 significantly alters the
activity in the case of a planar five-membered C-ring.
3. Substitution in the aromatic ring by electronegative groups like carboxyl,
carbomethoxyl, and acetyl groups eliminates activity, whereas alkyl or hydroxyl
groups at C-2 position retain, and in C-4 position reduce, activity.
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FIGURE 3. Some natural and synthetic cannabinoids.
7
8
4. A minimum length of the aromatic side chain is necessary to elicit activity,
and the branching of the alkyl side chain increases potency. Thus, 1’,2’-
dimethylheptyl or 1’, 1’-dimethylheptyl gives the most potent compounds.
Similarly, p-fluorophenyl alkyl and side chains as shown below retain good
activity:
—O—CH(CH3)(CH2)3-Ph,—CH2CH=CHCOC5H11,and—CH2CH2CH(OH)C2H5
5. On ring B, removal of the gem dimethyl group at C-6 decreases activity.
Replacement of one of the geminal methyl groups at C-6 by a hydroxymethyl
group retains activity (12 beta-hydroxy-delta-9-THC is as active as delta-9-
THC). Replacement of pyran O by N and ring expansion of ring B by one
carbon can retain activity.
6. In the alicyclic ring C, compounds with the double bond in delta-9-, delta-8-,
or delta-6a,10a-position are active. It is noteworthy that compounds with a
double bond in the delta-10,10a-position are also active, but only a few examples
are available at present. A 6a,10a-trans junction increases, and a cis junction
decreases, activity. The natural THCs are active in the 10a R and 6a R series
only. A methyl at C-9 increases and is optimum for activity, but metabolism to
the 11-hydroxy-methyl is not a prerequisite for THC activity, since g-nor-delta-
8-THC is active. Compounds are active even when no double bonds are present
in the ring, e.g., the HHCs. In these compounds, an equatorial group at C-9
increases activity, and an axial group decreases activity. Furthermore, the
activity is retained even when a diverse group is present, such as an epoxide, a
ketone, or an alcohol.
7. The C-ring can be substituted by a variety of nitrogen- and sulfur-containing
rings without loss of activity. With the nitrogen and sulfur analogs, the most
active central nervous system (CNS) agents are obtained when the heteroatom is
in a phenethyl orientation, e.g., inserted in place of C-7 or C-9.
8. Planarity of the C-ring is not a necessary criterion for activity.
9. In both carbocyclic and heterocyclic analogs, opening the pyran ring generally
decreases activity.
SAR AND DRUG DEVELOPMENT
It is noteworthy that the active constituent of marijuana, delta-9-THC, and a
closely related synthetic analog, nabilone, have been recently approved for
marketing in the United States as an antinauseant in cancer chemotherapy
treatment. This may mark the beginning of therapeutic drug development from
this field. It is quite obvious that the future development of clinically useful
drugs from this field will undoubtedly depend on the success achieved by
synthesis in introducing structural changes in the THC molecule, which will lead
to selectivity of pharmacological action. This presupposes the availability of
reliable animal models for screening this class of drugs. The shortcomings in this
area of pharmacological evaluation are numerous.
There is the difficulty of initial screening, i.e., the selection of compounds prior
to the more expensive and more sophisticated behavioral tests in dogs and
monkeys. Generally, the activity cage rotorod, the hypothermia, and the popcorn
tests in mice and rats are used for initial screening. What relevance these tests
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have in identifying potential therapeutic candidates is presently not clear.
Primarily, these tests only give an indication that the compound is "cannabis-like"
and will show a similar profile. There is need for the development of other
rodent models, which will provide a lead to selectivity of pharmacological action.
For more advanced screening, the presently available pharmacological models for
cannabinoids, such as the dog ataxia and the monkey behavioral tests, do provide
a good indication of the psychoactive component of these compounds, since there
is a good correlation in extrapolating from animal data to humans. But a
problem arises in quantifying the extent of separation of psychoactive and other
CNS side effects from therapeutic effects.
Unless progress is made in this direction, one would be left with no recourse but
to rely on the importance of early studies in humans. The extent of separation
of undesirable CNS side effects from clinically useful effects could only be
meaningfully gauged in human studies. This point is well illustrated by the
results obtained in the clinical evaluation of analgesics. Nabitan and
levonantradol, two synthetic nitrogen analogs of THC, were both developed as
analgesics in cancer and postoperative pain, respectively, but the incidence of
side effects was higher than the animal data indicated (Razdan and Howes 1983).
In drug development from this field, the above clinical experience highlights the
point that, so far, very few cannabinoids have been studied in the clinic, and the
baseline data generated are not sufficient to provide proper guidelines for
extrapolation of animal data to humans in terms of dosages and side effect to
therapeutic ratios. When more compounds have been clinically evaluated, the
interpretation of animal data will become more meaningful.
It appears that further modifications in the structures of nabitan and
levonantradol will be necessary to develop useful analgesics from this field. It
should be emphasized that the potential exists for development of novel
analgesics from this field, as cannabinoids act at different receptors than the
opiates (analgesic action is not antagonized by naloxone), do not have the
physical dependence liability and respiratory depression properties of the strong
opiates, and are orally active with a long duration of action.
Anticonvulsants are one area where animal studies have provided a good
indication for a clinical candidate from this field (Razdan and Howes 1983 and
references cited therein). Of all the natural constituents of marijuana studied for
antiepileptic activity, CBD was proposed as the agent of choice. This is
primarily because in animal screens it was found to be devoid of marijuana-like
CNS effects, a finding that was confirmed in humans. In the only clinical study
(Razdan and Howes 1983 and references cited therein), CBD was reported to be
effective. This bears out the animal model data. Further confirmation of these
results and more clinical studies will no doubt be required before CBD’s place in
the treatment of epilepsy can be judged.
There are a few other instances (Adams et al. 1942; Hartley et al. 1978; Leite et
al. 1982) where animal models have indicated a clear separation or dissociation of
cannabinoid (psychotropic effects) from other therapeutic effects. However, it
remains to be seen if they can be substantiated in the clinic.
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SAR AND MECHANISM OF ACTION OF CANNABINOIDS
Recent SAR studies have been directed toward elucidation of the mechanism of
action of cannabinoids. It is well known that in spite of extensive knowledge of
the pharmacological actions of cannabinoids, the mechanisms involved in
producing these effects have not been established (Dewey 1986; Martin 1986).
The effects of cannabinoids on the CNS are numerous and include CNS
depression, ataxia, psychoactive effects, hypothermia, analgesia, cardiovascular
effects, etc. They are known to alter neurotransmitter functionality, enzyme
activity, prostaglandin synthesis, membrane perturbation, etc. It is therefore
highly likely that multiple mechanisms are involved in producing the cannabinoid
behavioral syndrome.
Currently, two mechanisms are proposed which may account for the central
effects of cannabinoids, namely, general membrane perturbation, and direct
interaction with a specific cannabinoid receptor. If cannabinoids are producing
their effects solely by perturbation of membranes, there should not be a specific
antagonist but there may be a correlation between activity and membrane (lipid)
solubility. On the other hand, if they are interacting with a specific receptor and
binding sites, then there should be a strict SAR as well as a specific antagonist.
Strict structural requirements for cannabinoid behavioral activity are supported
by SAR studies. Stereospecificity has been demonstrated for delta-9-THC since
(-)-trans-delta-9-THC is many times more potent than the (+)-isomer in a
variety of tests (Mechoulam and Edery 1973; Jones et al. 1974; Martin et al.
1981). In the 3’-hydroxy-delta-9-THC series, the S-isomer is much more active
than the R-isomer (Martin et al. 1984b). Furthermore, greater potency is found
in cannabinoids with the trans ring junction (6a,10a) as compared to the cis
junction; the cis isomers are much less active (Martin et al. 1981).
Recent studies on the evaluation of cannabinoids for antagonistic properties have
shown that 10-N-ethylamino-CBD is a partial antagonist of delta-9-THC-
induced antinociception but does not produce an antagonism of delta-9-THC’s
effects on spontaneous activity and rectal temperature in mice. In addition, it
does not alter the behavioral effects of delta-9-THC in dogs (Jorapur et al. 1985;
Martin et al., this volume). Therefore, the attenuation of delta-9-THC’s effects
by this compound appears to be limited to mouse antinociception only. Another
compound which has shown interesting properties in this regard is the exocyclic
analog, delta-9,11-THC. Pretreatment with delta-9,11-THC in mice did not
attentuate any of the effects of delta-9,11-THC. The study of antagonistic
effects of this compound in the dog was hampered by the fact that it had some
depressant properties in this behavioral test. However, in the monkey test,
pretreatment with delta-9,11-THC attentuated the delta-9-THC-induced ptosis,
sedation, ataxia, and operant behavior. The delta-9-THC-induced operant
suppression was decreased by as much as 25 times. This suggests a lead for a
possible antagonist and points out that the monkey may be a better animal model
suited for characterizing cannabinoid antagonistic activity than other behavioral
tests (Beardsley et al., in press; Martin et al. this volume).
Based on the work discussed above and additional SAR developed recently,
Martin and coworkers have proposed that the pharmacological properties unique
to the cannabinoid class of drugs are produced by the interaction of delta-9-THC
with specific receptors, while cannabinoid-induced CNS depression is a general
phenomenon produced by nonspecific membrane interactions (Martin et al. this
volume). Examination of the pharmacological profile in mice, dogs, and
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monkeys of various cannabinoids, including the recently synthesized novel 11-,
12 beta-, and side-chain functionalized THCs, have led Martin’s group to classify
cannabinoids as follows: Analogs which produce the entire spectrum of
cannabinoid effects are grouped in class 1. CBD and many of its analogs appear
to be devoid of cannabinoid effects, but they are capable of producing weak
CNS depression and are grouped in class 2. Whereas, class 3 compounds are
potent CNS depressants that appear to lack other effects that are unique to
cannabinoids, and analogs in class 4 appear to exert selective CNS depression
(Martin et al. this volume). Therefore, recent studies indicate that structural
modifications in the cannabinoid molecule can lead to compounds which show
either a selective or a variety of pharmacological actions.
CONCLUSION
Despite the extensive knowledge about the pharmacological actions of
cannabinoids, the mechanisms involved in producing these effects have not been
established. Difficulties are encountered in correlating animal activity with
activity in man for this class of compounds, and this makes the task of clinical
evaluation and determination of therapeutic utility very complex. This is borne
out by the fact that the two most promising therapeutic areas for the
cannabinoids, antiemetic and antiglaucoma activities, were discovered
serendipitously without any preclinical pharmacology.
In spite of difficulties and complexity in the evaluation of these compounds,
progress is being made. Lately, several novel behavioral and drug discrimination
tests have been designed and introduced to test these compounds, and a
separation of several specific pharmacological actions has been noted in different
analogs. A basis for the pharmacological action of cannabinoids has been
proposed. Hopefully, with the continued progress in this field and the extended
clinical usage of delta-9-THC and nabilone, other areas of therapeutic use will
become evident, and the potential of this class of novel drugs will be realized.
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About 15 years ago, we formulated some tentative rules for cannabimimetic
structure-activity relationships (SAR) (Edery et al. 1971; Mechoulam and Edery
1973). These rules were based on work our group had done since 1964, when we
isolated and elucidated the structure of delta-1-tetrahydrocannabinol (delta-1-
THC) (Gaoni and Mechoulam 1964), as well as on research by numerous other
groups. Most of our work was done with rhesus monkeys; much of the work by
the other groups was done with either rodents or dogs. However, gratifyingly,
the results obtained with different species were qualitatively comparable.
Most of the rules have withstood the erosion of time, although exceptions have
been noted and certain refinements have to be made.
The generalisations listed below apply today:
1. A dihydro-benzopyran type structure with a hydroxyl group at the 3’
aromatic position and an alkyl group on the 5’ aromatic position seems to be a
requirement. Opening of the pyran ring generally leads to complete loss of
activity.
However, several major exceptions have been found, such as compounds (1) and
(2) and some of their derivatives (Johnson and Melvin 1986). Hopefully, future
work will throw light on these discrepancies,
2. The aromatic hydroxyl group has to be free or esterified. Blocking of the
hydroxyl group as an ether inactivates the molecule. It is possible that the esters
are actually inactive but undergo hydrolysis in vivo to the free phenols. Thus,
delta-1-THC acetate, when tested in vitro, shows negligible activity in
biochemical reactions in which delta-1-THC is active (Banerjee et al. 1975).
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3. An all carbon side chain on C-5’ is not an absolute requirement. The side
chain may contain an etheric oxygen (e.g., compound 3) (Loev et al. 1973).
4. 7-Hydroxy THCs, which are major metabolites, are very potent
cannabimimetics. Monohydroxylation on other position of the terpene ring also
usually leads to active derivatives. Dihydroxylation generally causes loss of
activity. Further oxidation of the C-7 hydroxyl group to a carboxyl group causes
inactivation.
5. Hydroxylation on the C-1" of the side chain abolishes activity. Hydroxylation
at the other side chain carbons retains activity with hydroxylation on C-3"
potentiating activity. Some of these hydroxylated compounds have been detected
as major metabolites.
6. Alkylation on the C-4’ aromatic position retains activity; alkylation on the C-
6’ position eliminates activity. Electronegative groups, such as carbonyl or
carboxyl, at either C-4’ or C-6’ eliminate activity.
7. The double bond isomers of THC show the following order of activity in
humans: delta-1-THC> delta-6-THC> delta-3-THC (Hollister 1974). Delta-5-
THC and delta-7-THC are inactive in animal tests, while delta-2-THC and
delta-4-THC have not been tested yet.
8. The 7-methyl group is not an absolute requirement for activity: 7-nor-delta-
1-THC (4) and 7-nor-delta-6-THC (5) are active in dogs (Wilson and May 1974).
9. The terpenoid ring may be exchanged by some heterocyclic systems (Pars et
al. 1977; Lee et al. 1983).
10. The 1,1- or 1,2-dimethyl heptyl (DMH) side chain strongly potentiates the
cannabimimetic activity of compounds which have low activity in the n-pentyl
series.
The above rules are, in reality, approximations. In the cannabinoid series, for
example, compounds which are considered inactive in some tests frequently show
low activity in other cannabimimetic tests.
The above SAR findings do not cover stereochemical requirements for
cannabimimetic activity. In the present summary, we will bring up to date the
SAR in this area, with emphasis on as yet unpublished material from our
laboratories.
C-1 EPIMERS
Reduction of the double bond in delta-1- or delta-6-THC leads to the formation
of two C-1 epimers (Gaoni and Mechoulam 1966). The equatorial epimer, in
which the methyl group on C-1 is almost in the plane of the hexahydro-
cannabinol molecule (compound 6a), is about as active in the rhesus monkey as
delta-6-THC and is about 20 times more active than the axial epimer (7a), in
which the methyl group is below the plane (Mechoulam et al. 1980).
The same relationship is observed when the C-1 substituent is an acetoxymethyl
group: epimer (6b), in which the C-1 substituent is equatorial, is active in
monkeys at doses of 0.5 mg/kg while the axial epimer (7b) is inactive at doses 10
times higher (Mechoulam et al. 1980).
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The same trend is observed in drug discrimination tests. Rats and pigeons
trained to discriminate between the presence and absence of the effects of delta-
1-THC (3 and 0.56 mg/kg, respectively) were tested for generalization with the
two epimeric 7-hydroxy-hexahydrocannabinols (6c and 7c). Both epimers
generalized with delta-1-THC in rats as well as in pigeons (table 1) (Jarbe et al.
1986). As expected, the equatorial isomer (6c) was considerably more active than
the axial one (7c). Surprisingly, compound (6c) was only 5 to 7 times more
active in the rat than (7c), while in the pigeon, compound (6c) was 85 times
more active. Apparently, species specificity in this test is very pronounced.
TABLE 1
Discrimination of 7-OH-Hexahydrocannabinols
(6c and 7c) to delta-1-THC
Hrs
Compound Compound
T H C (6c) (equat) (7c) (axial)
Rats (i.p.)
0.5
1.5
4.5
0.85 (0.94)
1.07 (0.94)
4.78 (0.79)
0.24 (0.95)
0.44 (0.997)
Pigeons (i.m.)
1.58 (0.98)
2.16 (0.96)
0.5 0.53 (0.92) 0.03 (0.99) 2.60 (0.58)
1.5 0.16 (0.91) 0.02 (0.87) 1.72 (0.97)
4.5 0.25 (0.94)
9.0 1.21 (0.70)
Median dose (mg/kg) effect estimates, ED50, according to logarithmic regression
analysis and within brackets corresponding fits (r) for the regressions are given.
Absence of an estimate (-) means no value in the dose-generalization curve
determination was above 50% drug appropriate responding (% RDP). (Jarbe et
al. 1986)
The above experimental data point out that, in the absence of other molecular
changes, the planarity at the C-1 position determines cannabimimetic activity.
The above tentative rule does not necessarily apply to other biological activities.
Thus, the axial 1-alpha-7-dimethylamino-hexahydrocannabinol (8) causes intense
yawning in monkeys, while the equatorial 1-beta-7-dimethylamino-hexahydro-
cannabinol (9) is inactive. Neither (8) nor (9) are cannabimimetic (Edery et al.
1984).
SUBSTITUTION ON C-1, C-2 VERSUS SUBSTITUTION ON C-1, C-6
Two groups of THC-type cannabinoids have been synthesized which differ only
in that the chemical groupings in one of them at C-1, C-2 are situated at C-1,
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C-6 in the other (but retain their stereochemistry). They show almost equivalent
cannabimimetic activity.
Thus, 2-alpha-hydroxy-1-beta-hexahydrocannabinol (10) is essentially inactive,
as is 6-alpha-hydroxy-1-beta- hexahydrocannabinol (11); 2-beta-hydroxy-1-
alpha- and 6-beta-hydroxy-1-alpha- hexahydrocannabinol (12 and 13,
respectively) are also inactive. However, both 2-alpha-hydroxy-1-alpha-
hexahydrocannabinol (14) and 6-alpha-hydroxy-1-alpha-hexahydro-cannabinol
(15) are active at the same dose levels (Mechoulam et al. 1980).
A biochemical rationalization of the above data is not obvious at present.
SUBSTITUTION ON C-6 AND C-5
Several groups have compared the cannabimimetic activity of 6-beta-hydroxy-
delta-1-THC (16) and 6-alpha-hydroxy-delta-1-THC (17) (for a review, see
Narimatsu et al. 1985). In man, the 6-beta-epimer (16), in which the hydroxyl
group is axial, is more active than (17); but the reverse has been observed in
mice and rabbits, and they are equiactive in rhesus monkeys. Recently, the
alpha-epimer (17) was again found to be less active than the 6-beta-epimer (16)
in a mouse catalepsy test but more potent in a test for hypothermia and
equipotent in barbiturate synergism.
5-beta-Hydroxy-delta-6-THC (18) and 5-alpha-hydroxy-delta-6-THC (19) have
been tested in rhesus monkeys only (Mechoulam et al. 1972). The 5-beta-epimer
(18), in which the hydroxyl group is equatorial, was six to eight times less active
than the 5-alpha-epimer (19), in which the hydroxyl group is axial.
The only conclusion that can be drawn (though somewhat fatuous) is that the
level of cannabimimetic activity of THCs hydroxylated at some allylic positions
seems to depend on the test used.
SUBSTITUTION ON THE SIDE CHAIN
A Pfizer group (Milne et al. 1980; Johnson and Melvin 1986) has found that
diastereoisomer A (20) is at least 10 times more potent than its side chain
counterpart, diastereoisomer B (21). in analgetic tests. As analgetic activity in
this series parallels cannabimimetic activity, one can presume that the same ratio
of activity will be observed in cannabimimetic tests.
Martin et al. (1984) have reported that (3"S)-3"-hydroxy-delta-1-THC (22) is
circa (ca) five times more active than delta-1-THC and is about seven times
more active than the R epimer (23) in THC discrimination in rats. Approxi-
mately the same ratio of activity was observed in dog ataxia tests; in
hypothermia, (22) and (23) are surprisingly equiactive. However, Martin and
coworkers pointed out that "calculation of exact potency ratios is complicated
somewhat by the lack of absolute purity of the isomers."
3,4-CIS-THCs
Racemic 3,4-cis-delta-1-THC (24), racemic 3,4-cis-delta-6-THC (25), and (+)-
3,4-cis-delta-1-THC appear to be essentially inactive in several animal tests
(Edery et al. 1971; Uliss et al. 1975; Martin et al. 1981).
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CANNABINOID ENANTIOMERS
Delta-3-THC
This cannabinoid in its racemic form was synthesized in the early 1940s.
Although attempts were made then to obtain the enantiomers in a pure form,
they were only partially successful. Recently, we were able to synthesize both
(1S)-delta-3-THC (26), [alpha]D - 117° and (1R)-delta-3-THC (27). [alpha]D +
114° with absolute optical purity (Srebnik et al. 1984). These enantiomers have
now been tested in human volunteers (Hollister et al., in press). Subjects
received progressively increasing intravenous doses of (1S)-delta-3-THC (26) and
(lR)-delta-3-THC (27), beginning with 1 mg (in 1 ml ethanol) followed by
progressive doubling of doses until. definite effects were observed.
Cannabimimetic effects with the (1S) epimer were noted at doses of 8 mg or
higher. No effects were noted with the (1R) epimer. (1S)-delta-3-THC (26) is
thus estimated to have a potency from one-third to one-sixth that of delta-1-
THC.
The behavioral cannabimimetic effects observed with (lS)-delta-3-THC (26)
were indistinguishable from those caused by delta-1-THC. As with delta-1-
THC, an increase in the pulse rate was also noted. These experiments are the
first ones with THC enantiomers in human subjects.
(-)-(3R,4R)-THCs versus (+)-(3S,4S)-THCs
The natural delta-1-THC and delta-6-THC have a (3R,4R) configuration and a
negative rotation. The synthetic route, which was developed by our laboratory
for delta-1-THC and delta-6-THC nearly 20 years ago (Mechoulam et al. 1967),
makes possible also the synthesis of the unnatural (3S,4S) enantiomers as the
starting material; verbenol (28) is available in both enantiomeric forms. This
sequence has been widely used for the preparation of (+) cannabinoids and
apparently is the only one still practical for the synthesis of (+)-delta-1-THC.
(+)-Verbenol on conden- sation with olivetol leads to (29), which on ring opening
leads to (+)-(3S,4S)-delta-6-THC (30), which can be converted with ease into
(+)-(3S,4S)-delta-1-THC (31).
In several tests for cannabimimetic activity (Edery et al. 1971; Jones et al. 1974;
Martin 1986), (+)-delta-1-THC (31) was ca 13 to 230 times less active than the
(-)-isomer. These results indicate pharmacologic enantiomeric preference rather
than absolute stereoselectivity. Indeed, Martin pointed out that, "while
cannabinoid SAR supports the concept of a specific cannabinoid receptor, a
disconcerting element is the apparent lack of greater stereoselectivity in some
animal models." However, because the starting material (+) verbenol was not
necessarily stereochemically pure, this conclusion is tentative at best.
Recently in our laboratories, we were able to prepare a pair of crystalline
enantiomeric cannabinoids (compounds 32 and 33) which could be recrystallized
to absolute enantiomeric purity. Their synthesis is based on myrtenol, which can
be obtained in both enantiomeric forms. The primary allylic group is first
blocked as a pivalate ester (reaction a) (compound 34). If the blocking group is
the more mundane acetate, the penultimate reaction (reaction e) proceeds in an
undesirable fashion leading to the benzofuran (36). Oxidation of (34) leads to
the crystalline ketone (35) which can be highly purified by crystallization. The
synthetic sequence then follows the standard procedure described above, leading
ultimately to the crystalline (+)-(3S,4S)-7-hydroxy-delta-6-THC-DMH (33). The
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configuration at C-3 and C-4 depends on the absolute configuration of
myrtenol (-) mrytenol leads to the (-) enantiomer (32); (+) myrtenol leads to the
(+) enantiomer (33).
Compounds (32) and (33) were tested in several independent cannabimimetic tests
in Jerusalem, in Uppsala, and in Tucson. In all tests, the (-) enantiomer (32)
exhibited potent cannabimimetic activity; the (+) enantiomer was inactive.
In Jerusalem, the compounds were examined in the mouse ring test. The (-)
enantiomer (32) was ca 100 times more active than natural delta-6-THC: the
ED50 of delta-6-THC was 5 mg/kg; the ED50 of (32) was 0.05 mg/kg. The (+)
enantiomer (33) was inactive up to 20 mg/kg. In Tucson, the same type of
results were observed in the rotorod neurotoxicity test in rats (see table 2). The
(-)-enan-tiomer (32) was ca 260 times more potent than natural (-)-delta-6-THC;
the (+)-enantiomer (33) was inactive at doses ca 2,000 times higher than those of
the ED50 of the (-)-enantiomer. In Uppsala, the compounds were tested in
generalization tests with rats and pigeons. (-)-7-OH-delta-6-THC-DMH (32)
was ca 87 times more active than natural delta-1-THC in the rat and ca 73 times
more active in the pigeon (see table 3). The (+)-enantiomer (33) was inactive at
doses ca 1,000 times and ca 4,500 times (for rats and pigeons, respectively)
higher than those of the ED50 of the (-) enantiomer (32).
TABLE 2
Dose-Response Parameters of THC Stereoisomers
in Rotorod (ROT) Neurotoxicity Tests in Ratsa
Drug
ROT-TD 5 0
(95% CL)
(-)-7-OH-delta-6-THC-DMH (32) 0.007
(0.005-0.009)
(+)-7-OH-delta-6-THC-DMH (33)
(-)-delta-6-THC
Not activeb
1.85
(0.98--3.45)
(+)-delta-6-THC 21.66
(19.81-23.68)
(-)-delta-6-THC-DMH 0.034
(0.031-0.040)
(+)-delta-6-THC-DMH 0.53
(0.37-0.76)
a Median toxic (TD50) dose and 95% confidence limits (CL) are in mg/kg.
b At 1.0, 7.0, and 15.0 mg/kg; higher doses were not tested due to insufficient
quantity of drug.
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TABLE 3
Generalization Tests with Various Doses of
(-)-delta-1-THC, (-)-7-OH-delta-6-THC-DMH, and
(+)-7-OH-delta-6-THC-DMH in Rats and Pigeons
Trained to Discriminate Between the Presence and
Absence of the Effects Induced by delta-1-THC
Dose Interval
Range Range
Compound n (mg/kg) (hr) (mg/kg)
(-)-delta-1-THC (R) 14 0.30-5.6 0.5-6.5 0.85
(-)-delta-1-THC (P) 7 0.10-0.56 0.5-9.0 0.16
(-)-7-OH-delta-6-
THC-DMH (32) (R) 11 0.003-0.03 0.5-6.5 0.0098
(-)-7-OH-delta-6-
THC-DMH (32) (P) 5-7 0.0001-0.0056 0.5-9.0 0.0022
(+)-7-OH-delta-6-
THC-DMH (33) (R) 4-9 3.0- 10.0 0.5-6.5 >10.0
(+)-7-OH-delta-6-
THC-DMH (33) (P) 4 3.0-10.0 0.5-9.0 >10.0
r
0.94
0.91
0.99
0.99
-
-
The animals, rats (R) and pigeons (P), were trained to discriminate between
(-)-delta-1-THC (3 mg/kg, rats; and 0.56 mg/kg, pigeons) and vehicle
administered 0.5-hr i.p. (rats) or 0.5-hr i.m. (pigeons) prior to session onset. The
ED50 values are based on the % RDP (percentage of responding to drug, THC,
associated position) during the test probe yielding the highest % RDP, i.e., the
lowest ED50 value. n = the number of observations on which data points are
based. ED50 values refer to logarithmic regression analysis, and r refers to the
correlation coefficient for the regression. The solubilization vehicle consisted of
5% (v/v) of propylene glycol, 2% Tween-80 (v/v), and 93% saline. In some
cases, 4% Tween-80 and 91% saline were used.
The above results show that (-)-7-hydroxy-delta-6-THC-DMH (32) is one of the
most active cannabimimetic substances prepared so far and that, apparently,
cannabimimetic activity resides exclusively in the (-)-(3R,4R)-enantiomer. We
assume that the results with the enantiomers (32) and (33) are also valid for the
enantiomers of delta-1-THC, i.e., that our results are of a general nature. This
assumption is based on the well-documented increase of cannabimimetic activity
on the exchange of the pentyl chain with a DMH chain and on hydroxylation of
the C-7 methyl group, which are the two features present in (32) and (33) and
absent in delta-1-THC.
The results of animal tests of the types described above with delta-1-THC, delta-
6-THC, and other cannabinoids have been shown to parallel activity in man
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TABLE 4
(+) 7-Hydroxy- -THC-DMH (33) and Morphine: Comparative Doses Producing 50 Percent
of the Maximum Possible Analgesic Effect
MPE50 (mg/kg sc) at Time of Estimated Peak Activity of Compounda,b
Compound Mouse (Sabra Strain) Bat (Sabra Strain)
Pawc Acetic Acidd Hote T a i l f T a i l f Hote
Clamp Writhing Pla te Clamp Clamp Pla te
(+) 7-OH- -THC- 0.9 0.2 0.1 0.8 4.9 0.3
DMH (33)g
Morphine HCLh 4.2 1.3 1.6 4.3 5.5 2.0
aAll morphine injected animals observed 1 hr postinjection.
bAll (+) 7-OH- -DMH injected animals observed 2 hr postinjection.
cHaffner et  al .  (1929);  an adaptation
dSophia et al. (1973)
- 30 sec cutoff.
- 20 min observation.
eWoolfe and MacDonald (1944)
fBianchi and Franceschini (1954)
- 30 sec cutoff.
-  30 sec cutoff.
gDissolved in 5% EtOH, 5% emulphor 620, and 90% ddH2O, with 5x10
-4M CuCl2 added subsequently.h Disso lved  in  0 .9% sa l ine .
(Hollister 1974). Hence, we assume that the results with (32) and (33) likewise
indicate parallel activity in man. If this correct, cannabimimetic activity in man
has a strict stereochemical requirement, which indicates a probable interaction
with a chiral biological system (enzyme, receptor site, etc.) and not just an
unspecific action due to the high lipid solubility of the cannabinoids.
ANALGETIC ACTION OF THE (+) ENANTIOMER (33)
As mentioned above, the cannabimimetic SAR does not necessarily parallel the
SAR of cannabinoids for other biological or therapeutic effects. Indeed, we have
found now that enantiomer (33), which (as noted above) does not cause
cannabimimetic effects, is a potent analgetic particularly in the presence of
cupric ions. In table 4, we present the results of several analgetic tests. In all
tests, (33) shows activity at (or above) the potency level of morphine. However,
as previously noted with delta-1-THC and other cannabinoids, the dose-response
curve is not sharp (as with morphine) but flat. Surprisingly, the level of
analgetic potency is retained over a period of 3 to 4 days. In some tests, activity
actually falls beyond a certain concentration, the dose-response curve assuming
an inverted U shape.
The above results show that it is possible to achieve complete dissociation
between cannabimimetic effect and analgetic action.
These preliminary results may be of considerable therapeutic value because
cannabinoids generally lack many of the side effects of opiates, such as high
addiction liability and respiratory depression.
SUMMARY
The SAR of cannabimimetic activity in the cannabinoid series are reviewed with
emphasis on the stereochemical requirements. Some new results are presented.
The most important are that a, in humans, (-)-(1S)-delta-3-THC is much more
active than (+)-(1R)-delta-3-THC; and b, with the 7-OH-delta-6-THC DMH
enantiomers (32) and (33), the activity in several animal species resides
completely in the (-)-(3R, 4R) enantiomer (32). the difference between the two
enantiomers being up to several thousand times. The (3R,4R)-enantiomer (32) is
much more active than delta-1- or delta-6-THC in animal tests, the exact level
of activity depending on the test employed. The cannabimimetically inactive (+)-
(3S,4S) enantiomer (33) was shown to be a potent analgetic in several animal
tests. Thus, a complete dissociation between the cannabimimetic and the
analgetic effects in a cannabinoid has been achieved, apparently for the first
time.
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Structure-Activity Relationships of
Tricyclic and Nonclassical Bicyclic
Cannabinoids
Lawrence S. Melvin, Ph.D., and M. Ross Johnson, Ph.D.
INTRODUCTION AND SUMMARY
The usefulness of marihuana has contributed to folklore and medicine for many
centuries (Li 1974; Lemberger 1980). However, a good medicinal chemical rationale
for the mechanism of action and structure-activity relationships (SAR) of
tetrahydrocannabinol ( -THC, 1) has not been forthcoming. Our interest in
attempting to dissect out the many therapeutic indications reported for THC led
us to question the chemical dogma of cannabinoids that the tricyclic pyran-
containing ring system of -THC was an absolute necessity for biological activity.
After the reported (Wilson et al. 1976) enhanced analgetic activity of 9-nor-9
hydroxyhexahydrocannabinol (HHC, 2), we became especially interested in locating
and defining the pharmacophore for analgesia in the -THC and HHC structures.
Based on the hypothesis that analgetic activity is a dissociable feature of the
cannabinoid molecule, we examined modifications of the side chain, the phenolic
moiety, and, most significantly, structures that lack the benzopyran ring present in
THC and HHC. In our initial studies, we found that a new grouping, the 1-methyl-4-
phenylbutyloxy C-3 side chain (3 l), elaborates a unique lipophilic region.
Replacement of the phenol substituent produced several derivatives which retain
analgetic activity in the codeine potency range. Introduction of a weakly basic
nitrogen at C-5 and deletion of the axial methyl group in the B ring, two structural
changes forbidden by traditional cannabinoid SAR, resulted in a unique family of
benzoquinolines with potent analgetic activity. The prototype of this series,
nantradol (4), exhibits potent and enantiospecific analgetic and antiemetic activity.
These early studies supported our three-point receptor model and led to the
synthesis of nonclassical cannabinoids.
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Synthesis of the first AC-bicyclic cannabinoid followed from our observation that the
pyran ring of HHC was not a requirement in this structural class for expression of
biological activity. Together, this observation and speculation about the necessity of
the lipophilic side chain, phenol and alcohol for biological activity was confirmed
with synthesis of 3-Z-[4-(1,1-dimethylheptyl)-2-hydroxyphenyl]cyclohexanol,
CP-47,497 (5). This compound was shown to possess a biological profile and potency
similar to HHC. Such activity and potency was highly dependent on the side chain but
was not as influenced by substitution in the cyclohexanol ring. Further structural
elaboration and development of SAR around CP-47,497 led to a more potent AC-
bicyclic derivative, (-)-3-Z-[4-(1,1-dimethylheptyl)-2-hydroxyphenyl]-4-E-(3-hydroxy-
propyl)cyclohexanol. The degree of importance of the three hydroxyl groups in this
structure was explored and only the phenolic hydroxyl was found to be an absolute
necessity. The two alcohol groups were seen to be modifiers of activity and potency.
Structural optimization of this derivative of CP-47,497 was achieved by incorporation
of the hydroxypropyl chain as a new fused ring and thus the synthesis of the first
ACD-tricyclic cannabinoid, (-)-1,2,3,4,5,5a ,6,7,8,8a -decahydro-4 [4-(1,1-dimethyl-
heptyl)-2-hydroxyphenyl]-6 hydroxymethylnaphthalen-2 ol. This rigid molecule
again exhibits an increase in potency and significantly shows total enantiospecificity
in favor of the levorotatory enantiomer. The combination of potency, stereo-
specificity, enantiospecificity, and well-defined SAR leads us to conclude that the
cannabinoidsexertat least their analgetic effect by interaction with a discreet, and as
yet unknown, receptor site.
ABC-TRICYCLICS
Analgesia and the Side Chain
Adams and his co-workers (1949) had demonstrated quite early that structural
alterations of the C-3 side chain of synthetic 6a,10a -tetrahydrocannabinols markedly
altered biologic potency (Mechoulam et al. 1976). However, since many of the
biologic effects measured in these early studies were nonanalgetic, we set out to
carefully determine specific structure-analgetic activity relationships of side chains in
the HHC series. Our search led us ultimately to examine four distinct classes of side
chains (alkyl, aralkyl, alkoxy, and aralkoxy) that are summarized in table 1 along with
their analgetic activity (Johnson et al. 1981A, 1981 B).
Initially, we examined the effect of the branched and extended alkyl derivatives 36
and 3c, side chains previously used in the and -THC (Loev et al. 1973)
and in the nabilone (Starkand Archer 1975) and nabitan (Pars et al. 1976) series. The
use of a side chain branched at the benzylic position, such as 3b and 3c, considerably
increase biologic activity relative to the n-amyl side chain. This increase in potency
may be due, in part, to a lessening of metabolic inactivation through benzylic
oxidation. Side chain c, with dimethyl substitution at the benzylic position, has the
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TABLE 1
Analgetic Activity of HHC Side Chain Derivatives
R= Compound Analgetic MPE50
(mg/kg)*
(-)- -THC
-CH2CH2CH2CH2CH3
-CH-CH-CH2CH2CH2CH2CH3
CH3 CH3
-C-CH2CH2CH2CH2CH2CH3
CH3 CH3
-CH2CH2C6H5
-CH-CH2CH2C6H5
CH3
-CH-CH2CH2CH2H5
CH3
-CH-CH2CH2CH2-4-C6H5N
CH3
-CH-CH2CH2CH2C6H5
CH3
-O-c-C6H11
-O-CH-CH2CH2CH2CH2CH3
CH3
-
3a
3b
3c
3d
3e
3 f
3g
3h
3i
3j
9.1
0.63
0.08
0.06
>10**
4.66
0.06
0.22
0.35
<10†
0.17
-O-CH-CH2CH2C6H5 3k 0.23
CH3
-O-CH-CH2CH2CH2C6H5 3l 0.07
CH3
-CH-CH2CH2OC6H5 3m 0.23
CH3
-CH-CH2CH2CH2-O-C6H5 3n 0.38
CH3
-CH-CH2-O-CH2CH2C6H5 3o 1.28
CH3
Morphine - 0.9
*Phenylbenzoquinone writhing in mice (PBQ), 0.3 hr after dose, s.c. **27%
protection at 10 mg/kg, s.c. †75% protection at 10 mg/kg, s.c.
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inside chain b. As can be seen in table 1, both 3b and 3c exhibit analgetic activity
considerably greater than that of HHC and -THC.
Having demonstrated that it was possible to increase the analgetic potency of HHC
by simple alkyl substitution in the side chain, we next turned our attention to aralkyl-
substituted derivatives in order to determine the effect of a pendant phenyl ring on
analgetic activity (previously studied in the nabitan series, cf. Winn et al. 1976). The
unbranched phenethyl side chain (3d ). which has approximately the same extended
chain length as HHC, was analgetically less active. However, the branched three-,
four-, and five-carbon homologs exhibited potent analgetic activity with a maximum
effect at four linear carbon atoms (3f ). The heteroaromatic 4-pyridyl derivative 3g,
while somewhat less potent than 3f , retained analgetic activity. Molecular models
show that 3f and 3g have approximately the same extended side chain length as 3b
and 3c.
Previous studies in the -THC series have shown that an oxygen atom directly
attached to the phenolic ring has a variable effect on biologic activity. Thus, while
unbranched ether side chains were reported to decrease activity (Edery et al. 1972),
branched ether side chains exhibited a small increase in activity relative to their
carbon isomers (Loev et al. 1973). Furthermore, simultaneous changes in the C-ring
and side chain have been shown to produce nonpredictive SAR (Loev et al. 1973).
Therefore, we reinvestigated this parameter to specifically assess the effect of a C-3
oxygen atom on analgetic activity in the HHC series. While the cyclohexyl derivative
3i retains some analgetic activity, the 2-heptyloxy derivative 3j possesses potent
analgetic activity (two to three times that of morphine).
TABLE 2
Compound
Morphine
Comparative Analgetic Effect of HHC Side Chains
MPE50 (mg/kg, s.c.)
c
Mouse Mouse Mouse Rat Rat
PBQ Writhinga Tail Flickb Hot Plateb Tail Pinchc Flinch Jumpc
0.9 5.72 4.23 4.77 10.3
3a 0.63 9.1 34.4 70.5 36.4
3b 0.06 3.0 0.32-0.56 N.T. 0.39
3f 0.06 0.25 0.55 0.49 0.47
3j 0.17 N.T. 0.56-1.0 0.65 N.T.
3l 0.07 0.33 0.46 0.38 0.38
3n 0.38 0.8 10 N.T. 2.7
a Values at 0.3 hr postdose. bValues at 1 hr postdose. cValues at 2 hr postdose.
Introduction of oxygen in the aralkyl derivative 3e yielded 3k. which is 20 times more
potent than 3e. Increasing the chain length by one carbon yielded 3l, which is fully as
potent as 3f and 3c. Since the extended chain length of 31 is greater than that of 3c
and 3f, this finding indicates that the oxygen atom itself and not just the chain length
affects analgetic activity. However, when the oxygen atom is not directly attached to
the phenolic ring of HHC, it generally behaves as a carbon unit. Thus, 3n and 3o more
closely resemble 3h than 3I. However, 3m does resemble its isomer 3k rather than 3f.
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We selected a potent member of each side chain class to more fully evaluate
analgesia across a range of stringent assays. Our results, reported in table 2, with 3a,
3b, 3f, 3j, 3I, and 3n confirm their ability to exhibit antinociceptive activity in tests
traditionally responsive only to the opiates.
These studies demonstrated that the C-3 side chain of HHC can be modified in a
structure-dependent fashion to yield derivatives that produce potent analgesia in
animals, previously characteristic only of the opiate analgetic class. In addition, we
have shown a unique effect for the placement of an oxygen atom directly attached
to the aromatic ring of HHC.
The Importance of the Phenol
Previous studies dealing with modification of only the phenolic portion of
cannabinoids have been limited to derivatives of -THC, -THC, and -THC
(Loev et al. 1973; Edery et al. 1972; Kurth et al. 1976; Matsumoto et al. 1977). These
studies have suggested, with some ambiguities, that optimal activity is associated
with only the phenol. With the potent prototype 31 in hand, we began a study of the
aromatic ring of HHC to determine the optimum structural requirements for
analgesia. initially, we studied modifications of 31 which replaced the phenol with
potential bioisosteric equivalents (Johnson et al. 19818; Melvin et al. 1980).
TABLE 3
Analgetic Activity of Phenol Replacements
Analqetic MPE50 (mg/kg)
a
X
Subcutaneousb Oralc
OH 0.07 0.11
H 30.5 30.2
CH3 >56 38.2
CH20H >56 24.6
COOH >56 -
NH2 11.3 32.5
NHSO2CH3 >56 -
NHCOCH3 >56 -
Cl >56 -
SH >56 -
Morphine 0.91 -
Codeine 6.7 21.3
-THC 5.93 7.98
aPhenylbenzoquinone writhing in mice (PBQ). b0.3 hr postdose. c1 hr postdose.
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Retaining the phenolic functionality (X = OH) appears to be a prerequisite for
optimum analgetic activity (table 3). Further, although analgesia in the range of
codeine is obtained for the amino substituent (X= NH2), substituents possessing
acidic hydrogens (X=COOH, NHSO2CH3, SH) do not mimic the phenol. Complete
removal of the phenol (X = H) yields a weakly active compound, as does replacement
by methyl and hydroxymethyl groups. The oral test data suggest that these latter
two groups are metabolically interconvertible, and it is equally likely that some
hydroxylation occurs at C-1 of the X = H analog yielding the active phenol derivative
3l .
C-5 and C-6 Positions
Since nuclear modification of the cannabinoids has been largely unsuccessful to date
(Mechoulam et al. 1976), we were impressed by the finding of potent analgesia in
animals for both the phenanthrene (Y = CH2) and the phenanthridine (Y = NH) (table
4) (Althuis et al. 1980; Milne et al. 1978).
TABLE 4
Analgetic Activity of C-5 and C-6 Modifications
R 1 R 2
CH3 CH3
CH3 CH3
MPE50 (mg/kg, s.c.)
Y Mouse PBQa Mouse Tailb Rat Tailc
Writhing Flick Pinch
CH2 0.78 1.3 1.1
O 0.07 0.33 0.38
CH3 H NH 0.4 0.7 1.0
aValues at 0.3 hr postdose. bValues at 1 hr postdose. cValues at 2 hr postdose.
The phenanthrene prototype is one to four times more potent than morphine in the
three tests shown in table 4. Although peak activity is generally observed 1 to 2
hours after dibenzo(b,d)pyrans, such as THC, this is not true for the phenanthrenes.
As shown in table 5, the peak activity of this compound occurs about 4 hours after
administration, and this activity remains near the maximum during the period of 2 to
8 hours after administration and drops off at 24 hours. It is further striking to note
that even 24 hours after dose, the phenanthrene has a tail-flick MPE50 less than that
of morphine 1 hour after administration.
The phenanthridine, nantradol (4), culminated our initial efforts to design a potent,
nonopiate analgetic. This is a significant finding since previous attempts utilizing a
cannabinoid-based phenanthridine nucleus resulted in compounds lacking biologic
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TABLE 5
Duration of Phenanthrene Analgetic Activity
Mouse Tail Rat Tail
Flick Pinch
MPE50 (mg/kg, s.c.)
Time (hr)
3.3 - 0.5
1.3 1.1 2.0
1.5 0.74 4.0
- 0.66 6.0
3.5 0.88 8.0
2.2 - 24.0
activity (Hoops et al. 1968; Biel 1970). Nantradol has a number of structural and
pharmacologic features which distinguish it from both the opiates and the
cannabinoids (Mast et al. 1979; Johnson and Milne 1980A). The most notable
structural differences are the presence of a weakly basic nitrogen in place of a pyran
oxygen, the deletion of an axial methyl group, and the introduction of an oxygen-
containing C-3 side chain. Nantradol is considerably more potent (20- to 100-fold)
than -THC as an analgetic and possesses two to seven times greater potency than
morphine across a full battery of analgetic tests (table 4). Like the opiates, nantradol
also possesses antidiarrheal and antitussive activity; however, unlike the opiates,
nantradol does not bind to the opiate receptor and its analgetic activity is not
blocked by naloxone in vivo (Milne et al. 1980A).
Phenanthridine Stereospecificity
Nantradol's substantial potency suggested to us that it might be acting specifically to
produce its analgetic effects. Therefore, we sought to determine if nantradol's
actions were stereospecific (Milne et al. 1980B; Johnson and Milne 1980B).
Nantradol has a total of five asymmetric centers; however, owing to its defined
stereochemistry at positions 6, 6a, 9, and 10a, it is an approximately equal mixture of
only 4 of the possible 32 isomers and has been studied in both animals and man as a
50: 50 mixture of two pairs of racemic diastereomers, both of which possess the trans-
6a,10a stereochemistry and have -oriented substituents at positions 6 and 9 (figure
1). The first step toward identifying the major active isomer was the separation of
nantradol into its component diastereomers, herein designated A and B.
Diastereomer A was found to be at least 10 times more potent than its C-3 side chain
counterpart diastereomer B in analgetic tests (table 6). These results clearly
demonstrate that isomer A contains the majority of nantradol’s analgetic activity.
Resolution of isomer A into its two optically active enantiomers demonstrated that it
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TABLE 6
Analgetic Activity of Nantradol Stereoisomers
MPE50 (mg/kg, s.c.)
Compound Mouse PBQ
Writhing*
Nantradol 0.4
Diastereoisomer A 0.2
Diastereoisomer B 1.7
Levonantradol 0.07
Dextronantradol 6.5
* 1 Hr after dose. †2 Hr after dose.
Mouse Tail
Flick*
0.7
0.2
2.4
0.2
>10.0
Rat tail
Pinch†
1.0
0.7
14.2
0.2
> 10.0
Rat Flinch
Jump†
1.4
0.3
2.4
0.3
> 10.0
is the levorotatory isomer, levonantradol, that possesses the largest portion of the
analgetic activity of nantradol, being four and two times more potent than
nantradol and diastereomer A, respectively. Importantly, the enantiomer
dextronantradol is at least 100 times less active than levonantradol.
Figure 1
NANTRADOL ISOMERS
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AC-BICYCLICS
Previously reported work and studies in our laboratories suggested that the
dimethyldihydropyran ring portion of HHC was not required for potent biological
activity. Unexpectedly, substitution of carbon (phenanthrenes) or nitrogen
(phenanthridines) for the oxygen of the pyran ring in HHC yielded compounds that
were of similar analgesic potency to HHC. Additionally, we showed in the work
leading to levonantradol that the geminal dimethyl group on the pyran ring of HHC
was not necessary for analgesic activity.
Thus, the dihydropyran moiety appeared to serve no other purpose than to firmly
anchor the phenolic ring and cyclohexyl ring in an active conformation. This
hypothesis led us to further postulate that HHC interacts at a receptor site by a three-
point contact (Milne and Johnson 1981). the three binding sites being the equatorial
alcohol, phenol, and C-3 side chain.
As a result of these considerations, we prepared (Melvin et al. 1982, 1984A) a novel
AC-bicyclic cannabinoid, 5 (CP-47,497), which is lacking the dihydropyran ring of
HHC. As table 7 shows, prototype 5 retains all the analgetic activity and potency of
HHC and is equipotent with morphine (Johnson et al. 1982; Milne et al. 1983). In
addition, 5 still exhibits many of the motor disruption effects in common with HHC
and the cannabinoids (Weissman et al. 1982). We believe these striking results can be
rationalized by considering the minimum energy conformation of 5. For the
calculated minimum energy conformation of 5 and HHC, the dihedral angle between
the C-OH (phenol) and C-OH (alcohol) bond is + 54.0° and + 41.3°, respectively. The
distance between the oxygen atoms in these calculated conformations was found to
be 5.0Å for 5 and 4.8Å for HHC. Thus, we propose that 5 readily assumes a
conformation quite similar to the rigid HHC molecule and is recognized by a
biological system as being equivalent to a tricyclic cannabinoid.
TABLE 7
Compound
Analgetic Activity Test Results of CP-47,497 (5)
MPE5O (mg/kg)
a
PBQb RTCc HPd TFe FJ f
5 1.0 4.7 8.1 4.4 4.2
HHC 0.63g 7.0 34.4 9.1 36.4
Ag-THC 5.9 29.1 >178h 55g,i 83.1
Morphine 1.8 4.8 4.2 5.7 10.3
aThe dose to produce 50% of the maximum possible effect (subcutaneous). bMouse
phenylbenzoquinone-induced writhing, 1 hr postdose. cRat tail clamp, 2 hr postdose.
dMouse hot plate, 1 hr postdose. eMouse tail flick, 1 hr postdose. fRat flinch jump, 2
hr postdose. g20 min postdose. hLess than 50% response at this dose. i>178 at 1 hr
postdose.
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We developed side chain SAR for 5 as compiled in tables 8 and 9. These tables
illustrate the optimum carbon side chains are 1,1-dimethylheptyl and 1,1-
dimethyloctyl, while the optimum alkoxy substituents are 2-octyloxy and 2-nonyloxy.
Table 10 compares carbocyclic ring size with analgetic activity, showing the optimum
sizes to be cyclohexyl and cycloheptyl (Melvin et al. 1984B). In addition, tables 8
through 10 record the effect on side chain and ring size of varying the
stereochemistry of the alcohol in 5 as well as the oxidation state (ketone vs. alcohol)
at the same carbon atom. Thus, analgetic potency varies with the alcohol position 5
as equatorial OH>axial OH ketone.
TABLE 8
PBQa Writhing Results for Alkyl Side Chains
MPE50 (mg/kg)
b
n/R Equatorial OH Axial OH =O
0 IAc IA IA
1 IA IA IA
2 IA IA IA
3 IA IA IA
4 11.9 > 56d 34.8
5 1.00 3.8 4.5
6 1.20 3.93 1.06
7 15.2 IA IA
8 IA IA IA
9 IA IA IA
–e IA IA IA
aMouse phenylbenzoquinone-induced writhing, 1 hr postdose. bThe dose to produce
50% of the maximum possible effect (subcutaneous). cIA, less than 20% inhibition at
56 mg/kg. d35% inhibition at 56 mg/kg. eThese compounds have the entire alkyl side
chain repiaced by H.
Substitution at the C-4 position of the cyclohexane ring of 5 maximized analgetic
potency in this series. The hydroxy propyl analog (-)-6 (CP-55,940) is shown in table
11 to be significantly more potent than morphine and to have at least a 200-fold
ratio of stereospecificity (Melvin et al. 1983A). Table 12 compares the effect of simple
n-alkyl versus n-hydroxyalkyl substitution at the C-4 position of 5. Analgetic potency
with alkyl substitution was maximized for n-propyl, while n-hydroxypropyl or n-
hydroxybutyl were the optimum hydroxyalkyl substitution.
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TABLE 9
PBQa Writhing Results for Alkoxy Side Chains
MPE50 (mg/kg)b
n R1/R2
4 CH3
5 CH3
6 CH3
2 C6H5
3 C6H5
4 C6H5
3f C6HS
Equatorial OH
22.3
5.04
9.3
~56e
38.0
IA
IA
Axial OH
>56c
>56
IAd
IA
>56
IA
IA
=O
>56
>56
>56
IA
>56
IA
IA
aMouse phenylbenzoquinone-induced writhing, 1 hr postdose. bThe dose to produce
50% of the maximum possible effect (subcutaneous). cLess than 50% inhibition at 56
mg/kg. dlA, less than 20% inhibition at 56 mg/kg. e57% inhibition at 56 mg/kg.
fThese compounds lack the CHCH3 in the side chain of the general structure.
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TABLE 10
Analgetic Test Results with Varying Ring Size
MPE50(mg/kg)
a
n R PBQb RTCc HPd TFe FJf
0 ~56g NTh NT N T NT
1 1.00 4.7 8.1 4 4 4.9
2
3
0
1
2
1.44 7.66 39.4 12.2 3.5
4.61 NT >56i ~32j NT
>56i NT N T NT NT
3.8 12.3 >56i 55.7 ~17.8k
1.53 5.64 <32 l 7.54 5.36
3 39.2 NT N T NT NT
0 IA
m NT NT NT NT
1 4.5 26.1 >32n 15.3 11.5
2 1.23 4.36 >32n 11.7 10.8
3 ~56° NT NT NT NT
aThe dose to produce 50% of the maximum possible effect (subcutaneous). bMouse
phenylbenzoquinone-induced writhing, 1 hr postdose. cRat tail clamp, 2 hr postdose.
dMouse hot plate, 1 hr postdose. eMouse tail flick, 1 hr postdose. fRat flinch jump, 2
hr postdose. g51% inhibition at 56 mg/kg. hNT = Not tested. iLess than 50%
inhibition at 56 mg/kg. j54% inhibition at 32 mg/kg. k58.7% inhibition at 17.8
mg/kg. l65.6% inhibition at 32 mg/kg. mIA, less than 20% inhibition at 56 mg/kg.
nLess than 50% inhibition at 32 mg/kg. °57.5% inhibition at 56 mg/kg.
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TABLE 11
Analgetic Activity and Stereospecificity of 6
Compound PBQa
(-)-6 0.07
MPE50 (mg/kg)
TFb HPc RTCd FJe
0.4 0.7 0.13 0.50
( +)-6 14.6
(±)-6 0.29 0.55 1.11 0.46 0.63
(±)-5 1.0 4.4 8.1 4.7 4.9
HHC 0.63f 9.1 34.4 7.0 36.4
Morphine 1.8 5.7 4.2 4.8 10.3
aMouse phenylbenzoquinone-induced writhing, 1 hr postdose. bMouse tail flick, 1 hr
postdose. cMouse hot plate, 1 hr postdose. dRat tail clamp, 2 hr postdose. eRat flinch
jump, 2 hr postdose. f0.3 hr postdose.
TABLE 12
Analgetic Activity for Analogs of (±)-5
R PBQ MPE50
(mg/kg)*
H
CH3
CH2CH3
CH2CH2CH3
CH2CH2CH2CH3
CH2CH2CH2CH2CH3
CH2OH
CH2CH2OH
CH2CH2CH2OH
CH2CH2CH2CH2OH
CH2CH2CH2CH2CH2OH
1.00
1.02
1.75
0.54
0.83
50
1.77
2.58
0.29
0.23
0.55
*Phenylbenzoquinone writhing in mice, 1 hr post subcutaneous dose.
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ACD-TRICYCLICS
The successful modification of HHC and subsequent derivatization of 5 giving the
more potent hydroxypropyl analog 6 encouraged us to further pursue this new lead.
Assuming we had found the optimum substitution at C-4 from our studies with 5, we
next chose to explore potential stereochemical requirements of this new primary
alcohol group. To this end, we prepared a more complex ring system, 7 (CP-55,244),
that incorporates a rigidly positioned hydroxypropyl moiety. From table 13, which
displays the analgetic test results obtained with rigid decalin 7, it is seen that this
compound is 2 to 10 times more potent than less rigid structure 6. A suggestion that
the axial hydroxymethyl group of 7 is optimally oriented comes from the lessened
(52x) potency observed for the equatorial isomer (± )-8 . Even more striking, (-)-7
now exhibits virtually complete stereospecificty of action versus (+)-7. This fact
supports our hypothesis that compounds such as 6 and 7 interact with a specific
receptor system.
TABLE 13
Analgetic Effect of (-)-7 vs. (-)-6 and Stereospecificity of (-)-7
MPE50 (mg/kg)
a
Compound PBQb RTCc Hpd TFe
(-)-7 0.02 0.06 0.07 0.03
FJ f
0.11
(+)-7 >100 - - - -
(±)-7 0.054 0.22 0.24 0.15
(±)-8 2.86 6.83 - -
-
-
(±)-5 1.0 4.7 8.1 4.4 4.9
(-)-6 0.07 0.13 0.7 0.4 0.5
HHC 0.63g 7.0 34.4 9.1 36.4
Morphine 1.8 4.8 4.2 5.7 10.3
aThe dose to produce 50% of the maximum possible effect. bMouse
phenylbenroquinone-induced writhing, 1 hr postdose. cRat tail clamp, 2 hr postdose.
dMouse hot plate, 1 hr postdose. eMouse tail flick, 1 hr postdose. fRat flinch jump, 2
hr postdose. g0.3 hr postdose.
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DISCUSSION
We have detailed the SAR for side chains of ABC-tricyclic cannabinoids showing
optimum effects from both alkyl and alkoxy substitution. The necessity for phenolic
functionality at C-1 of HHC was confirmed. Nitrogen and carbon were successfully
substituted for the dihydropyran oxygen of HHC. Structural dissection of HHC led to
the synthesis of AC-bicyclic cannabinoids and demonstration that the rigid B-ring
(dihydropyran ring) is not required for biological activity. The biological activity of
AC-bicyclic cannabinoids supports our hypothesis that cannabinoids have three sites
of receptor recognition (side chain, phenol, and alcohol). The synthesis of ACD- and
ABCE-multicyclic cannabinoids demonstrates that there is structurally unexplored
space proximate to the HHC molecule.
The extreme potency and stereospecificity of these synthetic, nonclassical
cannabinoids, and their retained activity at the extremes of structural elaboration,
lead us to believe that these compounds are exerting their effects by acting at an as
yet unknown receptor site.
The current studies demonstrate the ability to achieve extreme biological potency in
structures that diverge significantly from the classical cannabinoid ring system. This
and the clear relationship between the stereochemistry and biological activity of
these compounds provides support for the premise that they interact in very specific
and important ways with biological systems. However, it seems likely that further
improvements in selectivity between the desired biological activity and the typical
cannabinoid side effects will be necessary before the full therapeutic potential of
these compounds is fully realized. It is possible that the next round of discovery in
this area, possibly leading to greater selectivity, will be sparked by the identification
of a novel site of cannabinoid action involving a distinct neurotransmitter system.
Toward this end, the potent and stereochemically defined compounds described
herein could provide important tools to facilitate this effort.
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ABSTRACT
Cannabidiol (CBD) exhibits anticonvulsant activity in
experimental animals and in man. As part of a structure-
activity study, analogs were prepared wherein the terpene unit,
the aryl unit, and/or the side chain were modified. Thus,
several pinenyl and carenyl derivatives, aryl ethers and
acetates, and a variety of 1",1"-dialkylhexyl and 1",1"-
dialkylheptyl analogs were synthesized. The compounds were
evaluated for anti-convulsant activity in seizure susceptible
(AGS) rats and for neurotoxicity in the rat rotorod (ROT) test.
Comparisons of stereoisomers of CBD and several analogs revealed
a general lack of stereoselectivity for anticonvulsant and other
CNS properties of this class of compounds.
INTRODUCTION
(-)-Cannabidiol [CBD, (-)-la] is a neutral major cannabinoid of
cannabis with potential therapeutic utility. In humans, the
drug has antiepileptic efficacy (Cunha et al. 198O) and possibly
antidystonic activity (Consroe and Snider 1986) and exhibits no
significant side effects. It also has no cannabimimetic
activity, i.e., subjective effects in common with cannabis or
its neutral major psychoactive ingredient, (-)-delta-9-tetra-
hydrocannabinol [(-)-delta-9-THC (2), also known as delta-1-
THC (Razdan 1986)]. In laboratory animals, (-)-CBD has
selectivity of anticonvulsant action relative to neurotoxic
effects (Consroe and Snider 1986) and is inactive in models that
predict cannabimimetic activity (Razdan 1986). This dichotomy
of action between (-)-CBD and (-)-delta-1-THC has led to many
investigations of the structure-activity relationships (SAR) in
cannabinoids (Razdan 1986). However, most of these studies have
been carried out with THC analogs and with laboratory animal
models of cannabimimetic activity; thus, virtually all knowledge
of cannabinoid SAR is based on the psychoactive component of
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cannabis-like effect (Razdan 1986). On the other hand, some
studies evaluating the anticonvulsant effects of CBD
stereoisomers (Leite et al. 1982) and putative metabolites
(Carlini et al. 1975) in mice have been reported. We have been
carrying out an interdisciplinary
the antiepileptic potential and SAR of new synthetic CBD analogs
research project to evaluate
in rats. Some of our results have been published (Consroe et
al. 1981, 1985), and the present report provides an overview of
these findings and of new data on the anticonvulsant and
differential neurotoxic activities of
MATERIALS AND METHODS
additional CBD analogs.
The audiogenic seizure (AGS-susceptible) rat model of epilepsy
(Dailey and Jobe 1985) was used to assess anticonvulsant
activity, and the rat rotorod (ROT) paradigm (Dunham and Miya
1957) was used to assess differential neurotoxicity (i.e.,
reflecting mainly sedation and/or incoordination), of CBD
analogs. For AGS tests, male and female, 150 to 225-gm,
genetically epilepsy prone rats (from the Uaz:AGS-SD colony of
the University of Arizona, or from the GEPR-3 colony at the
University of Illinois) were used (Consroe et al. 1981, 1985;
Dailey and Jobe 1985). For ROT tests, male and female, 150 to
225-gm rats (from the Uaz:AGS-SD colony or the Hsd:(SD)BR colony
of the Harlan Sprague Dawley Company, Indianapolis, IN) were
used. As detailed previously (Consroe et al. 1981, 1985) CBD
analogs (suspended in a vehicle of 10% polysorbate 80 and 90%
distilled water) were injected intravenously (iv) and rats were
tested 15 minutes later (a peak-effect time for both tests). In
the AGS test, responses to sound were recorded as the presence
or absence of seizure (i.e.,
generalized flexion).
generalized clonus or clonus and
In the ROT test, effects were measured as
the ability or inability (i.e., neurotoxicity) of trained rats
to remain on a revolving drum (rotorod) for 60 seconds.
Separate groups of ten to fifteen rats were used for each dose
of drug tested and, typically, three to six doses of each analog
were used for each AGS and ROT test. For appropriate dose-
response data, median effective anticonvulsant (ED50) and
neurotoxic (TD50) doses and regression line parameters were
calculated by computer-assisted probit analysis (Dixon 1977).
Subsequent calculations of 95% confidence limits (CL) and
comparisons between slopes and median doses (i.e., ED50 and TD50
potency comparisons) were carried out using the method of
Litchfield and Wilcoxon (1949). which we have incorporated into
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a BASIC program for use on a microcomputer. Protective indexes
(PI = ROT-TD50/AGS-ED50) also were calculated where possible.
Cannabidiol a n a l o g s were prepared by condensation of the
appropriate terpene alcohol (+)-p-mentha-2,8-dien-1-ol (-)-P-
mentha-2,8-dien-3-ol, (-)-2-caren-4-ol, (+)-verbenol, (-)-
verbenol: -(+)-8-acetoxyverbanol, (-)-8-acetoxyverbanol, (+)-8-
pivaloxyverbanol, or (-)-8-pivaloxyverbanol with a 5-
substituted resorcinol according to the methods of Petrazilka et
al. (1969) and Razdan et al. (1974). The synthesis of 5-
(1',1',1'-trialkyl)resorcinols have been described previously
(Singh et al. 1981). Olivetol (5-n-amylresorcinol), (-)-
limonene, (+)- and (-)- -(-pinene, (-)-myrtenol, and (+)-trans-p-
mentha-2,8-dien-1-0l were obtained from commercial sources and
were used as received.
(-)-cis-p-Mentha-2,8-dien-1-ol was prepared from (-)-limonene by
the method employed by Rickards and Watson (1980) for the
synthesis of (+)-cis-p-mentha-2,8-dien-1-ol from (+)-limonene.
(-)-p-Mentha-1,8-dien-3-ol (Leite et al. 1982) was obtained as a
1:3 mixture of cis- and trans-isomers from the sodium boro-
hydride-cerium trichloride reduction (Luchie et al. 1982) of p-
mentha-1,8-dien-3-ol (Dauben et al. 1969). (-)-trans-4-Caren-3-
ol was obtained by the reaction of
(-)-3 ,4 -epoxycarane
sodium phenylselenide on
(Cocker and Grayson 1969), followed by
oxidation of the phenylselenide and elimination of the
selenoxide (Uzarewicz and Zientek 1977). (+)- and (-)-Verbenol
were obtained as mixtures of cis- and trans-isomers from (+)-
and (-)- -pinene (Whitham 1961)) respectively. (+)-Myrtenol
was prepared by selenium dioxide oxidation of (-)- -pinene
followed by reduction with sodium borohydride. (+)- and (-)-
Myrtenols were acylated with acetic anhydride or pivaloyl
chloride in pyridine to obtain the corresponding acetate or
pivalate, and the latter were subjected to allylic oxidation
with chromium trioxide/pyridine (Dauben et al. 1969) and then
reduction with dibutyllithfum aluminium hydride (DiBAH) to give
the corresponding 8-acetoxy- and 8-pivaloxy-verbenols.
The optical purity of (+)-CBD obtained from either (-)-p-mentha-
1,8-dien-3-ol or (-)-p-mentha-2,8-dien-1-ol was calculated to be
83% based on observed D values of + 80± 10 for the two
chemically pure samples. Optical purities for the cannabidiol
analogs derived from (+)-3-carene and (+)- and (-)- -pinene
were not determined, but were estimated to be in the range of
80% to 95% based on the optical purities of the starting
materials. Structures of the final compounds were confirmed by
proton nmr and elemental analysis, which agreed within ± 0.4% of
the theoretical values. The cannabidiols prepared along with
data for their anticonvulsant and neurotoxic activities are
provided in table 1.
RESULTS AND DISCUSSION
Dose-response data for standard compounds phenytoin (PHT),
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TABLE 1
Preliminary and Completed Dose-Response Data of
Standard Anticonvulsants and CBD Analogs in ROT and AGS Testsa
Compd. No. ROT AGS PI
Phenobarbital
Carbamazepine
Phenytoin
28.9 10.8 2.7
(26.0-32.2) (8.5-13.8)
33.9 12.8
(9.7-16.9)
2.7
(32.6-35.4)
23.9 14.7
(22.3-25.6) (11.1-19.6)
1.6
(-)-CBD: Aryl Ring Modificationsb
Compd. No. R1 R2 R3 ROT AGS PI
(-)-1a H H H 30.7 14.9 2.1
(26.1-36.1) (10.9-20.1)
lb AC AC H 47.9 11.5 4.2
(43.2-53.2) (9.5-13.9)
1c H AC AC O/10 at O/l2 at ---
31 mg/Kg 15 mg/Kg
1d CH3 CH3 H O/10 at O/10 at ---
31 mg/Kg 15 mg/Kg
1e CH3 H H O/10 at 2/10 at ---
31 mg/Kg 15 mg/Kg
(-)-CBD: Side Chain Modificationsc
Compd. R1 R2 R3 R4 R5 ROT AGS PI
No.
(-)-3a CH3 CH3 H H
3b CH3 C2H5 H H
C 5H 1 1 2.1 (2.3-6.3)
0.6
C5H11 6/10 at ---
31 mg/Kg 15 mg/Kg
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3c CH3 CH2CH=CH2 H H C5H11 O/10 at O/10 at ---
31 mg/Kg 15 mg/Kg
(-)-3d CH3 CH3 H H C4H9 6/10 at 6/10 at ---
3e CH3 C2H5 H H C4H9
31 mg/kg 15 mg/Kg
9/10 at 4/10 at ---
31 mg/Kg 15 mg/KG
3f CH3 CH2CH=CH2 H H C4H9 O/10 at 1/10 at ---
31 mg/Kg 15 mg/Kg
3gH H CH3 CH3 C5H11 1O/1O at 4/10 at ---
31 mg/Kg 15 mg/Kg
(+)-CBDsc
Compd. No. R ROT AGS PI
(+)-1a
(+)-3a
C5H11 39.7 16.2 2.5
(36.6-42.9) (14.6-18.0)
1 ,1-DMH 10/10 at 9/10 at ---
31 mg/Kg 4 mg/Kg
(-)-Pinenyl CBDs
Compd. No. R1 R2 R3 ROT
(-)-4a CH3 H C5H11 8/10 at
(-)-4b
31 mg/Kg
CH3 H 1,1-DMH 9.2
(6.8-12.3)
(-)-4c CH2OAC H 1,1-DMH 2.6
(1.8-3.7)
(-)-4d CH20AC AC 1,2-DMH 4/4 at
(-)-4e
31 mg/Kg
CH20Pv H 1,1-DMH O/6 at
31 mg/Kg
AGS PI
7/10 at ---
15 mg/Kg
5.2
(3.6-7.4)
1.8
2.5
(1.4-4.3)
1.0
4/10 at ---
15 mg/Kg
5/10 at ---
15 mg/Kg
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(+)-Pinenyl CBDs
Cmpd. No. R1 R2 R3 ROT AGS PI
(+)-4a CH3 H C5H11 5/10 at 1/10 at ---
31 mg/Kg 15 mg/Kg
(+)-4b CH3 H 1,1-DMH 1.9 0.7
(1.6-2.2) (O.5-1.O)
2.7
(+)-4c CH20Ac AC 1,2-DMH 9/10 at 4/10 at ---
4 mg/Kg 4 mg/Kg
(+)-4e CH20Pv H 1,1-DMH 4/10 at 8/10 at ---
4 mg/Kg 4 mg/KG
(+)-4f CH20Ac AC 1,1-DMH 1O/1O at 9/9 at ---
4 mg/Kg 4 mg/Kg
(+)-Carenyl CBDs
Compd. No. R ROT AGS PI
(+)-5a
(+)-5b
C5H11 99.8 18.1 5.5
1,1-DMH
(90.4-110.1) (16.2-20.3)
3.7 3.4
(3.3-4.1) (3.0-3.9)
1.1
aMedian toxic (TD50) and effective (ED50) doses and 95%
confidence limits (in parentheses) are in mg/Kg, iv
PI = protective index = ROT-TD50/AGS-ED50. Ratios refer to the
number of rats protected against AGS or number of rats toxic/
number of rats tested (at the iv dose listed). Chemical
abbreviations are: AC = acetyl; DMH = dimethylheptyl; and
Pv = pivaloyl.
bData taken, in part, from Consroe et al. (1981).
cData taken, in part, from Consroe et al. (1985).
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phenobarbital (PB), and carbamazepine (CBZ); (-)-CBD [(-)-
1a] and a few selected analogs; plus single dose comparisons
[for most compounds equivalent to the calculated AGS-ED50 and
ROT-TD50 of (-)-1a] are presented in table 1. In the AGS test,
peak-effect times were observed 15 minutes after (-)-1a, CBD
analogs, and PHT; 30 minutes after PB; and 45 minutes after CBZ
injections. Vehicle administration neither protected against
AGS nor caused ROT toxicity.
In an earlier study (Consroe et al. 1981), it was observed that
certain aryl modifications in (-)-1a markedly reduced both anti-
AGS activity and ROT neurotoxicity. For example, 1d, the
dimethylether of (-)-1a, is inactive in the AGS and ROT tests at
15 and 31 mg/Kg, respectively, and the monomethyl ether (1e) is
marginally active in the AGS test and inactive in the ROT test
at the same doses. These earlier data are repeated in table 1.
The monoacetate of 3'-acetyl CBD (1c), obtained by photo-Fries
rearrangement of CBD diacetate (1b), was similarly inactive in
both tests. It was therefore concluded (Consroe et al. 1981)
that both phenolic hydroxyl groups of CBD must be free for anti-
AGS and ROT activities to occur. Weak anti-AGS activity of 1e
could be due to inefficient demethylation to 1a. Intramolecular
hydrogen bonding between the free phenolic group and the 3'-
acetyl group of 1c may be responsible for its lack of activity.
The lack of anti-AGS activity in abn-CBD analogs (Consroe et al.
1981) indicates that the positions of the hydroxyl groups on the
aromatic unit are important.
CBD diacetate (1b), in contrast to the ethers, was found to be
equivalent to 1a in anti-AGS potency in a single dose comparison
(Consroe et al. 1981). It was tentatively concluded that 1b is
efficiently hydrolyzed by esterases in vivo to la which is
responsible for the anti-AGS activity. The neurotoxicity of 1b,
on the other hand, was significantly lower than that associated
with 1a. These preliminary findings prompted us to perform
complete dose-response and time course studies on 1b. Dose-
response data (table 1) reveal an ED50 of 11.5 mg/Kg and a TD50
of 47.9 mg/Kg for 1b, as compared with 30.7 mg/Kg and 14.9
mg/Kg, respectively, for 1a. Thus, the protective index (PI) of
1b is two times greater than the PI of 1a. Comparative time
course studies of la and lb at equiactive doses indicate that
the anti-AGS effects of 1a have a more rapid onset and a longer
duration than those of 1b. The ROT neurotoxic effects of the
two agents, on the other hand, follow a similar time course.
The slightly greater anti-AGS potency of 1b and its
significantly reduced ROT neurotoxicity as compared with 1a,
together with the time course differences, suggest that the
sites of action of the two effects may be different. If,
indeed, 1b must be converted to 1a in vivo in order to be
active, then this conversion must- be very efficient.
Acetylation of the phenolic groups of 1a could serve to increase
the lipophilicity of the compound, thereby facilitating its
penetration into the central nervous system. At the same time,
the phenolic groups are protected from inactivation by
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conjugating enzymes.
We have recently investigated the effects of structural
modification of the side chain of CBD on anti-AGS and ROT
potencies (Consroe et al. 1985). The compounds investigated
were the branched chain compounds 3a-3g. For anti-AGS activity,
the order of potency (-)-3a 7 3b = 1a >3c was observed in the
1",1"-dialkylheptyl series, while it was 1a> 3e > 3d = 3f in
the 1",1"-dialkylhexyl series. In the ROT neurotoxicfty test,
the rank order of potencies was (-)-3a > (-)-1a 7 3b 7 3c in the
1",1"-dialkylheptyl series and 3e > 3d = 1a in the 1",1"-
dialkylhexyl series. Thus, optimal anti-AGS potency, together
with maximal neurotoxicity, was observed with the 1", 1"-
dimethylheptyl analog (-)-3a. The 1" ,1"-dimethylhexyl analog
(-)-3d, on the other hand, is significantly less potent than
(-)-3a. Leite et al.
anticonvulsant and CNS
(1982) observed similar enhancemeent in
depressant potencies of 1" ,1"-
dimethylheptyl analogs of CBD in mice. In contrast, the 1"-
methyl-1"-ethylheptyl analog 3b exhibited anti-AGS activity
comparable to that of 1a, but was considerably less neurotoxic.
Additional studies on this compound (which, like side chain
analogs 3c-, 3e, and 3f, is a diastereoisomeric mixture due to
asymmetry at the 1"-carbon) appear to be warranted. The 1"-
methyl-1"-ethylhexyl analog 3e, on the other hand, is
significantly more neurotoxic than (-)-1a, but significantly
less potent in the AGS test. The basis for the remarkable
differences in the side chain analogs differing by a single
carbon atom remain to be explained. Significant neurotoxicity
and some anti-AGS activity are retained in the 1",2"-
dimethylheptyl analog 3g.
Early comparisons of CBD analogs derived from (+)- and
(-)- -pinene suggested that the anti-AGS effects of CBD and its
derivatives might be stereoselective. Thus, (-)-4a (which is
stereochemically related to (-)-1a) was significantly more
potent than its enantiomer (+)-4a in the AGS test when each was
administered in a dose of 15 mg/Kg (Consroe et al. 1981).
However, Leite et al. (1982) found that (-)-1a and (+)-1a were
essentially equiactive as anticonvulsants (protection against
pentylenetetrazole seizures) and as CNS depressants
(prolongation of phenobarbital sleeping time) in mice. A
parallel lack of stereoselectivity was observed for the highly
potent 1" ,1"-dimethylheptyl enantiomers (-)-3a and (+)-3a. A
general lack of stereoselectivity for the anti-AGS and ROT
neurotoxic effects of CBD and its derivatives was recently
confirmed (Consroe et al. 1985). Thus, (-)-1a is marginally
more potent than (+)-1a in both the AGS and ROT tests, while
(+)-4b is somewhat more active than (-)-4b in the two tests (see
table 1). . There are insufficient data with which to
quantitatively compare (-)-3a and (+)-3a, but it is evident that
both are highly active in the AGS and ROT tests. Similarly, the
enantiomeric pair (-)-4d and (+)-4d appear to exhibit comparable
anti-AGS and ROT neurotoxic potencies. On the other hand, (+)-
4e is apparently more potent than (-)-4e. These two enantiomers
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seem to be worthy of further study since single dose data
suggest that each will exhibit a favorable protective index.
The general lack of stereoselectivity for the anti-AGS and ROT
neurotoxic activity of la and its analogs stands in stark
contrast to the situation with THC-like compounds (see Mechoulam
et al., this volume). Thus, (-)-delta-6-THC analogs that are
stereochemically related to (-)-delta-1-THC (2) are markedly
more potent than their (+)-enantiomers in both AGS and ROT
tests. These findings suggest that the mechanisms of anti-
convulsant and central nervous system depressant actions of CBDs
and THCs may be different.
The CBD analog derived from (+)-delta-3-carene, i.e., (+)-5a, is
of interest because of its high protective index. Thus,
although (+)-5a has an ED50 of 18.1 mg/Kg in the AGS test and is
therefore comparable to (+)-1a (to which it is stereochemically
related) in potency, it has a TD50 of approximately 100 mg/Kg.
This separation of activities is, unfortunately, not maintained
in the 1",1"-dimethylheptyl derivative (+)-5b, which has a PI of
1.1.
Solid state (X-ray crystallographic, Jones et al. 1977).
solution (Tamir et al. 1980; Kane et al. 1984), and theoretical
(Kane et al. 1984) studies all indicate that the 3-olivetyl and
4-isopropenyl groups of CBD prefer a dfequatorfal conformation.
These functionalities in the highly ri gfd pinenyl derivatives 4,
on the other hand, are held in a diaxial conformation. The less
rigid carenyl derivatives 5 no doubt also prefer a diaxial
conformation. Since the energy difference between the
diequatorial and diaxial conformations of CBD may be slight, it
is possible that the "active form" of the molecule may be its
energetically less favored diaxial conformer.
The following structure-activity generalizations have emerged
from these studies: The aryl unit and the side chain of CBD are
highly sensitive to structural modification. Most changes in
the aryl unit, e.g., blocking or changing the positions of the
phenolic groups, greatly decreased anti-AGS activity. Optimal
anti-AGS and ROT neurotoxic effects were observed in 1"-1"-
dimethylheptyl derivatives. On the other hand, the terpene unit
appears to be relatively insensitive to structural changes.
Derivatives of -pinene and delta-3-carene are as potent as
(-)-1a and there is a general lack of stereoselectivity
associated with the terpene unit.
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Anticonvulsant and Neurotoxic
Effects of Tetrahydrocannabinol
Stereoisomers
Paul Consroe, Ph.D., and Raphael Mechoulam, Ph.D.
ABSTRACT
Enantiomers of delta-6-tetrahydrocannabinol (THC),
delta-6-THC-1", 1"-dimethylheptyl (DMHP), and 7-OH-
delta-6-THC-l", 1"-DMHP were assessed for their ability
to block audiogenic seizures in genetically epilepsy-
prone rats. The stereoisomers were evaluated also for
their ability to produce differential neurotoxicity in
the rat rotorod (ROT) paradigm. Potency comparisons
among the compounds revealed modest to profound
stereoselectivity for anticonvulsant and neurotoxic
activities, a general increase in both activities with
the DMHP and 7-OH modifications of delta-6-THC, and some
favorable separation between anticonvulsant and
neurotoxic activities with selected THC analogs.
INTRODUCTION
Two important generalizations of tetrahydrocannabinol
activity are that DMHP side chain analogs are much more
potent than are their n-pentyl side chain homologs
(Razdan 1986), and that (+)-optical isomers are
substantially less active than are their (-)-enantiomers
(Dewey et al. 1984). These structure-activity
relationships (SAR) are based largely on studies
beginning over four decades ago with analogs of the
unnatural racemic delta-3-THC (also known as delta-6-
alpha-10-alpha-THC) and on studies beginning over two
decades ago with derivatives of (-)-delta-1-THC (also
known as (-)-trans-delta-9- THC) and (-)-delta-6-THC
(also known as (-)-trans-delta-8-THC), the latter being
the major and minor psychoactive principles of cannabis,
respectively (Mechoulam and Edery 1973). The activities
of the natural THCs (each having an n-pentyl side chain)
and a few DMHP analogs of delta-3-THC have been
determined in humans --most commonly as a function of
their cannabimimetic activity, i.e., cannabis-like
subjective effects such as the euphoric "high" (Pradhan
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1984; Razdan 1986). The (+)-THC isomers and a wider
range of DMHP analogs have been evaluated in laboratory
animals -- most commonly in dog, monkey, and/or rodent
behavioral paradigms (Dewey et al. 1984; Pradhan 1984).
The relative potencies of cannabinoids in these animal
tests are thought to be largely reflective of their
potential to produce cannabimimetic effects in humans
(Razdan 1986).
Unfortunately, many investigations carried out to date
have used impure optical isomers, such as the often-
studied  1", 2" -DMHP homologs of (-)-delta-6-THC (four
possible isomers) and racemic delta-3-THC (eight
possible isomers). Depending upon the proportion of
isomers, the racemic mixtures may show significant
variability in their potencies and activities (Pradhan
1984). Interestingly, substantial variability in
activity was cited as the reason for the termination
(Hardman et al. 1971, p. 296) of an otherwise promising
(and the only) clinical trial of DMHP analogs of THC in
epileptic patients (Davis and Ramsey 1949).
In light of the above considerations, we sought to
evaluate the stereoselectivity relationships of six
stereoisomers of THC. The compounds were assessed for
anticonvulsant and (rotorod) n eurotoxic activities in
the rat --activities which pertain to a potential
therapeutic application of cannabinoids.
MATERIALS AND METHODS
The cannabinoids employed, along with their structural
formulae, are illustrated in figure 1. (+)-Delta-6-THC,
and (+)- and (-)- stereoisomers of delta-6-THC-l", 1"-
DMHP were circa 97% optically pure, and 7-OH-delta-6-
THC-l",l"-DMHP (also known as 11-OH-trans-delta-8-THC-
1',1'- DMHP) was 99.9% optically pure. These
cannabinoids were synthesized by Mechoulam et al. (this
volume). (-)- Delta-6-THC was 96.7% optically pure and
was obtained from the National Institute on Drug Abuse.
The audiogenic seizure- (AGS-) susceptible rat model of
epilepsy (Dailey and Jobe 1985) was used to assess
anticonvulsant activity, and the rat ROT paradigm
(Dunham and Miya 1957) was used to assess differential
neurotoxicity (i.e., reflecting mainly sedation and/or
incoordination), of the THC compounds. Male, 150-200
gm, genetically epilepsy-prone rats (Dailey and Jobe
1985) were used for the AGS tests; and male, 150-200 gm
rats (Hsd: (SD)BR; Harlan Sprague Dawley Company,
Indianapolis, IN) were used for the ROT tests. As
detailed previously (Consroe and Man 1973; Consroe et
al. 1985), cannabinoids were prepared in a vehicle of
10% polysorbate 80 and 90% distilled water, and were
injected intravenously (i.v.); and rats were tested 15
60
minutes (for DMHP analogs) or 30 minutes (for the parent
THC isomers) later, the respective peak-effect times for
both tests. In the AGS test, responses to sound were
recorded as the presence or absence of seizure (i.e.,
generalized clonic convulsions). In the ROT test,
effects were measured as the ability or inability (i.e.,
neurotoxicity) of trained rats to remain on a revolving
rotorod for 60 seconds.
FIGURE 1
Separate groups of 10 to 15 rats were used for each
dose, and 3 to 6 doses of each cannabinoid were used for
each AGS and ROT test. Median effective anticonvulsant
(ED50) and neurotoxic (TD50) doses and regression line
parameters were calculated by computer-assisted probit
analysis (Dixon 1977). Subsequent calculations of 95%
confidence limits (CL) and comparisons between
and median doses (i.e.,
slopes
ED50 and TD50 potency
comparisons) were carried out by using the equations of
Litchfield and Wilcoxon (1949). We have incorporated
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these equations into a GW BASIC program for use on a
microcomputer operating under MS-DOS. Finally, the
protective index (PI) of compounds was calculated by the
usual method (i.e., PI = TD50/ED50).
RESULTS AND DISCUSSION
Table 1 presents the dose-effect parameters of the THC
stereoisomers. Comparisons among these data reveal
several salient findings.
TABLE 1
Dose-Response Parameters of Delta-6-THC Stereoisomers in
Audiogenic Seizure (AGS) and Rotorod (ROT) Neurotoxicity
Tests in Rats1
Drug ROT-TD50 AGS-ED50
(95% CL) (95% CL) PI
(-)-7-OH-THC-1",1"-DMHP 0.007 0.004 1.75
(0.005-0.009)(0.002-0.007)
(+)-7-OH-THC-l", 1"-DMHP Not active2 Not active3
(-)-THC4 1.85 4.70 0.39
(0.98-3.45) (3.11-7.09)
(+)-THC 21.66 15.23 1.42
(1g.81-23.68)(12.42-18.68)
(-)-THC-l", 1"-DMHP 0.035 0.041 0.85
(0.031-0.040) (0.037-0.046)
(+)-THC-1", 1"-DMHP 0.53 0.89 0.60
(0.37-0.76) (0.73-1.1)
1Median toxic (TD50) and effective (ED50) doses and 95%
confidence limits (CL) are in mg/kg, i.v. PI =
protective index = ROT-TD50/AGS-ED50.
2At 1.0, 7.0, and 15.0 mg/kg, i.v.; higher doses were
not tested due to insufficient quantity of drug.
3At 0.1, 1.0, and 4.0 mg/kg, i.v.; higher doses were not
tested due to insufficient quantity of drug.
4Data taken from Consroe and Man (1973).
First, the (-)-enantiomers are significantly (P < .05)
more potent (or substantially more active) than are
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their respective (+)-enantiomers in both anticonvulsant
(AGS) and neurotoxicity (ROT) tests. For anticonvulsant
activity, (-)-delta-6-THC is 3 times more potent than
(+)-delta-6-THC, and (-)-delta-6-THC- 1",1"-DMHP is 22
times more potent than (+)-delta-6-THC-1",1"- DMHP.
Also, (-)-7-OH-delta-6-THC-1",1"-DMHP is extremely
potent and its (+)-enantiomer is not active in doses up
to 1,000 times higher. For neurotoxic activity, (-)-
delta-6-THC is 12 times more potent than (+)-delta-6-
THC, and (-)-delta-6-THC-1",1"-DMHP is 15 times more
potent than (+)-delta-6-THC-1",1"-DMHP. Again, (-)-7-
OH-delta-6-THC-1",1"-DMHP is extremely potent and its
(+)- enantiomer is not active in doses up to 2,143 times
higher.
Although neither these nor any other pairs of optically
pure THC stereoisomers have been evaluated for
anticonvulsant or ROT neurotoxicity effects, the
comparative activities (or in some cases, dose-response
potencies) of the enantiomers of delta-1-THC (Dewey et
al. 1984) and of delta-6-THC (Consroe et al. 1982; Dewey
et al. 1984) have been ascertained in several other
laboratory animal paradigms. In all cases, the (-)-
isomers were more active than their respective (+)-
isomers; and for the enantiomers of delta-6-THC,
differences in activity ranged from about fourfold to
fiftyfold depending upon the species and the
pharmacological test system used. While it is clear
there is a stereoselectivity of action for the THCs,
such is not the case for cannabidiol (CBD), a
noncannabimimetic cannabinoid of cannabis. In a
previous study (Consroe et al. 1985), we found that the
natural (-)-CBD was equipotent to the unnatural (+)-CBD
in both AGS and ROT tests. These findings suggest that
stereoselective receptor mechanisms may be important for
many effects of the THCs, including their anticonvulsant
and neurotoxic activities. However, it is unlikely that
such receptor mechanisms underlie the latter effects of
CBD.
Second, the 1", 1"-DMHP and 7-OH modifications of THC
greatly increase potencies in both anticonvulsant and
neurotoxic paradigms (table 1). (-)-Delta-6-THC-l",l"-
DMHP is 115 times more potent in the AGS test and 53
times more potent in the ROT test than is (-)-delta-6-
THC. (-)-7-OH-delta-6-THC-1",1''-DMHP is 1,175 times
more potent in the AGS test and 264 times more potent in
the ROT test than is (-)-delta-6-THC. Additionally,
(+)-delta- 6-THC-1", 1"-DMHP is 17 times more potent in
the AGS test and 41 times more potent in the ROT test
than is (+)-delta-6-THC. However, the "inactivity" of
(+)-7-OH-delta-6-THC-1",1"-DMHP is an enigma. Because
of limited quantity of the latter drug, we were unable
to evaluate doses higher than 4 mg/kg in the AGS test
and 15 mg/kg in the ROT test. Nevertheless, these doses
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are not too different from the AGS-ED50 (15.23 mg/kg)
and ROT-TD50 (21.66 mg/kg) of (+)-delta-6-THC.
Aside from this apparent exception, the present results
are generally congruent with many previous data showing
potency increases with 1 ",2"-DMHP and 7-OH modifications
of the THCs (Mechoulam and Edery 1973; Pradhan 1984;
Razdan 1986). Additionally, several 1",2"-DMHP analogs
of (+/-)-delta-3-THC (i.e., compounds existing as a
mixture of 4 to 8 possible isomers) have been tested for
anticonvulsant and ROT neurotoxic activities in rodents
and their potencies compared to that of (-)-delta-1-THC
(Karler et al. 1974; Plotnikoff et al. 1975). Depending
on the analog, species, seizure test, and other
experimental conditions, potency increases ranging
from about twofold to sixteenfold were reported.
Finally, a perusal of the PIs of cannabinoids evaluated
in the present study (table 1) show that only (-)-7-OH-
delta-6-THC-l", 1"-DMHP (PI = 1.75) and (+)-delta-6-THC
(PI = 1.42) have a favorable separation between
anticonvulsant and (ROT) neurotoxic activities.
In a previous study (Consroe et al. 1985), we determined
the i.v. potencies of three major antiepileptic drugs in
our rat AGS and ROT tests. A collation of these data
indicates that the PIs of the above THC analogs are
similar to that of phenytoin (PI = 1.6), but are lower
than those of phenobarbital (PI = 2.7) and carbamazepine
(PI = 2.7). The clinical efficacy of these classic
antiepileptic drugs is unquestionably good; but the
therapeutic usefulness of each of these agents,
especially of phenytoin, is limited in many patients by
sedation, incoordination, and/or other neurologic side
effects (Livanainen and Savolainen 1983; Keranen and
Sivenius 1983). Our comparative, albeit limited,
preclinical data suggest that the THC analogs might have
this same type of therapeutic limitation. Additionally,
(-)-7-OH-delta-6-THC-1", 1"-DMHP has recently been found
to be extremely potent (and, in fact, the most potent
cannabinoid ever tested) in the drug discrimination
learning (DDL) test in rats and pigeons (Mechoulam et
al., this volume). As this test (Jarbe et al. 1981;
Weissman 1981) is a qualitative and possibly a
quantitative predictor of cannabimimetic activity, (-)-
7-OH-delta-6-THC-1",1"-DMHP would appear to be a poor
candidate for therapeutic application. On the other
hand, (+)-delta-6-THC is essentially inactive in the DDL
paradigm (Jarbe et al. 1981) and, thus, would be
predicted to have minimal, if any, cannabimimetic
activity. While the presently determined PI of (+)-
delta-6-THC is certainly not optimum, other (+)-THC
analogs might have better selectivity of anticonvulsant
activity relative to neurotoxic action. Further
evaluation of (+)-THC analogs, such as (+)-7-OH-delta-6-
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THC-1", 1"-DMHP , would appear to be an important
endeavor for future research in this area.
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Different Cannabinoids Exhibit
Different Electrophysiological
Properties
Stuart A. Turkanis, Ph.D., and Ralph Karler, Ph.D.
INTRODUCTION
Delta-9-tetrahydrocannabinol (THC) is a nonselective, centrally active drug that
produces a wide variety of pharmacological effects (Truitt and Braude 1974;
Paton 1975); for example, in conscious animals, this cannabinoid causes a
complex mixture of central depressant and excitatory responses ranging from
sedation, anticonvulsant effects, and motor toxicity to overt convulsions (Karler
and Turkanis 1981). Fifteen years ago there were few marijuana-related
electrophysiological investigations, and those mainly involved marijuana extracts
(Boyd et al. 1971, 1974; Pirch et al. 1972; Truitt and Braude 1974; Paton 1975);
consequently, we began a series of electrophysiological investigations of the
pharmacological properties of THC. Our approach was multifarious: 1) to
evaluate the cannabinoid’s responses at various levels of organization ranging
from the cerebral cortex to the neuromuscular junction, 2) to assess the drug’s
effects on pools of neurons as well as on single excitable cells, 3) to use
conscious animals when possible in order to avoid the confounding problems of
anesthesia, and 4) to evaluate the active form of the cannabinoid by using in
vitro test preparations. The goals of our research were twofold: to describe the
electrophysiological effects of THC, and to uncover possible synaptic mechanisms
of action for these effects.
Another important feature of our research has been the electrophysiological
evaluation of the properties of cannabidiol (CBD), a drug that was seldom
studied prior to our work because it was considered to be pharmacologically
inactive (Hollister 1973). The data presented here represent an extensive
comparison of the properties of the psychoactive THC with the nonpsychoactive
CBD (Perez-Reyes et al. 1973). In addition, it is well documented that THC is
metabolized in vivo to various pharmacologically active metabolites (Burstein
1973); therefore, in order to understand the pharmacology of the parent drug, it
is necessary to determine the properties of its active metabolites. For this reason,
we comparatively evaluated the effects of THC’s principal metabolite, 11-
hydroxy-THC, and its hydroxylated metabolites. The findings demonstrate that
different cannabinoids can produce markedly different neuropharmacological
responses.
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METHODS
The procedures for the study of the electrophysiological preparations and
descriptions of the experimental designs of the various cannabinoid studies have
been published in detail elsewhere: electrically produced transcallosal cortical
evoked responses in rats (Turkanis and Karler 1981a), photically evoked cortical
after discharges in rats (Turkanis et al. 1977), cobalt-caused epilepsy in rats (Chiu
et al. 1979), iron-caused epilepsy in rats (Turkanis and Karler 1982), electrically
induced limbic afterdischarges in rats (Smiley et al. 1979), cat spinal-cord
preparation (Turkanis and Karler 1983, 1984a, 1986), isolated bullfrog ganglia
(Turkanis and Karler 1975), and isolated frog sartorius neuromuscular junctions
(Turkanis and Karler, in press).
For parenteral preparations, the cannabinoids were dispersed in isotonic sodium-
chloride solution with the aid of Tween 80 and ultrasound (Turkanis et al. 1974).
For bathing solutions, the cannabinoids were dispersed in Ringer solutions with
the nonionic detergent Pluronic F68 and ultrasound (Turkanis and Karler 1975,
in press). Pentylenetetrazol (PTZ) was dissolved in isotonic sodium-chloride
solution. Vehicle and drug preparations were administered intraperitoneally (i.p.)
for the cortical and limbic studies and intravenously (i.v.) for the spinal-cord
studies.
RESULTS
The effects of THC, CBD, and PTZ on the amplitude of the initial phase of
transcallosal cortical evoked responses in rats were investigated (Turkanis and
Karler 1981a). Specifically, THC in the lower dosage range (0. 1-1.0 mg/kg)
markedly increased the evoked response amplitude, whereas higher dosages (1.2-
6.0 mg/kg) elicited only depression. Our reference convulsant, PTZ, in
subconvulsant doses (10-20 mg/kg), like THC, enhanced potential amplitude.
Both THC and PTZ also increased electrically caused cortical evoked potentials in
the monkey (Boyd et al. 1971). In contrast, CBD over a wide dosage range (0.l-
80 mg/kg) exerted only depressant effects. In summary, the findings
demonstrate qualitative differences in the pharmacological properties of the two
cannabinoids.
We also compared the effects of THC, CBD, and PTZ on photically evoked
cortical afterdischarges in rats (Turkanis et al. 1977); THC (5-10 mg/kg), but not
CBD, produced a PTZ-like increase of cortical potentials. In contrast to the
results with electrically caused responses, high THC doses (50-100 mg/kg) did
not affect photic potentials; furthermore, neither THC nor CBD displayed any
depressant properties in this test system.
The results of our limbic afterdischarge investigations also demonstrate that THC
and CBD exhibit different neuropharmacological properties (Smiley et al. 1979).
THC in a dosage range of 0.3 to 3.0 mg/kg elicited only a threshold increase--a
depressant response; doses of 5 to 15 mg/kg, however, caused an even greater
rise in threshold, but also a prolongation of the afterdischarge. This prolongation
of the response is an electrophysiological manifestation of the drug’s excitatory
properties. In contrast to THC, CBD (0.3-200 mg/kg) only depressed the
afterdischarge; that is, it increased the threshold, shortened the duration, and
reduced the amplitude. In summary, low THC doses and all CBD doses yielded
depression, whereas relatively high THC doses produced concurrent excitation
and depression of the limbic afterdischarge.
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The effects of cannabinoid on iron-epileptic rats are complex: THC (1-20 mg/
kg) elicited excitation by producing behavioral signs of central nervous system
(CNS) stimulation, generalized bursts of epileptiform potentials, and frank
convulsions (table 1 and figure 1); in addition, it produced depression by causing
motor toxicity and reduction of focal epileptic activity (table 1 and figures 1 and
2).
TABLE 1
Influences of Cannabinoids on Conscious Iron-Epileptic
Rats with Chronically Implanted Cortical Electrodes
Treatment Dosage
Range
Focal Precipita- Bursts CNS Motor
Epileptic tion of of Epilep- Excita- Toxicity
Activity Convul- tiform tion
sions Potentials
(mg/kg,
i.p.)
THC
11 -Hydroxy-
THC
 8-Beta-
hydroxy-
THC
CBD
PTZ
l-20 - Yes
l-20 - No
0.5-20 0 Yes
l-100 0 No
5-20 0 Yes
Yes
Yes
Yes
No
Yes
Yes
Yes
No
No
No
Yes
Yes
No
No*
No
- = decrease; 0 = no change. Each drug was studied in at least six different
experiments. Behavioral signs of CNS excitation were vocalization, hissing, and
jumping. For additional details, refer to figures 1 and 2 and to Turkanis and
Karler 1982.
*The median-effective motor-toxic dose of CBD in nonepileptic control rats is
173 mg/kg, i.p. (Smiley et al. 1979).
11-Hydroxy-THC (1-20 mg/kg) exerted THC-like effects with one major
exception; that is, it did not precipitate convulsions (table 1 and figure 2). The
properties of 8-beta-hydroxy-THC, another THC metabolite, were different
compared with those of either the parent compound or the 11-hydroxy
metabolite. In doses of 0.5 to 20 mg/kg, it exerted only excitation, as evidenced
by bursts of epileptiform potentials and convulsions (table 1 and figures 1 and 2).
In contrast, CBD, even in doses up to 100 mg/kg, was devoid of all of THC’s
effects. In addition, pretreatment with CBD markedly altered the responses to
THC in the following ways: Focal depression was partially blocked, generalized
epileptiform activity was enhanced, and convulsions were abolished. In general,
the cannabinoids exhibited a wide spectrum of CNS effects in iron-epileptic rats,
functional significance of the cannabinoid-caused generalized but the
pharmacological profile of each agent was demonstrably different. The bursts of
functional significance of the cannabinoid-caused generalized epileptiform
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FIGURE 1. Influences of cannabinoids on electrocorticogram of conscious iron-
epileptic rats. The iron-caused epileptic focus was located in the parietal cortex;
recordings were obtained from screw electrodes chronically implanted on the focus
and other cortical sites. The position of the iron focus was identical to that of the
cobalt focus (figure 3 and table 2). A1 depicts recording 15 min after vehicle;
A2, recording 15 min after THC. B illustrates generalized bursts of epileptijorm
potentials jrom three different rats: B1 and B2 represent potentials observed 45-
60 min after THC: B3 and B4, potentials 15-20 min after 8-beta-hydroxy-THC;
B5 and B6, potentials 10-15 min after PTZ (adapted from Turkanis and Karler
1982).
potentials is unknown, but these potentials look like the electrical manifestation
of a seizure. In support of such a possibility, the convulsant control PTZ
produced seizurelike discharges that are indistinguishable from those caused by
THC and its metabolites (table 1 and figure 1). In addition, THC and its
metabolites also evoked these generalized seizurelike discharges in nonepileptic
control rats.
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FIGURE 2. Influences of cannabinoids on iron-induced focal epileptic potentials
in conscious rats. Throughout each experiment, focal electrocorticograms and
integrals of the electrocorticogram voltage were recorded. The data shown are
maximum changes in the integrals of the electrocorticographic voltage over a 5-
min period, which are expressed as a percentage of the internal vehicle control
values obtained in each experiment. Percentage oj control focal activity is plotted
against the cumulative dose. Each dose-effect curve represents the results
obtained from an experiment with one rat. For additional details, refer to
figure 1 and to Turkanis and Karler 1982. Copyright 1982 by Pergamon Press
(New York).
The effects of THC, its 11-hydroxy metabolite, and CBD were assessed in
cobalt-epileptic rats. As shown in table 2 and in figure 3, THC (0.5-100 mg/kg)
increased the frequency of focal epileptic potentials, elicited generalized bursts of
epileptiform potentials, and precipitated or exacerbated convulsions.
11-Hydroxy-THC (1.0-20 mg/kg) exerted only one of the three THC excitatory
responses, namely, bursts of epileptiform potentials. Again, CBD (0.5-200
mg/kg) only produced depression-suppression of the spontaneous convulsions.
Each of the drugs, therefore, produced characteristic effects in this test system.
The five investigations with conscious animals described above involved pools of
cortical and limbic neurons, and the results demonstrated that the cannabinoids
can exert a complex mixture of excitatory and depressant electrophysiological
effects. The next step in our research program was to uncover possible synaptic
sites and mechanisms of cannabinoid actions. Initial studies with cat spinal
monosynaptic reflexes indicated that cannabinoid effects at this level were
comparable to those in higher centers. Specifically, THC in low doses (0.05-
0.15 mg/kg, i.v.) increased the reflex itself and posttetanic potentiation (PTP),
whereas higher doses of THC (0.2-0.75 mg/kg, i.v.) and all doses of CBD
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TABLE 2
Influences of Cannabinoids on Conscious
Cobalt-Epileptic Rats with Chronically
Implanted Cortical Electrodes
Treatment Dosage Range Frequency Effect on Bursts of
(mg/kg, i.p.) of Focal Convulsions Epilepti-
Epileptic form
Potentials Potentials
THC 0.5-100 + + Yes
11-Hydroxy-
THC 1 0-20 0 0 Yes
CBD 0.5-200 0 No
+ = increase; - = decrease; 0 = no change. THC and CBD were studied in eight
epileptic rats, and 11-hydroxy-THC was studied in three animals due to a limited
drug supply. The production of generalized bursts of epileptiform cortical
potentials by THC and its metabolite also occurred in control rats. For additional
details, refer to figure 3 and to Chiu et al. 1979.
FIGURE 3. Influence of THC and CBD on frequency of spontaneously firing
focal epileptic potentials recorded from a cobalt-induced focus in the left parietal
cortex. Each point represents the results from a different conscious rat and is the
maximum frequency expressed as a percentage of predrug vehicle control. For
additional details, refer to table 2 and to Turkanis and Karler 1981b. Copyright
1981 by The American College of Clinical Pharmacology (New York).
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(0.05-14 mg/kg, i.v.) were only depressant (Tramposch et al. 1981; Turkanis and
Karler 1984a). In this context, intracellular recording techniques were used on
single spinal motoneurons in order to define the cannabinoids’ synaptic
pharmacology.
FIGURE 4. Excitatory effects of THC on electrophysiological responses of single
spinal motoneurons in spinal cats. Each trace represents the electronically
obtained average of 16 consecutive potentials. A and B are from two different
cats. A depicts THC-caused increase of EPSP amplitude: AI, control response
20 min after vehicle; A2, response 20 min after drug. The increase in amplitude
is at least partially attributable to an increase in membrane resistance. EPSPs
were recorded jrom a triceps surae motoneuron. B depicts THC-caused limited
depression of IPSP amplitude: B2, control response 20 min after vehicle: Bs,
response 20 min after drug; B3, response 30 min after drug. The figure
illustrates the limited efficacy of THC in reducing the amplitude of lPSPs
because the effect of 10 mg/kg (B3) is no greater than that of 0.1 mg/kg (B2).
For additional details, refer to table 3. (Adapted from Turkanis and Karler
1983.)
THC effects on the parameters of single spinal motoneurons are compli-
cated: The drug (0.01-0.1 mg/kg) produced excitation by increasing excitatory
postsynaptic potentials (EPSPs) and by decreasing inhibitory postsynaptic
potentials (IPSPs) (table 3 and figure 4).
THC’s responses on the two synaptic potentials appear to be unrelated to
alterations of the afferent input because up to 10 mg/kg, i.v., of the drug had no
measurable effects on compound-nerve action potentials recorded from the dorsal
roots (Turkanis and Karler 1984b). EPSP enhancement, however, is at least
partially attributable to an increase in membrane resistance (table 3). In addition
to excitation, THC produced depression by raising the firing threshold and
reducing soma action-potential amplitude (table 3); thus, in single neurons, as in
conscious animals and pools of neurons, the cannabinoid exerted dual effects.
11-Hydroxy-THC’s effects were similar to those of the parent compound, except
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TABLE 3
Influences of Cannabinoids on the Afferent
Input and on Single Spinal-Motoneuron
Parameters in Spinal Cats
Treatment EPSP Membrane IPSP Firing Nerve Soma
Ampli- Resis- Ampli- Thresh- Action Action
tude tance tude old Potential Potential
THC + + - + 0 -
11-Hydroxy-
THC + + 0 + 0 -
CBD - 0 0 + 0 -
+ = increase; - = decrease; 0 = no change. All of the effects occurred between
0.01 and 0.1 mg/kg, i.v., except for the reduction of the soma action potentials;
the latter was affected by 0.2-0.5 mg/kg 11-hydroxy-THC and 1-5 mg/kg THC
and CBD. Compound nerve-action potentials (afferent input) were recorded
extracellularly from dorsal roots; the other measurements were made with
intracellular microelectrodes from motoneuron somas. Measurement of excitatory
EPSPs, IPSPs, membrane resistance, and firing threshold were made from single
spinal motoneurons with intracellular glass microelectrodes filled with 3M
potassium-acetate solution. EPSPs were evoked by stimulating the triceps surae
or posterior-biceps semitendinosus nerves, and IPSPs were evoked by stimulating
the quadriceps nerve. Membrane resistance was determined by passing sufficient
current to produce small depolarizations. The threshold for the production of the
soma potential was the voltage required to fire the cell consistently. For
additional details, refer to figures 4 and 5 and to Turkanis and Karler 1983,
1984a, 1984b, 1986.
that the metabolite did not depress IPSPs (table 3). Again, CBD (0.1-5 mg/kg)
was only a depressant; that is, it raised the firing threshold, depressed the
amplitude of soma action potentials, and reduced the EPSP amplitude (table 3
and figure 5). In relation to mechanisms and sites of drug action, the
cannabinoids’ effects on the firing threshold and amplitude of soma action
potentials and on membrane resistance indicate that changes in postsynaptic ionic
conductances are involved.
Subsequent cannabinoid investigations were carried out with isolated synaptic
preparations. The goals of these studies were twofold: to determine the active
form of the cannabinoid by avoiding in vivo drug metabolism, and to uncover
possible synaptic mechanisms and sites of drug action. To this end, the effects
of several cannabinoids were evaluated on PTP of extracellularly recorded action
potentials in isolated bullfrog ganglia: Two THC metabolites, 11-hydroxy-THC
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FIGURE 5. Depressant effects of CBD on electrophysiological responses of
single spinal motoneurons in spinal cats. Traces in A are electronically obtained
averages of 16 consecutive potentials: traces in B and C are of single potentials.
A, B, and C are from three different cats. A depicts CBD-caused depression of
EPSP amplitude; responses measured 30 min after vehicle and 30 min after drug.
B illustrates CBD-elicited increase in firing threshold; responses measured 20 min
after vehicle and 20 min after drug. C shows the CBD-caused depression of the
soma action potential; responses measured 30 min after vehicle and 30 min after
drug. The effects shown in A, B, and C are not the result of changes in
membrane resistance or resting membrane potential. For additional details, refer
to table 3. (Adapted from Turkanis and Karler 1986.)
and 8-alpha, 11-dihydroxy-THC, in low concentrations (01.-0.33 µM) reduced
PTP, whereas THC, in concentrations as high as 25µM, exerted no effect (figure
6).
Drug-induced changes in PTP may also relate to THC’s anticonvulsant as well as
to its convulsant properties, since a reduction in PTP has been reported to be an
electrophysiological mechanism of action for such antiepileptic agents as
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FIGURE 6. Influences of cannabinoids on PTP at isolated bullfrog paravertebral
ganglia X. PTP was defined as an increase in the amplitude of the extracellu-
cellularly recorded ganglionic potentials following a period of tetanic stimulation
and is expressed as the ratio of posttetanic to pretetanic potential amplitudes.
Bracketed o = the mean and standard deviation of four control values; values
60 min after drug treatment. Raising the THC concentration above 25 µM
reduced the amplitude of the pretetanic potential, thereby invalidating calculations
of PTP (Turkanis and Karler 1975). Copyright 1975 by Pergamon Press (New
York).
phenytoin (Esplin 1957). Our research demonstrates that THC in vivo, depending
upon the dose, can either increase or decrease PTP of cat spinal monosynaptic
reflexes; therefore, similar effects in higher centers may contribute to the drug’s
convulsant and anticonvulsant properties. Our CBD results with spinal reflexes
substantiate a role for PTP because the drug only depresses PTP and is only
anticonvulsant.
The cannabinoids’ effects on IPSPs of spinal motoneurons may also provide a
possible explanation for THC’s convulsant properties. In this instance, THC, like
the convulsant strychnine (Kuno and Weakly 1972), reduces the amplitude of
spinal motoneuron IPSPs. The 11-hydroxy-THC data are consistent with
involvement of inhibitory potentials because the metabolite, unlike THC, does
not affect IPSPs and is not a convulsant. On the other hand, THC, unlike
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strychnine, precipitates convulsions only in special circumstances; that is, in
cobalt- and iron-epileptic rats (tables 1 and 2), in epileptic beagles (Feeney
1979), and in a special strain of rabbits (Martin and Consroe 1976). The reason
for the restricted convulsant activity of THC may be due to its limited efficacy
in reducing inhibitory potentials. In short, the cannabinoids’ anticonvulsant and
convulsant activities are probably associated with several pharmacological
properties of the drugs as well as related to the susceptibility of the subjects.
Intracellular recordings from such single cells as spinal motoneurons and
neuromuscular junctions may provide information about possible electro-
physiological mechanisms and sites of the cannabinoids’ central actions. First,
the synapse is likely to be the major site of drug action: As demonstrated in in
vivo experiments, synapses are affected by relatively low THC doses (0.01-0.1
mg/kg, i.v.), whereas doses up to 10 mg/kg, i.v., failed to modify compound
action potentials of axons (table 3). Second, cannabinoids can exert both pre-
and post-synaptic effects; for example, THC caused excitation presynaptically by
enhancing neurotransmitter release and postsynaptically by increasing membrane
resistance. In addition, THC produced depression presynaptically by reducing
neurotransmitter release and postsynaptically by decreasing neurotransmitter
response. Lastly, cannabinoid-induced effects on the motoneuron soma, that is,
changes in membrane resistance, firing threshold, and action-potential amplitude,
indicate that the drugs alter postsynaptic ionic conductances. Depression of
neurotransmitter responses may be due to drug-receptor interactions or to
changes in postsynaptic ionic conductances. Nevertheless, if these drug responses
occur in the CNS, they suggest possible mechanisms and synaptic sites of action
for the cannabinoids’ central excitatory and depressant properties, and the
consistent pattern of the drugs’ effects at every level of organization studied--
from the cerebral cortex to the neuromuscular junction--validate these
conclusions.
It is possible that a higher THC concentration might reduce PTP, but raising the
concentration above 25 µM markedly reduced the amplitude of the pretetanic
potential and invalidated the calculation of PTP. These findings support those of
Brady and Carbone (1973), who found that 11-hydroxy-THC, but not the parent
compound, depressed the action potentials of squid giant axons. Like THC’s
metabolites, CBD (33-100 µM) was pharmacologically active; that is, it reduced
PTP. It is noteworthy that the isolated ganglion, like the squid axon, only
displayed depression in response to the cannabinoids.
The purpose of the next study was to determine whether THC affects neuro-
transmitter release in an electrophysiologically functional system; specifically,
a preparation in which nerve-action potentials release neurotransmitter. To
accomplish this aim, we evaluated the influences of THC on neurotransmitter
release by determining electrophysiologically the mean quantum content of the
endplate potential (m) (Katz 1969). A neuromuscular preparation was selected
because it is one of the limited number of preparations in which m can be
measured, while the rationale for using a cholinergic system was that
cannabinoids have been reported to affect cholinergic pathways (Drew and Miller
1974); therefore, intracellular recording techniques were used with isolated frog
sartorius neuromuscular junctions to describe the effects on transmitter release
(Turkanis and Karler, in press). The results were again complex: The frequency
of miniature endplate potentials (m.e.p.ps) was increased by THC, decreased by
CBD, and unaffected by 11-hydroxy-THC, whereas m.e.p.ps amplitude was
depressed by all three cannabinoids. In addition, m was first increased and then
decreased by THC and its 11-hydroxy metabolite, but CBD produced only
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depression. Changes in m and m.e.p.ps frequency indicate presynaptic sites of
drug action, and reduction of m.e.p.ps amplitude suggests a postsynaptic site.
The pre- and post-synaptic effects described here are possible mechanisms of
action for the drug-caused amplitude changes of evoked and synaptic potentials
in the CNS.
DISCUSSION
At every level of organization studied--from pools of cortical neurons to
individual spinal motoneurons and neuromuscular junctions--the cannabinoids
produce excitation and/or depression. This pattern of drug response suggests that
the observed effects on single neurons may account for the mechanisms of action
of the cannabinoids in conscious animals; for example, if the effects on single
spinal motoneurons are applicable to higher centers, then they may contribute to
the cannabinoids’ anticonvulsant activity. In fact, THC and CBD raise thresholds
for electrically induced minimal convulsions in conscious animals (Karler and
Turkanis 1981b), and the drugs raise the threshold for electrically induced
afterdischarge (seizure discharges) in pools of limbic neurons (table 3). Both
effects reflect the drugs’ anticonvulsant activity, and both effects may be the
direct result of an increased firing threshold in individual neurons.
The results of comparative electrophysiological investigations of THC with its
11-hydroxy metabolite can be classified, as shown in table 4, into three
categories: In the first, both drugs produced similar responses; that is, the two
drugs were either equipotent or 11-hydroxy-THC was more potent than the
parent cannabinoid; for example, dose-effect relations for depression of cobalt-
induced focal epileptic activity were identical for both drugs; in contrast, the 11-
hydroxy metabolite was 10 times more potent than THC in the production of
generalized cortical bursts of epileptiform potentials in cobalt-epileptic rats. In
the second category, only THC has pharmacological activity (table 4). Finally, in
two in vitro test systems, only 11-hydroxy-THC has activity (table 4). In this
case, the interpretation of the findings is not complicated by drug metabolism,
and the data suggest that the 11-hydroxy derivative may account for some of the
in vivo responses to the parent drug. In brief, the results indicate that there are
both quantitative and qualitative differences between THC and its principal
metabolite and that, depending upon the effect, the metabolite may contribute to,
be dissociated from, or account for THC’s activity.
The data also demonstrate marked differences in the neuropharmacological
properties of two major marijuana constituents, that is, THC and CBD. These
findings confirm our previously drawn conclusions (Turkanis and Karler
1981b): First, THC is a nonselective, centrally active drug producing both
excitation and depression; second, CBD is a relatively selective central depressant.
In fact, CBD appears to be devoid of all of THC’s central stimulatory properties,
including psychotoxicity. In general, the results of the electrophysiological
studies of the cannabinoids repeatedly illustrate that different cannabinoids
possess different properties.
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TABLE 4
Comparison of the Electrophysiological Effects
of THC and its 11-Hydroxy Metabolite
I. Responses produced by both cannabinoids:
A. Cortical bursts of epileptiform potentials in cobalt- and
iron-epileptic rats,
B. Depression of cortical focal epileptic activity in iron-epileptic rats,
C. Enhancement of spinal motoneuron EPSPs,
D. Increase in motoneuron membrane resistance,
E. Depression of motoneuron action potential,
F. Depression of m.e.p.ps amplitude, and
G. Increase and subsequent decrease of mean quantum content of
endplate potentials.
II. Responses produced only by THC:
A. Depression of spinal motoneuron IPSP, and
B. Enhancement of m.e.p.ps frequency.
III. Responses produced only by 11-hydroxy-THC:
A. Depression of PTP at isolated bullfrog ganglia, and
B. Depression of action potentials of isolated squid giant axons
(Brady and Carbone 1973).
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Molecular Determinants for
Cannabinoid Activity: Refinement
of a Molecular Reactivity Template
Patricia H. Reggio, Ph.D.
INTRODUCTION
Numerous studies of structure-activity relationships (SARs) in the cannabinoid
series have been published; e.g., see review by Sofia (1978) and some more recent
work by Martin et al. (1984a, 1984b) and Narimatsu et al. (1985). An
observation which emerges from a review of all of these studies is that some
cannabinoids can be structurally dissimilar as in delta-9-tetrahydrocannabinol
(delta-9-THC) and Abbott 40656 (Rosell et al. 1979) and yet can have similar
activities; whereas others, which show only slight structural differences as in 10-
alpha-OH-delta-8-THC and 10-beta-OH-delta-8-THC (Edery et al. 1971). can
exhibit dramatic activity differences (figure 1). This observation emphasizes that
a common basis for the activity of these compounds must be sought in more than
their mere three-dimensional structures.
Traditionally, cannabinoid SARs have been focused almost entirely on the
independent contribution of certain structural groups ("functional groups") of the
molecules. These SARs have been compiled into extensive "lists of requirements"
(Razdan 1984). Certain regions or conformations of the molecules have been
proposed to be important. These regions or conformations include a methyl
group in the plane of the aromatic ring, a free phenol, and a free C-4(C-5’)
aromatic position (Edery et al. 1971); the phenolic hydroxyl group (Uliss et al.
1975); the side chain (Osgood et al. 1978); nonplanarity (Binder et al. 1979); and
planarity of the molecule (Burstein et al. 1983). Stereoselectivity in the activity
of the tetrahydrocannabinols has been reported (Dewey et al. 1984). This type of
approach in SAR studies often assumes the following: that functional groups
must react directly with specific sites in the receptor, that modification of one
group does not affect the reactivity of another, and that geometric and
stereometric factors, such as distance and spatial relationships between functional
groups, are all important. Such focus on isolated aspects of the cannabinoids
ignores the fact that the molecular properties that are directly responsible for the
molecular interactions (that lead to the pharmacological effect) are encoded in the
entire molecular structure. To date, no characterization of the entire molecule
and correlation of this characterization with activity has been attempted in the
cannabinoid field.
The importance of quantum chemical methods in describing the physical and
chemical properties of molecules is evident in every facet of modern chemical
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FIGURE 1. Cannabinoids (a) which are structurally dissimilar yet exhibit similar
activities, and (b) which are structurally similar yet exhibit different activities.
From Reggio and Mazurek 1987. Copyright 1986 by Elsevier Science Publishers
B.V. (Amsterdam).
research and is very well documented. In the study of biological systems,
experimental data must be obtained in a variety of forms and from many
different sources. The value of quantum chemical approaches to the study of
biological systems is in an ability to analyze, interpret, and rationalize all
experimental observations on molecular processes in a unified language based on
the primary principles of physics. Considerable evidence exists proving the
relative success of theoretical approaches. These approaches have elucidated
specific mechanisms of drug action, have provided a basis for rational drug
design, and have led to conclusions about the nature of drug-receptor
interactions (Dearden 1983; Vida and Gordon 1984). We have used theoretical
approaches to successfully describe the molecular determinants for binding of
methylenedioxytryptamines at SHT/LSD receptors (Reggio et al. 1981) and have
also used theoretical approaches to explain the role that tautormerism plays in the
activation of the histamine-H2 receptor by 2-methyl and 4-methylhistamine
(Reggio and Mazurek 1987). The basic assumption in any of these theoretical
studies of drug action is that the interaction between drugs and their biological
targets is dependent on the same molecular parameters that determine chemical
interactions and reactions. Molecular Reactivity Characteristics (MRCs) such as
molecular electrostatic potentials (MEP), polarizabilities, and proton affinities are
molecular properties that determine specific chemical reactivity. In theoretical
studies of structure-activity relationships, such MRCs are used to establish how
the information necessary for receptor recognition and activation is encoded in
the molecular structure of the drug.
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Despite the extensive application of theoretical methods in the study of many
pharmacological systems, very little attention has been focused on the
cannabinoids to date. Those theoretical studies on cannabinoids which have been
published have not focused on the calculation of molecular reactivity
characteristics. Most of these studies have concentrated on the calculation of
conformation in an attempt to predict the most probable geometry (lowest energy
conformer) and its relation to activity. The structures and energies of delta-9-
THC and three other cannabinoids obtained by Westheimer calculations and
extended Huckel molecular orbital calculations have been reported (Archer et al.
1970). Theoretical studies of cannabinoids with analgetic and anticonvulsant
activity have also been reported (Johnson et al. 1982; Tamir et al. 1980). The
work presented here extends beyond the considerations which have prevailed in
theoretical studies of the cannabinoids. The aim of this work is to reveal
elements of molecular reactivity that are related to psychopharmacological
activity.
A major step in identifying the MRCs necessary for cannabinoid activity was to
select a template molecule (a molecule with demonstrated activity whose MRCs
can be used as a basis for comparison with those of other cannabinoids). Since
(-)trans-delta-9-THC (delta-9-THC) has been reported to be the major
psychoactive component of cannabis (Gaoni and Mechoulam 1964, 1971) and
since studies indicate that it can exert behavioral effects without metabolic
activation (Carney et al. 1979), delta-9-THC was chosen as the template molecule
for this study. Figure 2 illustrates the numbering systems which are commonly
employed in the literature for delta-9-THC.
FIGURE 2. An illustration of the two numbering systems which are commonly
employed for the cannabinoids. From Reggio and Mazurek 1987. Copyright 1986
by Elsevier Science Publishers B.V. (Amsterdam).
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Our first working hypothesis deals with two components of the delta-9-THC
structure which confer reactivating characteristics upon the molecule that are
crucial to activity. These components are the lone pairs of electrons of the
phenol oxygen (these lone pairs generate reactivity properties dependent on the
orientation of the OH bond relative to the carbocyclic ring, Ring A), and the
orientation of the carbocyclic ring, Ring A (this ring and its orientation generate
hydrophobic properties). The spatial arrangements of these reactivity
characteristics are the components of the template to which the characteristics of
other cannabinoids can subsequently be compared.
Template for Cannabinoid Activity
Recently, we reported the characterization of the template molecule delta-9-THC
(Reggio and Mazurek, 1987). Since the molecular reactivity characteristics of
delta-9-THC are to be used as a basis of comparison with other cannabinoids,
the essential features of the template are presented here. The reader should refer
to the original paper (Reggio and Mazurek 1987), however, for all calculational
details.
The lowest energy conformer of delta-9-THC as obtained by conformational
analysis is shown in figure 3. It is clear from this figure that delta-9-THC is a
nonplanar molecule. The carbocyclic ring (Ring A) of delta-9-THC exists in a
half-chair conformation. Ring B assumes a conformation such that the axial C6
methyl group is on the same side of the molecule as H
H10a than is the other methyl group. In this optimized
10a and is much closer to
structure, the phenolic
hydrogen points away from the carbocyclic ring (dihedral angle, C2-C1-0-H = -
lo). Figure 4 shows a different perspective of the molecule. Here, delta-9-THC
is shown in the direction parallel to the vector from C2 to C10b.From this
perspective, the conformation of the carbocyclic ring (Ring A) causes the top
part of the ring to move to the left, thus permitting no protrusion of Ring A into
the bottom face of the molecule. It is part of our working hypothesis that this
orientation is necessary for cannabinoid activity. The conformation of the
carbocyclic ring may allow for nondirectional hydrophobic interactions.
The lone pairs of electrons of the phenol oxygen generate directional reactivity
properties dependent on the orientation of the OH bond relative to the
carbocyclic ring. Studies of molecular energy as a function of rotation about the
C1-O axis reveal that two minimum energy conformations of the phenolic OH
exist. In Conformation I, the phenolic OH is slightly bent out of the plane of
the aromatic ring with the hydrogen pointing away from Ring A (C2-C1-O-H
dihedral angle,  = -1°). In Conformation II, the phenolic hydrogen is below the
plane of the aromatic ring and is pointing toward Ring A ( = 155°). The
conformation of the rest of the molecule remains essentially unchanged.
The molecular electrostatic potential (MEP) is a molecular reactivity characteristic
that determines specific chemical reactivity. It is an important determinant of
drug action. The electrostatic potential field extends into space and influences
nearby molecules. Unless the fields of a drug and its receptor are complemen-
tary, they will not attract or bind to one another. Indeed, electrostatic forces
appear to guide an incoming drug into its receptor site and align so that shorter
range binding forces can take effect (Tucker 1984). Therefore, a very direct
indication of the nature and extent of electrostatic drug-receptor interactions can
be obtained by mapping the potential generated by a molecule.
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FIGURE 3. Conformation of delta-9-THC (with propyl side chain) as
determined by MM2. From Reggio and Mazurek 1987. Copyright 1986 by
Elsevier Science Publishers B.V. (Amsterdam).
FIGURE 4. Conformation of delta-9-THC as determined by MM2: here the
perspective of Ring A is viewed in the direction parallel to the vector from C2 to
C10b . From Reggio and Mazurek 1987. Copyright 1986 by Elsevier Science
Publishers B.V. (Amsterdam).
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The calculated electrostatic potential patterns generated by the bottom face of
delta-9-THC in each of its minimum energy conformers are shown in figures 5
and 6. These patterns are composed of lines of equipotential energy in kcal/mole
that would be felt by a test positive charge placed at any specified point on the
map. Figures 5 and 6 illustrate the regions of negative potential in planes
parallel to the benzene ring at distances of 1.5 Ås below the plane of the ring.
Because delta-9-THC is a nonplanar molecule. the MEPs differ depending upon
whether the molecule is viewed from above or below. We found that the change
in the position of the phenol group from Conformation I to Conformation II
caused a distinguishable difference in the MEPs of the two conformers when
viewed from the bottom face.
At this stage of the investigation, it was impossible to identify which conforma-
tion of the phenolic OH of delta-9-THC (I or II) was more relevant at the site of
action. Hence, the MEPs shown in figures 5 and 6 along with the conformation
of Ring A, as illustrated in figure 4, formed the preliminary set of molecular
reactivity characteristics for cannabinoid activity.
Refinement of the Template
In order to refine our template, a comparison of the MRCs of delta-9-THC with
those of another cannabinoid was undertaken. Edery et al. (1971) reported that
in rhesus monkey behavioral tests the replacement of the phenolic hydrogen of
delta-9-THC with a methyl group renders the molecule inactive. This inactive
cannabinoid, O-methyl-delta-9-THC (figure 7), was selected for comparison in
order to assess the importance of the position of the lone pairs of electrons of the
phenol oxygen. We report here the results of our comparison of the properties of
O-methyl-delta-9-THC with those of the delta-9-THC reactivity template.
METHODS OF PROCEDURE
Conformational Study of O-Methyl-Delta-9-THC
The first step in the characterization was the conformational analysis of O-
methyl-delta-9-THC. The force field or molecular mechanics method as encoded
in the program MM2 (Allinger and Yuh 1980) was used in this analysis. The
force field available in MM2 has been parameterized for oxygen containing
molecules and has proven satisfactory for the calculation of structures and
energies of oxygen containing compounds (Allinger et al. 1980). The X-ray
structure of delta-9-THC Acid B (Rosenquist and Ottersen 1975) was used to
obtain an input geometry (i.e., bond lengths, bond angles, and dihedral angles for
the fused ring skeleton of delta-9-THC). Necessary atoms were added to this
skeleton at standard bond lengths and bond angles (Mitchell and Cross 1965) to
produce an input geometry for O-methyl-delta-9-THC in the MM2 calculation.
In the calculational scheme for the template molecule, delta-9-THC, molecular
size constraints necessitated reducing the pentyl side chain to propyl (Reggio and
Mazurek 1987). In order to maintain consistency, the side chain in O-methyl-
delta-9-THC was also reduced to propyl. Such a modification was acceptable
since the focus of this study is on the fused ring structure and the phenol group
and not on the side chain.
Because the position of the methoxy group was very important to our working
hypothesis, two studies of the molecular energy as a function of rotation about
the C1-O axis were conducted. In the first study, the dihedral driver option in
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FIGURE 5. Molecular electrostatic potential of the bottom face of delta-9-THC
(Conformational I). Contours represent the MEP in a plane 1.5Å below the
aromatic ring. Values are in Kcal/mole. From Reggio and Mazurek 1987.
Copyright 1986 by Elsevier Science Publishers B.V. (Amsterdam).
FIGURE 6. Molecular electrostatic potential of the bottom face of delta-9-THC
(Conformational II). See figure 5 for details. From Reggio and Mazurek 1987.
Copyright 1986 by Elsevier Science Publishers B.V. (Amsterdam).
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FIGURE 7. O-methyl-delta-9-THC
the MM2 program (Allinger and Yuh 1980) was used. Rotations in 36 steps were
made about the C1-O axis.
In the second study, an SCF calculation was performed for a model fragment of
O-methyl-delta-9-THC (see figure 8). The Gaussian 80 system of programs and
the STO-3G basis set were employed here (Fluder et al. 1980). Initially, all
atoms in the fragment were frozen in their optimized positions. These positions
were determined by MM2 calculations for the full molecule. Rotations of the
methoxy group in 18 steps were made about the C1-O axis.
RESULTS AND DISCUSSION
Conformational Analysis
Figure 9 shows the minimum energy conformer of O-methyl-delta-9-THC as
obtained from the MM2 calculation. Previous studies have predicted that the
cyclohexene ring (Ring A) of delta-9-THC should exist predominantly in a half-
chair-like conformation (Archer et al. 1970). The present calculations indicate
that Rng A retains this conformation in O-methyl-delta-9-THC. As a result of
the interaction between the C6 methyl groups and H6a , Ring B assumes a con-
formation such that the axial C6 methyl group is on the same side of the
molecule as H10a and iS much
substituents on C6 and C6a
closer to H10a than is the other methyl group. The
are staggered with respect to one another (optimized
C10a -C6a -C6 -O5 dihedral angle is 63°). Here, the numbering system employed is
the same as that for delta-9-THC (see figure 2).
The C1 methoxy group is subject to steric interaction with the C10 proton. This
interaction causes the methoxy oxygen to bend slightly out of the plane of the
benzene ring. The methoxy group optimizes at a position away from Ring A
(optimized C2-C1-O-C dihedral angle is -5°).
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FIGURE 8. Model fragment for O-methyl-delta-9-THC.
FIGURE 9. Conformation of O-methyl-delta-9-THC (with propyl side chain) as
determined by MM2.
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Optimized bond lengths are within .01 Å of the following values: Csp P2-Csp2
1.40 Å, Csp 2-Csp3 1.51 Å, Csp 3-Csp 3 1.54 Å, Csp2-O 1.37 Å, Csp3-O
1.41 Å, Csp2-H 1.10 Å, and Csp3-H 1.11 Å.
Figure 10 shows a perspective of the molecule viewed in the direction parallel to
the vector from C2 to C10b From this perspective, the conformation of Ring A
causes the top part of the ring to move to the left, thus permitting no protrusion
of Ring A into the bottom face of the molecule. A comparison of figure 10 with
figure 4 reveals that the position of Ring A in O-methyl-delta-9-THC mimics
that of Ring A in delta-9-THC.
The results of the MM2 study of molecular energy as a function of rotation
about the C1-O axis are summarized in figure 11. There are local minima at  =
-500 and 85° separated by a 0.8 kcal barrier. The SCF results for the model
fragment of O-methyl-delta-9-THC agreed very well with those above. The
SCF method pinpointed two minimum energy conformers  = -5° and  = 85°
separated by a 1.0 kcal barrier.
It is clear from figure 11 that a  of 155° (which corresponds to Conformation II
of delta-9-THC) does not represent an energy minimum for the molecule. In
fact, in the MM2 study, the conformation with  = 155° is 7.3 kcal higher in
energy than the minimum energy conformer of O-methyl-delta-9-THC.
In its minimum energy conformation, the methoxy group of O-methyl-delta-9-
THC essentially adopts Conformation I of the template. In this conformation,
the lone pairs of electrons of the phenol oxygen are directed toward Ring A.
However, the methoxy group cannot mimic Conformation II of the template in
which the lone pairs of electrons of the phenol oxygen are directed away from
Ring A. On the basis of these results, the inactivity of O-methyl-delta-9-THC
can be explained by the fact that the molecule cannot mimic Conformation II of
delta-9-THC. These results seem to indicate, then, that it is Conformation II
which is the more relevant conformation at the site of action.
In an early SAR study, Edery et al. (1971) postulated the need for a free phenol
for cannabinoid activity. Recently, Binder and Franke (1982) have proposed a
picture of delta-9-THC interacting with its hypothetical receptor. In this
picture, the phenolic hydrogen is shown to form a hydrogen bond with the
receptor. Such a hypothetical drawing implies the necessity of a phenolic
hydrogen for activity. It is possible to argue from this viewpoint that O-methyl-
delta-9-THC is inactive due to its lack of a phenolic hydrogen. Although the
demonstrated activity of some esterified THC would argue against the necessity
of a phenolic hydrogen for activity, there appears to be no definitive compound
yet synthesized which can answer this question. In the next stage of our
investigation, we hope to propose new cannabinoids which could be useful in
delineating an answer.
CONCLUSIONS
The finding that O-methyl-delta-9-THC cannot mimic Conformation II of delta-
9-THC in which the lone pairs of electrons of the phenol oxygen are directed
away from Ring A has led to a refinement of our template for cannabinoid
activity. This inability of O-methyl-delta-9-THC to mimic Conformation II may
cause the inactivity of the molecule. As a result of this finding, we have
tentatively refined our template for cannabinoid activity to include two aspects.
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FIGURE 10. Conformation of O-methyl-delta-9-THC (with propyl side chain)
as determined by MM2.
FIGURE 11. Conformation of O-methyl-delta-9-THC as determined by MM2:
here the perspective of Ring A is viewed in the direction parallel to the vector
from C2 to C1 O b .
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1. The first aspect is the orientation of the lone pairs of electrons of the
phenol oxygen such that these lone pairs point away from Ring A
(Conformation II) (these lone pairs generate directional reactivity
properties).
2. The second aspect is the orientation of Ring A such that the ring moves
out of the bottom face of the molecule (this conformation is likely to
allow for nondirectional hydrophobic interactions).
Further refinements of this template will be made in subsequent comparisons of
the template MRCs with those of other cannabinoids.
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Different Cannabinoids Exhibit
Different Pharmacological and
Toxicological Properties
Ralph Karler, Ph.D., and Stuart A. Turkanis, Ph.D.
INTRODUCTION
By the mid-1970s. the anticonvulsant properties of the cannabinoids were well
documented (Loewe and Goodman 1947; Karler et al. 1973, 1974; Carlini et al.
1975; Consroe et al. 1976). but an analysis of their therapeutic potential as
antiepileptics had not yet been carried out. For this reason, a major goal
originally of our marijuana-related research was to determine the cannabinoids’
antiepileptic potential by the use of conventional laboratory tests for anticon-
vulsant and toxic properties (Turkanis and Karler 1981). The aim was to define
the relative selectivity of desired-to-undesired effects of these agents. In the
course of these studies, which involved many different cannabinoids, we
observed that there exist among these drugs, not only quantitative differences,
but also qualitative differences. The accretion of these differences ultimately
provides a profile of the pharmacological characteristics of the cannabinoids as a
class of drugs. The data presented below represent examples from our investiga-
tions of some properties of the cannabinoids, specifically related to their
antiepileptic potential.
METHODS
The anticonvulsant characteristics were measured in a variety of tests in order to
obtain a spectrum of properties for comparative purposes; the tests included both
electro- and chemo-shock tests. Because a major toxic effect of the clinical
antiepileptics is central depression, neurotoxicity was determined in terms of
motor toxicity, a classical measure of central nervous system (CNS) depression.
The details of the anticonvulsant and motor-toxicity tests have been previously
described (Karler et al. 1974; Turkanis et al. 1974).
The cannabinoids were dispersed in isotonic sodium chloride solution with the
aid of Tween 80 and ultrasound (Turkanis et al. 1974), and all drug and vehicle
preparations were administered intraperitoneally (i.p.). All determinations of
potency were made from dose-effect curves, which were obtained at peak-effect
times; and anticonvulsant potencies were expressed as either the effective-dose 50
(ED50) or the anticonvulsant-dose 50 (AD50), and motor toxic potency as the
toxic-dose 50 (TD50).
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RESULTS
Figure 1 illustrates the dose-effect curves for anticonvulsant activity in a
maximal electroshock (MES) test and motor toxicity in a bar-walk test.
FIGURE 1. Dose-effect relationships for cannabinoids in MES and bar-walk
tests. The bar-walk test was carried out just prior to the MES test at the peak-
effect times: THC and DMHP, 2 hr; CBD, 1 hr. The AD50s and their 95%
confidence limits (mg/kg, i.p.) are 12 (8-19) for DMHP, 92 (74-115) for THC,
and 122 (94-159) for CBD. The TD50s and their 95% confidence limits (mg/kg,
i.p.) are 4.7 (3-7) for DMHP, 82 (66-103) for THC, and 170 (144-200) for
CBD. Each point represents the results obtained jrom about 15 male Charles
River mice (ICR) weighing 15-26 gm. AD50s and TD50s and their 95%
confidence limits were calculated by methods described by Litchfield and
Wilcoxon (1949). THC = delta-9-tetrahydrocannabinol; CBD = cannabidiol;
DMHP = dimethylheptylpyran.
In this study, we compared DMHP, THC, and CBD. At the time, these three
compounds were selected for our initial studies for a variety of reasons: THC
was included because we intended to use it as the prototype cannabinoid; CBD
was included because it lacks the psychotoxicity of THC; and, finally, DMHP
was studied because it was thought to be the compound that had been tried with
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apparently some success in epileptic children (Davis and Ramsey 1949). DMHP
was later found, like CBD, to be nonpsychoactive in humans (Lemberger et al.
1974). In the upper half of this figure, we compared the dose-response curves
for these three drugs against MES, which is one measure of anticonvulsant
activity. Some points are clear from these data: first, that all three compounds
were anticonvulsant in the MES test; second, that the psychotoxicity of THC is
separable from the anticonvulsant activity because the nonpsychoactive CBD and
DMHP are both anticonvulsant; and, finally, in terms of anticonvulsant potency,
the dose-response curves illustrate that there is a big difference in potency
between DMHP and the other two drugs.
The separation between psychoactivity and anticonvulsant activity encouraged us
to continue this study and to pursue other aspects of the potential toxicity
problem. One property that especially interested us was motor toxicity because
all antiepileptic drugs are motor toxic. The lower half of the figure illustrates
that the cannabinoids are also motor toxic, as measured in a bar-walk test; in
these instances, potency in terms of motor toxicity appeared to be directly
proportional to the anticonvulsant potency; that is, the greater the anticonvulsant
potency, the greater the motor-toxic potency.
The data shown in table 1 represent the continuation of our study of relative
potencies with respect to the anticonvulsant and toxic effects of a large number
of cannabinoids. The drugs included in table I were not selected for their
structural characteristics; rather, they were included in the study because they
were the drugs that were available to us at the time. Nevertheless, the data
shown illustrate that most of these compounds displayed both anticonvulsant and
motor-toxic activity and that the potency relative to THC varied. For example,
in the MES test, the 11-hydroxy derivative is about seven times as potent as is
THC; and, similarly, it is about three or four times as potent in terms of motor
toxicity. The remaining compounds listed in the table illustrate the quantitative
differences in both anticonvulsant activity and motor toxicity, even in such a
limited sample of cannabinoids. The anticonvulsant activity ranged from a
fraction of that of THC, as illustrated by THC Acid B, to many times that of
THC, as in the case of d,1,threo-DMHP. Similar ranges were observed for the
motor-toxic activity in the bar-walk test.
At this point in our studies, one of the frequent criticisms that we received was
that the anticonvulsant dose of THC in the mouse, about 100 mg/kg, is very
high--approximately 100 times that of the psychoactive dose in humans;
therefore, the meaning of the anticonvulsant effects vis-a-vis humans was
questioned. To address this question, we examined the potency of some of the
cannabinoids in three different species: the mouse, the rat, and the frog. The
data are shown in table 2.
Here, we can see a very wide range of potency for these drugs. At the extremes,
the AD50 for both THC and CBD in the mouse is about 100 mg/kg; in the frog,
it is about 0.1 mg/kg. This species variability is not seen for either phenytoin or
phenobarbital. The point of this table is that there are large species differences
in the potency of the cannabinoids, which means that it is not possible to
extrapolate meaningful potency data from animals to humans; therefore, the
anticonvulsant dose in the mouse (or the frog) cannot be equated with a
psychoactive dose in humans. An anticonvulsant dose in humans can only be
determined in humans.
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TABLE 1
Relative Potencies of Cannabinoids in Anticonvulsant
and Motor Performance Tests in Mice
Drug MES Test Bar-walk Test
THC 1.0 1.0
11-Hydroxy-THC 7.1 3.6
8 Alpha-hydroxy-THC * 0.7
8 Beta-hydroxy-THC 1.0 *
THC Acid A 0.5 0.2
THC Acid B 0.3 0.2
Delta-8-THC
9-Nor-delta-8-THC
1.0
0.8
1.7
1.3
CBN
9-Nor-9 alpha-hydroxy-
hexahydro CBN
9-Nor-9 beta-hydroxy-
hexahydro CBN
0.4
0.8
2.2
0.4
0.8
1.7
CBD 0.8 0.5
DMHP 7.7 15
d,l,Threo-DMHP 14
d,l,Erythro-DMHP 4.0
Cannabichromene * 0.4
The relative potency is the ratio of the median-effective THC dose to that of
another cannabinoid. The average median-effective THC dose was 100 mg/kg,
i.p., for anticonvulsant effects in the MES test and 80 mg/kg, i.p., for motor
toxicity measured in a bar-walk test.
*Compound lacks activity within the dosage range tested.
–No data available.
The data shown in figure 2 represent another example of species differences in
response to the cannabinoids. The figure depicts dose-effect curves for the
motor toxicity of THC and CBD in the rat. These two drugs are of similar
motor-toxic potency in the mouse (about 100 mg/kg); but in the rat, the TD50
for THC is about 7 mg/kg, compared with 175 mg/kg of CBD. In the rat,
therefore, THC is about 25 times as toxic as is CBD and about 10 times as toxic
as it is in the mouse. Again, the species differences in response to these two
cannabinoids are striking; and they serve to re-emphasize the inappropriateness
of extrapolating data from one species to another, including humans.
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TABLE 2
Species Differences in Drug Potencies
in the Maximal Electroshock Test
AD50 (mg/kg)*
Drug Mouse Rat Frog
THC
CBD
Phenytoin
Phenobarbital
100
120
9
12
5
50
5
12
0.1
0.1
10
8
*Values calculated from dose-response data. From Karler and Turkanis 1981.
Copyright 1981 by The American College of Clinical Pharmacology, Inc. (New
York).
FIGURE 2. Dose-effect relationships for THC and CBD in a bar-walk test with
rats. The TD50s and their 95% confidence limits (mg/kg, i.p.) are 6.6 (4.8-9.0)
for THC and 173 (156-192) for CBD. The values were calculated by methods
described by Litchjield and Wilcoxon (1949). Each point represents results jrom
6-8 male Sprague-Dawley rats weighing 250-280 gm. The relative potency for
CBD compared to THC was 0.04 (Smiley et al. 1979).
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The data in table 3 illustrate the comparative selectivity of the cannabinoids, as
described conventionally in terms of the protective index, that is the ratio of the
TD50 to the ED50. The point of the experiment was to examine the quantitative
relationship between anticonvulsant activity and motor toxicity in order to
determine if these two effects are separable. Motor toxicity is a major side
effect of all antiepileptic drugs. In pharmacological terms, we were raising the
issue here of the selectivity of these compounds as anticonvulsants relative to
their general CNS depressant activity. Clinically, the usefulness of any drug, in
part, depends upon its selectivity for a desired effect.
TABLE 3
Effects of a Single Dose of Cannabinoid in Mice
in a Maximal Electroshock and a Bar-walk Test
Drug
Peak-effect ED50
Time (hr)* (mg/kg)
TD50
(mg/kg)
Protective
Index
(TD50/ED50)
DMHP 2 13 5 0.4
Delta-9-THC 2 100 80 0.8
CBN 1 230 230 1.0
CBD 1 120 180 1.5
11-Hydroxy-THC 1 14 22 1.6
Delta-8-THC 2 83 152 1.8
All experiments were performed at an ambient temperature of approximately
22°C; ED50 and TD50 values were calculated by the method of Litchfield and
Wilcoxon (1949) from conventional dose-response curves based on 3-6 doses with
15-20 animals for each dose; drugs were administered i.p.
*The peak-effect times for the anticonvulsant and toxic effects were similar.
From Karler and Turkanis 1976. Copyright 1976 by Plenum Publishing Corp.
(New York).
In this table are listed the protective index data for DMHP, delta-9-THC,
cannabinol (CBN), CBD, the 11-hydroxy metabolite, and delta-8-THC. For
DMHP, the ED50 against the maximal electroshock is 11.5 mg/kg and the TD50
is 4.6 mg/kg, yielding a protective index of 0.4. Similarly, the protective index
for delta-9-THC is 0.8; for CBN, 1.0; for CBD, 1.5; for 11-hydroxy-THC, 1.6;
and for delta-8-THC, 1.8. For comparative purposes, the protective index for
phenobarbital is 1.5 (Karler and Turkanis 1981). These data clearly illustrate that
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the anticonvulsant and motor-toxic activities are at least partially separable,
ranging from DMHP and THC, which are more motor toxic than anticonvulsant,
to CBD, 11-hydroxy-THC, and delta-8-THC, which exhibit more anticonvulsant
than toxic activity.
The data in table 4 represent a summary of the results obtained from five
different convulsive threshold tests. All of the anticonvulsant data described
above have been limited to only one convulsive test, that is, the MES test. There
are, however, many such tests, and table 4 contains the comparative results of
THC and CBD from a variety of electro- and chemo-shock tests.
TABLE 4
Anticonvulsant Properties of the Cannabinoids
Convulsive
Threshold Test THC CBD
Minimal
60-Hz-EST
6-HZ-EST
Pentylenetetrazol
- +
+ +
- 0
Maximal
MEST
Pentylenetetrazol
+ +
+ +
+ = anticonvulsant activity; - = proconvulsant activity; 0 = no activity.
CBD is anticonvulsant in four of the five tests; THC, however, has a very
different spectrum of activity because it is anticonvulsant in three tests, but is
proconvulsant in the 60-Hz-EST and the pentylenetetrazol minimal threshold test.
This was the first evidence that we had to indicate that THC exerts not only
depressant effects but also excitatory effects. Subsequently, we have observed
THC’s excitatory properties in many other experimental situations. For example,
THC can precipitate frank convulsions in cobalt- and iron-epileptic rats (Chiu et
al. 1979; Turkanis and Karler 1982); THC enhances electrically induced limbic
seizure activity in the rat (Smiley et al. 1979); and THC increases the rate of
kindling to both electrical and chemical stimuli (Karler et al. 1984). In striking
contrast, in all of these test situations, CBD displays only anticonvulsant or
depressant properties. We have also observed THC excitatory effects at every
level of organization of the nervous system, from the intact animal to the synapse
(Turkanis and Karler 1981). In none of these tests has CBD shown any
excitatory activity. On these grounds, we have concluded that the excitatory
properties of the cannabinoids are completely separable from the depressant
properties.
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The data shown in figures 3 and 4 represent the influence of chronic THC or
CBD treatment on their anticonvulsant properties. All of the anticonvulsant data
described above were derived from acute experiments. In contrast, the data in
figure 3 were obtained from animals treated for 22 days with a single daily dose
of THC. The top of the figure shows the results from the 6-HZ-EST test. On
day 1, THC raised this convulsive threshold about 20 V, which reflects its
anticonvulsant activity in this test. During the course of the 22 days, tolerance
developed because the anticonvulsant activity decreased. In the next test, the 60-
Hz-EST, THC is proconvulsant because on day 1 it decreased seizure threshold
by 2 mA, but again tolerance appeared to develop with repeated daily treatment.
Finally, in the third test, the maximal EST, THC acutely is anticonvulsant
because it elevated the threshold on day 1, but again tolerance developed to this
effect. The two curves at the bottom of the figure illustrate that the tolerance in
these instances is a true tolerance because there were no significant changes in
either the brain- or the plasma-THC concentrations with chronic treatment.
Figure 4 presents the results of chronic CBD treatment in the identical
experimental paradigm as that used for the previous THC study. But the results
are very different. In the two seizure-threshold tests shown at the top of the
figure, that is, the 6-HZ- and 60-Hz-EST tests, the anticonvulsant activity of
CBD progressively increased with chronic treatment, just the opposite response
from the tolerance observed with THC.
An enhanced response to a given dose of drug administered chronically has been
termed by some investigators as "reverse tolerance," and it is a phenomenon that
has been repeatedly described for CNS locomotor stimulants, such as cocaine,
amphetamine, and morphine (Post and Kopanda 1975; Segal and Mandell 1974;
Shuster et al. 1975). This may be the first report of "reverse tolerance"
developing to depressant effects, in this case, anticonvulsant effects. The
instances of "reverse tolerance" again clearly distinguish CBD from THC. The
results of the maximal EST indicate that tolerance develops to the other two
effects. With respect to this test, CBD resembles THC because tolerance
developed to both of the drugs.
Although antiepileptics are taken chronically, studies of chronic effects of these
drugs are conspicuously absent from the literature. For this reason, we included
phenytoin in our cannabinoid study and found that in one of the tests, tolerance
developed; in another test, there was no change in pharmacodynamics; and in the
third test, "reverse tolerance” developed (Karler et al. 1982). The "reverse
tolerance" in this case is of special interest because it is clinically recognized that
there exists a time lag of a few weeks before the antiepileptic activity of
phenytoin completely manifests itself. Currently, there is no explanation for the
time lag, but our animal data suggest that the lag may be due to the time
required to develop "reverse tolerance." In any event, the phenomenon of
"reverse tolerance" may add a new dimension to the study of antiepileptic drugs,
as well as to the study of cannabinoids.
DISCUSSION
The data presented were selected to provide an overview of what we consider to
be some of the more important pharmacological characteristics of the
cannabinoids that have emerged from our whole-animal studies of their
anticonvulsant properties. We have seen, for example, as have others, that the
anticonvulsant activity is separable from the psychoactivity. Without such a
separation, these drugs would have no clinical potential as antiepileptics. We also
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FIGURE 3. Influence of repeated THC treatment on ESTs. In each test, 60 mice
were given 10 mg/kg THC i.p. once daily, and another 60 mice, vehicle. The
points indicate the differences in EST between drug- and vehicle-treated groups.
—— = period of daily treatment: ----- = period oj withdrawal. Brain and
plasma values represent data from 6-8 mice. On day 1 the vehicle-control values
were 23 (21-24) V for the 6-Hz-EST, 5.9 (5.7-6.1) mA Jor the 60-Hz-EST and
7.5 (7.0-8.0) mA for the MEST and, as determined by a relative potency test of
Litchfield and Wilcoxon (1949) (P < 0.05), were significantly different from the
drug-treated groups. From Karler et al. 1982. Copyright 1982 by Springer-
Verlag (Heidelberg).
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FIGURE 4. Influence of repeated CBD treatment on the ESTs and on brain and
plasma-drug concentrations. On day 1 vehicle-control values were 21.5 (20-23) V
for the 6-HZ-EST, 5.4 (5.1-5.8) mA for the 60-Hz-EST and 7.9 (7.6-8.3) mA
for the MEST, and on day 1 only the 6-HZ-EST and MEST vehicle-control values
were significantly different from those obtained from CBD-treated groups as
determined by a relative potency test. See figure 3 for additional information.
From Karler et al. 1982. Copyright 1982 by Springer-Verlag (Heidelberg).
observed that among the different cannabinoids, there are differences in potency,
there are differences in the protective index, and there are species differences in
response to them. None of these observations is too surprising because such
differences are general characteristics of drugs. Detailed structure-activity
studies would probably yield cannabinoids with more selectivity as
anticonvulsants than those that we have studied. The "reverse tolerance" to CBD
was a surprise. What this means vis-a-vis an antiepileptic drug is not clear, but
the observation that a similar response to chronic phenytoin treatment raises the
possibility that the clinical efficacy of phenytoin may, in part, be due to "reverse
tolerance." Although "reverse tolerance" was not observed for THC in the
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anticonvulsant study, the CBD data illustrate that "reverse tolerance" can occur to
cannabinoid effects; therefore, the toxicological or pharmacological evaluation of
any cannabinoid should involve the assessment of effects in chronically treated,
as well as acutely treated, animals.
In the course of our studies, we have tried to emphasize that anticonvulsant
activity is not a single entity; rather, it is a complex group of effects. That point
is clearly seen in the case of THC which is anticonvulsant in some tests and
proconvulsant in others. This resembles the clinical response generally to
antiepileptic drugs. Phenytoin, for example, is effective in the treatment of
grand mal epilepsy; however, it can exacerbate absence seizures. The reverse is
true for ethosuximide. In animal studies, these drugs resemble THC because they
all exhibit both anticonvulsant and proconvulsant properties. In retrospect, what
is interesting about CBD as an anticonvulsant is that we have not yet seen any
indication of an excitatory effect on CNS function. In this sense, it may be
unique as an anticonvulsant. Despite a number of favorable properties of CBD,
its future as an antiepileptic--at least in this country--is not very promising.
Although the anticonvulsant drug-screening program sponsored by the National
Institute of Neurological and Communicative Disorders and Stroke (NINCDS)
screened CBD and found it to have anticonvulsant activity, it has not been
recommended for clinical trial, and it is the NINCDS recommendation that
determines which new antiepileptics will be clinically tested in this country. The
drug industry in the past has been reluctant to develop new antiepileptics because
the potential market is too small to justify the drug developmental expense.
Even now that the NINCDS is providing much of the developmental costs, what
drug company would be willing to bear the marketing cost of a nonpatentable,
marginally profitable drug such as CBD? It is for this reason that we are
pessimistic about the future of CBD as an antiepileptic. It may remain just as
we found it: a very interesting laboratory drug.
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INTRODUCTION
The currently proposed mechanisms by which the cannabinoids could be
producing their central effects involve either general membrane perturbation or
direct interaction with a specific cannabinoid receptor. The difficulty in defining
the mechanism by which -THC alters central function could be because the
cannabinoid behavioral syndrome represents a composite of several independent
effects, rather than a single event. Therefore, it is possible that both mechanisms
play an important role in the total behavioral effect of the cannabinoids. The
observed behavioral syndrome may be a composite of multiple independent
effects, each of which could be a function of either a nonspecific cannabinoid
action or, alternatively, of a specific cannabinoid effect which might be modified
(at higher drug doses) by nonspecific interactions. It is our objective to determine
whether either of these mechanisms is responsible for -THC’s effects. If
cannabinoids are interacting with specific binding sites, then there should be a
strict structure-activity relationship (SAR) as well as a specific antagonist.
Alternately, if the cannabinoids are producing their effects solely by perturbation
of membranes, there should not be a specific antagonist, but there may be a
correlation between activity and membrane (lipid) solubility as measured by
partition coefficients. The partial development of a SAR for several cannabinoid
behavioral effects has been established by evaluating the agonistic and antagonistic
activity of newly synthesized analogs in a variety of behavioral test systems.
These tests include spontaneous activity, rectal temperature and analgesia (mouse),
blood pressure, heart rate, and respiratory rate (rat), static ataxia (dog), and
conditioned operant behavior (monkey) (Martin et al. 1975, 1984a, 1984b;
Beardsley et al., in press). Additionally, attempts have been made to distinguish
those cannabinoid structural features associated with only a portion of the
behavioral syndrome normally observed with THC as an effort to determine if a
unique SAR exists for each behavioral measure, which would support the notion
that the cannabinoid syndrome is composed of multiple behavioral effects (Martin
1986). We propose that the pharmacological properties unique to the cannabinoid
class of drugs are produced by the interaction of -THC with specific receptors,
while cannabinoid-induced central nervous system (CNS) depression is a general
phenomenon produced by nonspecific membrane interactions.
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METHODS
Cannabinoids
The analogs 1-24, 32, and 33 were synthesized by Dr. Raj Razdan and 25,
29, and 31 by Dr. Everette May. Compounds 26-28 were obtained from the
National Institute on Drug Abuse and compound 30 was provided by the National
Cancer Institute. The procedure of Olson et al. (1973) was used to prepare
micellar suspensions of cannabinoids suitable for injection. The cannabinoids (10
mg) were dissolved in 100 µl of a 1:1 mixture of 95% ethanol and emulphor (a
polyoxyethylated vegetable oil manufactured by GAF) by sonification. This
solution was then diluted with ethanol:emulphor:saline (1:1:18) to provide the
desired concentration, and injected intravenously (i.v.), unless stated otherwise.
Spontaneous Activity, Rectal Temperature, and Antinociceptive
Activity in Mice
Analogs are evaluated initially in these three tests in order to assess their general
pharmacological activity. To conserve limited supplies of drugs, these
measurements are recorded sequentially in the same animal as described
previously (Martin et al. 1984a, 1984b; Jorapur et al. 1985). Male ICR mice
(22-30 g) are housed in the laboratory for 24 hr before treatment. The ambient
temperature of the laboratory, which varies from 22 to 24 °C from day to day, is
recorded at the beginning and end of each experiment. Rectal temperature is
determined by a thermistor probe (inserted 25 mm) and a telethermometer (Yellow
Springs Instrument Co., Yellow Springs, OH) just prior to vehicle or drug
administration. Following the initial temperature determinations, control tail-flick
reaction times are determined for each animal as described below. The mice are
then injected i.v. with either vehicle or drug (0.1 ml/10 g of body weight) and
immediately placed in individual photocell activity chambers. After the animals
have acclimated for 5 min, interruptions of the photocell beams are recorded for a
10-min session. The mice are removed from the activity chambers, and tail-flick
response is determined 5 min later. Rectal temperature is measured 60 min after
drug administration. The spontaneous activity of the treated animals is expressed
as percent of control, and the ED50s(and confidence limits) are determined by the
method of Litchfield and Wilcoxon (1949). The difference between rectal
temperature before and 60 min after treatment is calculated for each mouse.
The antinociceptive activity procedure is essentially the same as that described by
D'Amour and Smith (1941) and Dewey et al. (1970). A mouse's tail is placed on
a notched block so as to occlude a slit over a photocell detector. Heat is applied by
a 100-watt lamp mounted in a reflector. The apparatus is arranged so that when
the operator turns on the lamp a timer is activated. When the mouse flicks its tail,
the light falls on the photocell and automatically stops the timer. The intensity of
the lamp is adjusted to give a normal reaction time between 2 and 4 sec. A control
reaction time is taken for each animal prior to treatment. The mice then receive an
i.v. injection of the drug and are tested at the appropriate time. A maximum
10-sec cut-off (latency) time is employed in order to prevent damage to the
animal’s tail. The antinociceptive response is expressed as a percent of the
maximum possible increase in latency. Percent response is calculated from the
equation: % R = (T - Tc/10 - Tc) x 100 where T is the mean test reaction time, and
Tc is the control reaction time. The ED50 (and confidence limits) are determined
by the method of Litchfield and Wilcoxon (1949).
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Static Ataxia in Dogs
The ability of cannabinoids to produce static ataxia (an effect unique to
psychoactive cannabiioids) and other characteristic behavioral effects is examined
in mongrel dogs of either sex (10-18 kg). On the test day, the animals are moved
from their home cages to the observation room, and behavior is evaluated for 5 to
10 min prior to drug administration. The normal behavior of each animal (which
includes spontaneous activity, gait, tail tuck, hyperreflexia, etc.) is recorded.
Each animal is then injected i.v. with either the cannabiioid or the vehicle (1 ml/kg
of body weight), and their behavior is rated at 5-min intervals according to the
static ataxia scale as described previously (Walton et al. 1938; Martin et al. 1975)
and as depicted in table 1. Typical test sessions consist of four animals that
receive either vehicle, -THC (0.2 mg/kg which typically produces a rating of
3-4), or one of two other cannabinoid treatments. Only one of the experimenters
is knowledgeable to the treatment. Behavior is scored by three observers who are
"blind" with regard to treatment.
TABLE 1
Quantitation of the Behavioral Effects Produced by Cannabinoids in Dogs
Score Behavioral Effects
0
1
2
3
4
5
6
No effect
Slight depression of activity, slight static ataxia seen only after
the dog has been standing in one position for 3 to 5 min.
Walks with a prance-like placement of feet, exaggerated reflex
to a swinging hand, and static ataxia after standing in one
position for 2 to 3 min.
Tail  is  often tucked, some loss of tone in hind legs as
evidenced by a semisquatting position, static ataxia more
pronounced and seen after dog stands in one position for 1 to 2
min, and nodding may be observed 30 to 60 min after
injection.
Marked static ataxia, sways forward and backward and/or side
to side, and almost falls after standing in one position for 1
min.
Cannot stand for longer than 30 sec without almost falling and
often plunges about.
Lies prostrate on the floor.
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Conditioned Operant Responding in Monkeys
Rhesus monkeys are trained on a multiple timeout 3-min fixed-ratio x schedule to
lever press for food pellets as described by Beardsley et al. (in press). During drug
testing, the animals receive cumulative dosing of cannabinoids, as described in table
5, and the dose at which the behavioral sign appears is recorded. The vehicle did
not produce any of the indicated behavioral signs nor did it suppress conditioned
responding.
Protocol for Determining Antagonistic Activity
Analogs with little or no agonistic activity in these tests are evaluated for antagonistic
activity. Antagonism in spontaneous activity and rectal temperature measures is
studied in one group of mice, whereas antinociceptive activity is evaluated in a
separate group of animals. A subthreshold dose of the analog (or vehicle) is
administered i.v. 10 min prior to an i.v. administration of -THC (ED50 dose for
producing hypoactivity) or vehicle. Spontaneous activity and rectal temperature are
measured (described above) in the following treatment groups: analog plus -THC
(A), analog (B), -THC (C), and vehicle (D). Antagonism of hypothermia is
calculated from the following equation:
%AD h y p o t h e r m i a. = {1 - [(A -B) ÷ (C -D)]} x 100 where A through D represent the
differences between preinjection and postinjection (60 min) rectal temperatures. The
antagonism of hypoactivity is calculated from the following equation:
%AD
hypoactivity = {1-[1-(A ÷ B)] ÷ [1- (C ÷D)]) x 100 where A through D
represent the spontaneous activity (counts per 10-min period). To measure
antagonism in the tail-flick procedure, the analog is administered i.v. 10 min prior to
an i.v. dose of -THC (ED80 dose for producing antinociception). The mice are
tested 5 min after the second injection. Two injections of vehicle into the tail vein
have no effect on the tail-flick response. The results are expressed as percent
antagonism of the THC antinociceptive effect. The AD50 values (and confidence
limits) are determined by the probit analysis method of Litchfield and Wilcoxon
(1949).
Antagonistic activity of analogs is evaluated in dogs by pretreating i.v., with either
vehicle or analog, 10 min prior to the i.v. administration of either vehicle or -THC
(0.2 mg/kg). In this way, each test session consists of the following treatments:
vehicle, analog, -THC, and analog + -THC. Behavioral activity is evaluated
for 60 min after the -THC injection. The maximum effect of -THC is usually
observed between 15 and 30 min after administration. Analogs are evaluated at the
highest possible dose in duplicate or triplicate. Analogs with antagonistic activity are
evaluated at two other doses (in duplicate) so that AD50 values can be calculated.
Dogs are retested at weekly intervals, but never more than four times total.
Development of tolerance has not been observed when low doses of cannabinoids
are given as infrequently as once a week.
RESULTS
Antinociceptive Studies
Cannabinoids have previously been considered to be weak antinociceptive agents
(Buxbaum 1972; Dewey et al. 1972; Chesher et al. 1973; Sofia et al. 1973; Noyes et
al. 1975; Wilson et al. 1976; Bloom et al. 1977; Gilbert 1981; Sofia and Barry
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1983). However, i.v. administration of -THC demonstrates that it has
antinociceptive properties comparable to those of morphine sulfate (Martin 1985a).
SAR studies demonstrate that the structural requirements for cannabinoid-induced
antinociceptive activity, as measured in the tail-flick procedure, are quite similar to
those necessary for inducing hypoactivity and hypothermia (Martin 1985b). These
findings, coupled with the observation that i.v. administration of -THC (ED50 =
1.9 mg/kg) results in consistent and potent antinociceptive activity, suggest that the
tail-flick procedure is a reasonable test for assessing agonistic and antagonistic
activity of cannabinoids.
Evaluation of Agonistic Activity of CBD Analogs
The behavioral profiles and structures of CBD analogs evaluated for
pharmacological activity in mice are presented in table 2. Interest in these
10-N-substituted analogs is derived from early suggestions that CBD itself exhibited
some antagonistic properties (see Martin 1986 for a recent review). The ethylamino
(1) and propylamino (2) analogs are as potent as -THC in decreasing spontaneous
activity and rectal temperature, but exhibit only slight antinociceptive activity
(Jorapur et al. 1985). Additionally, 1 lacks specific cannabinoid effects in the dog
static-ataxia test, although it does produce CNS depresson at i.v. doses of 1 to 2
mg/kg. An interesting aspect of these two analogs' activity profile is their high
toxicity (LD50 = 5 mg/kg), whereas the LD50 of CBD is >100 mg/kg. However,
other lo-substituted CBD analogs (3-10) have been prepared, and they are
relatively inactive in all mouse tests. The N-methyl- N-propargyl (7) and
morpholino (10) CBD analogs are diacetyl derivatives which are weakly active (
-THC) in producing hypoactivity, but inactive in the other two tests. Due to
concerns regarding the penetrability of N-mustards into the CNS, analog 3 was also
evaluated following intraventricular (i.v.t.) administration, and doses up to 150
µg/mouse (  5 mg/kg) do not alter spontaneous activity or tail-flick latency in mice,
but they do produce a 3.8 °C drop in rectal temperature. An identical i.v.t. dose of
-THC produces a 5.5 °C decrease in temperature, as well as a 68% decrease in
spontaneous activity and a 55% increase latency in the tail-flick response. Only the
ethylamino analog 1 has been evaluated in the dog static-ataxia test, and it failed to
produce the classical cannabinoid syndrome. However, it did produce CNS
depression at i.v. doses of 1 to 2 mg/kg, which was consistent with its effects in
mice. Therefore, it appears that this analog may be prototypic of a cannabinoid with
potent CNS depressant properties, but without antinociceptive or static-ataxia
properties. The lack of agonistic properties in the other CBD analogs make them
suitable for testing as antagonists.
Evaluation of Agonistic Activity of -THC Analogs
The importance of the C-11 position has been well documented. The general
consensus is that hydroxylation at this position increases biological activity, whereas
removal of the C-11 position decreases potency (Martin et al. 1975). Numerous
substitutions have been made at C-11 of -THC (11-21) and the results are
summarized in table 3. Alkylamino (11-14) or thioacetyl (16) substitutions have
more or less resulted in loss of agonistic activity in the mouse tests with the
exception of the N-methyl analog (11) which was as potent as -THC in
depressing spontaneous activity. The N-mustard (13, acetate of 14) was
administered i.v.t. as described for analog 3 and found to be inactive up to doses of
150 µg/mouse. The alkyl analogs (17-21) are primarily additions of a bulky
substituent at C-11 which dramatically attenuate behavioral activity.
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TABLE 2
Phamacological Activity of CBD and Structurally Related Analogs in Micea
R
Pharmacological Profile
S.A. b R.T. c T.F. d
CBD 0.08
1 -NHC2H5 1.15
2 -NHC3H7·HCl 1.10
3 -N(CH2CH2Cl)2 N.T.
e
4 -N3 <0.20
5 -SH <0.02
6 -Br f < 0.08
7 -N(CH3)CH2C=CH
f 0.25
8 -N[CH(CH3)2]2
f <0.05
9 -NHCO(CH2)3NH2 0.08
10 -cN(CH2CH2)2O
f 0.2
0.03 <0.03
0.44 ~0.30
1.00 ~0.40
N.T. N.T.
<0.05 <0.20
0.05 <0.20
0.15 <0.20
0.03 <0.06
0.03 <0.06
0.11 <0.08
0.02 <0.06
a Pharmacological potency of i.v. analogs relative to that of i.v. -THC.
b Spontaneous activity — the ED50 of -THC (2.3 mg/kg) was divided by
that of the analog. Less than (<) indicates the analog did not produce a 50%
effect at the highest dose tested. Therefore, the ED50 was divided by the
highest dose tested. cRectal temperature — the dose of -THC (3.0
mg/kg) that produced a 1.6 °C decrease in rectal temperat
dose of the analog that produced a comparable effect. d
ure divided by the
Tail-flick response
— the ED50 of -THC (1.9 mg/kg) was divided by that of the analog.
Less than (<) indicates the analog did not produce a 50% effect at the
highest dose tested. e Not tested. fDiacetyl derivatives previously reported
(Jorapur et al. 1985).
113
TABLE 3
Pharmacological Activity of -THC and Structurally Related Analogs in Micea
R b
Pharmacological Profile
S.A. R.T. T.F.
-THC 0.23 0.98 0.28
11
12
13
14
15
16
17
18
19
20
21
"
"
"
22
23
24
25
26
27
28
R l
-CH2NHCH3
c 0.21
-CH2NHCH2CH3 <0.20
-CH2N(CH2CH2Cl)2 acetate <0.20
-CH2N(CH2CH2Cl)2 < 0.07
-SH N.T.
-SCOCH3 < 0.20
-C6H5
c 0.03
-CH2C6H5
c 0.07
-CH(CH3,)2
c 0.09
-CH2CH2CH2CH3
C 0.07
-CH(OH)CH2CH3
c 0.06
R2
-NH2 0.82
-NHCH2CH3 0.92
-SCOCH3 <0.20
R3 and/or Side Chain
-O2C(CH2)3N(CH2CH2)2O 0.22
-O- 1.1
Side chain = -(CH2)5N
+(CH3)3
Side chain = -(CH2)5Br 1.1
Side chain = -(CH2)5OAc 0.79
0.04
< 0.05
0.08
0.03
N.T
0.06
0.08
0.04
0.02
0.27
0.03
0.94 < 0.30
0.82 < 0.60
0.06 < 0.20
0.34 0.11
1.13 N.T.
2.44
~1.0
N.T.
~ 0.20
< 0.20
0.06
N.T
< 0.20
N.T.
"
"
"
a Potency of analogs relative to -THC as described in legend of table 2.
b R1 and R2 = -CH3, R3 = -OH unless indicated. 
c Martin et al. 1984a.
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Substitutions have also been made at position 12 of -THC, which is comparable
to position 10 of CBD. Both 12ß-amino- -THC (22) and the corresponding
ethylamino derivative (23) effectively reduce spontaneous activity and rectal
temperature as potently as -THC, but have little or no effect on tail-flick
response. In contrast, introduction of a thioacetyl group (24 ) reduces activity
compared to -THC. Analogs 22 and 23 were similar to the CBD analogs 1 and
2 in that they too were quite toxic (lethal at 6-10 mg/kg). The pharmacological
effects of 1-morpholinobutyryl - -THC (MB- -THC, 25) were compared to the
values obtained for -THC tested during the same session, and the data suggest
MB- -THC is somewhat less potent (0.3-0.1) than -THC. The values
obtained with -THC were similar to those previously reported, and the potency
range for the effects of MB- -THC is similar to that obtained for -THC
relative to -THC (Martin et al. 1984a). These data would seem to support the
notion that MB- -THC is metabolized rapidly by liver enzymes in vivo to
-THC, which is probably responsible for the observed behavioral effects (Zitko
et al. 1972).
The possibility that -THC exerts some of its effects by interacting with a
specific receptor has recently gained partial support from the studies of Nye et al.
(1985) who defined a stereoselective, saturable, high affinity site for tritiated
5'-trimethylammonium- -THC phenolate (5'-TMA, 26) binding. Therefore, in
order to determine the relevance of this binding site to the behavioral effects of the
cannabinoids, 5'-TMA has been evaluated and compared to -THC in our
cannabinoid assays. Pharmacological comparison reveals that both -THC and
5'-TMA induce hypothermia (2.6° and 3.0°, respectively) at 5 mg/kg, and decrease
spontaneous activity (ED50 = 10 mg/kg and 2.1 mg/kg, respectively) in the mouse
after i.v. administration. -THC and 5'-TMA also induce hypothermia (4.4° and
5.0°, respectively at 100 µg), as well as hypoactivity (ED50 = 46 µg and 133 µg,
respectively) after i.v.t. administration in the mouse. In the do both drugs, as
well as -THC, produce mild sedation. However, only - and -THC
produce static ataxia (at 0.4 mg/kg and 0.2 mg/kg i.v., respectively), while
5'-TMA is inactive at doses up to 1.0 mg/kg (i.v.). Although 5'-TMA exhibits
CNS depressant properties, it appears to lack the specific behavioral effects that
are typically produced by psychoactive cannabiioids.
The 5'-bromo- (27) and 5'-acetyl- (28) -THC analogs are similar in potency to
to both 5'-TMA and -THC in producing hypoactivity. However, 27 is more
potent in decreasing rectal temperature (2.8 °C at 1 mg/kg). Analog 28 does
produce hypothermia (maximum effect of 2.8 °C at 30 mg/kg), but not in a
dose-related fashion (a 1.5 °C drop at doses of 1,3, and 10 mg/kg).
Evaluation of Agonistic Activity of -THC Analogs
The behavioral data demonstrate that 1-O-succinyl- -THC (29) possesses a
pharmacological profile similar to that of -THC. However, the analog is less
potent than -THC in depressing spontaneous activity and in producing
hypothermia and antinociception. While 29 appears to retain cannabinoid activity,
one cannot rule out the possibility that the pharmacological activity is due to in
vivo hydrolysis to -THC. These data support the contention that substitutions
at the phenolic hydroxyl of -THC reduce pharmacological activity.
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Alkylating agents of - and -THC have been prepared for the purpose of acting
as receptor probes. The N-mustard -THC-1-bis(2-chloroethyl)carbamate (30 )
was found to be inactive if administered intraperitoneally (i.p.) or orally (p.o.),
which suggests that this ester is not rapidly hydrolyzed in vivo to -THC.
However, 30 is active after either i.v. or i.v.t. administration. Following i.v.
administration (table 4), 30 is at most only 0.06 times as potent as -THC. In
contrast, i.v.t. administration of the 30 produces effects on rectal temperature
equivalent to that of -THC and is 0.2 times as potent as -THC in producing
hypoactivity (the tail-flick latency was not tested). These data suggest that the
ability of 30, and possibly other N-mustards, to enter the CNS may be limited.
TABLE 4
Pharmacological Activity of -THC and Structurally Related Analogs in Micea
Rb
Pharmacological Profile
S.A. R.T. T.F.
-THCc 1.00 1.00 1.00
29 R3 = succinyl 0.15 0.30 0.34
30 R3 = -02CN(CH2CH2Cl)2 0.06 0.01 <0.01
31 R2 = -(CH2)5Br 1.21 2.80 19.0
32 R2 = -(CH2)2CHOH-C2H3
d
S-3'-OH 6.20 1.00 N.T.
R-3'-OH 0.90 0.92 N.T.
R/S-3'-OH 2.50 0.89 N.T.
33   -THC 0.28 0.07 0.09
a Potency of i.v. analogs relative to i.v. -THC on the spontaneous
activity (S.A.), rectal temperature (R.T.), and tail-flick (T.F.) response
measures; calculated as described in the legend of table 2. b R1 = -CH3, R2
= -C5H11, and R3 = -OH unless indicated otherwise. 
c The ED50 is 2.3 and
1.9 mg/kg for S.A and T.F., respectively, and a 1.6 °C drop occurs at 3
mg/kg. d Based on previously reported values (Martin et al. 1984a).
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The 5'-bromo- -THC analog (31) is similar to the 5'-bromo- -THC analog
(27) in potency and profile. Analog 31 (table 4) is equipotent to -THC in
reducing spontaneous activity and is roughly 3-fold more otent in producing
hypothermia. Interestingly, 31 is 19-fold more potent than -THC in the mouse
antinociception test. Tests are currently under way to determine if 27 , the
5'-bromo- -THC analog, also shares this characteristic.
Introduction of a hydroxyl group at the 3' position of the side chain (32 ) results in
an R/S 3'-OH racemic mixture that retains cannabinoid-like activity (Martin et al.
1984a). Final resolution of each of the compounds results in a S-3'-OH mixture
contaminated by 9% of the R isomer, and in an R-3'-OH mixture contaminated by
15% of the S isomer. Therefore, it is possible that the pharmacological effects
observed by one of the "pure" isomers is partially (or totally) due to the opposite
isomer. However, the pharmacological profiles of the racemate and each of the
isomers suggest that the S isomer is 6-fold more potent at reducing spontaneous
activity than -THC. The R isomer also produces hypoactivity, but the result
could be because 15% of the administered compound is actually the S isomer. In
contrast, the ability of both the R and the S isomer, as well as the racemate, to
produce hypothermia is nearly identical, and in fact is equipotent with -THC.
These data suggest that there is a specific side chain stereospecificity required for
one effect (hypoactivity) that is not required for another (hypothermia). In fact, it
is possible that the S, but not the R, isomer produces hypoactivity, while both
isomers are equipotent in producing hypothermia.
Evaluation of Cannabinoids for Antagonistic Properties
Since 10-N-ethylamino-CBD (1 ) is a partial antagonist of -THC-induced
antinociception (Jorapur et al. 1985), this compound has been tested further for
antagonistic activity. Although 1 lacks specific cannabinoid effects in the dog
static-ataxia test, pretreatment with 0.5 mg/kg (i.v.) of 1 does not alter the
behavioral effects of -THC in dogs. Compound 1 also does not produce an
antagonism of -THC's effects on spontaneous activity and rectal temperature.
Therefore, the attenuation of -THC's effects by 1 appears to be limited to
mouse antinociception. Additionally, 2 also produces a partial antagonism (38%
at 3 mg/kg) of -THC-induced antinociception, similar to 1. However,
compound 2 also does not block -THC’s effects on spontaneous activity and
rectal temperature, and therefore is not being tested further. The evaluation of the
10-bromo-CBD diacetate analog (6 ) for antagonistic activity indicates no alteration
of -THC-induced antinociception at doses up to 30 mg/kg.
The 12ß-amino- -THC analog (22) does not alter -THC-induced hypoactivity
and hypothermia as expected due to its agonistic activity. However, 22 does
produce a slight attenuation in -THC's antinociceptive activity. Doses of 22 of
0.3 to 3.0 mg/kg antagonized -THC’s effects by 25%.
Assessment of the antagonistic activity of the N-mustard -THC-1-bis
(2-chloroethyl) carbamate (30) following i.v. administration reveals that this
compound is not an antagonist. High doses of 30 (100 mg/kg) attenuate the
effects of -THC administered 24 hr later, but this blockade appears to be due to
desensitization, rather than antagonism, since -THC itself produces a similar
effect. However, it is possible that lower doses of 30, or a different experimental
protocol, might reveal antagonistic properties.
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TABLE 5
- and -THC's Effects on Conditioned Operant Responding in Monkeys
Cumulative Dose (mg/kg)a
Operant
T e s t Monkey Ptosis Ataxia Sedation Suppression
Vehb
-THcd
-THCe
-THCf
I N T g
-THC d
639
M661
M572
824
639 0.250 0.25
M661 0.125 0.50
M572 0.125 0.50
824 0.250 1.00
0.50
1.00
1.00
0.25
0.050
0.250
0.125
0.005
639
M661
1.000
639
M661
M572
824
1.000
0.500
639
M661
M575
824
1.50
1.50
1.00
1.00
0.500
0.250
0.125
1.00
639 0.25
M661 0.25
M572 0.25
824 0.25
1.00
1.00
1.00
0.50
0.25 0.125
0.50 0.500
0.50 0.500
0.25 0.005
a Cumulative dose equals the summation of all previous doses. bVehicle
consists of emulphor: ethanol: saline in a ratio of 1:1:18, respectively. c
The effect was not observed. d-f Total cumulative dose of 1.0 mg/kg of
-THCd, 1.0 mg/kg of -THCe, and 5.0 mg/kg of -THC
f. g A
cumulative dose of 1.0 mg/kg -THC preceded infusions of -THC.
All monkeys received a maximum cumulative dose of 10 mg/kg of -THC
within the normal 1-hr experimental session. Monkeys 639 and M661
received additional 0.5 mg/kg infusions of -THC after the session to
provide a total cumulative dose of -THC of 1.5 and 2.0 mg/kg,
respectively.
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TABLE 6
Selective Pharmacological Profiles of Cannabinoids Analogs
Class 1 - All Cannabinoid Effects
-THC
-THC
11-OH- -THC
S-3'-OH- -THC
Class 2 - Weak CNS Depressant Devoid of other Cannabinoid Effects
10-Azido-CBD (4)
10-Sulfhydryl-CBD (5)
10-Bromo-CBD diacetate(6)
10-Morpholino-CBD diacetate (10)
10-(N-Methyl-N-propargylamino)CBD (7 )
10-(N,N-Diisopropylamino)CBD (8 )
10-[(4-Aminobutyryl)amino]CBD (9 )
CBD
-THC (33)
11-N-Ethylamino- -THC (12)
11-N-Bis(2-chloroethyl)- -THC ( 13 & 14)
11-Thiol- -THC (15)
11-Thioacetyl- -THC (16)
9-nor-9-Phenyl- -THC (17)
9-nor-9-Benzyl- -THC (18)
9-nor-9-Isopropyld -THC (19)
9-nor-9-nButyl- -THC (20)
Class 3 -Potent CNS Depressant Devoid of other Cannabinoid Effects
10-N-Ethylamino-CBD (1)
10-N-Propylamino-CBD (2)
12ß-amino- -THC (22)
12ß-ethylamino- -THC (23)
-THC (33) (dogs only
5'-trimethylammonium-
)
-THC phenolate (26)
Class 4- Selective CNS Depressant Devoid of other Cannabinoid Effects
10-N,N-Bis-chloroethyl-CBD (3 ) - hypothermia, i.v.t.
11-Methylamino- -THC (11) - hypoactivity
9-nor-9-nButyl- -THC (20) - hypothermia
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Agonistic Effects of -THC in the Mouse, Dog and Monkey
The exocyclic analog (33) , -THC, was investigated extensively as a result of
the suggestions of Binder and his colleagues (Binder et al. 1979; Binder and
Franke 1982; Semjonow and Binder 1985) that this analog should lack
psychoactive properties and would be useful for delineating nonspecific and
specific cannabinoid binding in in vitro assays. The pharmacolocal profile of
-THC in mice is similar to that of -THC, even though -THC is less
potent in all tests (table 4). It appears to be approximately 4, 15, and 11 times less
active than -THC in depressing spontaneous activity, reducing body
temperature, and producing antinociception in mice, respectively (Beardsley et al.,
in press).
Antagonistic Effects of -THC
The effects of -THC pretreatment on the actions of -THC in mice, dogs,
and monkeys have also been studied (Beardsley et al., in press). -THC
pretreatment did not attenuate any of the effects of -THC in mice. Evaluation of
-THC for cannabinoid antagonistic properties in the dog is hampered by the
fact that it has some depressant properties in this behavioral test. However,
pretreatment with either 0.5 or 1.0 mg/kg of -THC 15 min before -THC
does not result in an attenuation of the effects of the latter. One of the most
intriuing observations in the monkey tests is the finding that pretreatment with
-THC attenuates -THC-induced ptosis, sedation, ataxia. and operant
behavior in monkeys (table 5). The importance of this observation is that
-THC produces more than a modest reduction in the effects of -THC in
most cases. -THC-induced operant suppression is decreased by as much as 25
times. Although it may be premature to describe this interaction in monkeys as
antagonism, two exciting leads emerge. This exocyclic compound suggests
further possible alterations in the cannabinoid structure for developing an
antagonist, and implies that the monkey may be better suited for characterizing
cannabinoid antagonistic activity than other behavioral tests.
SUMMARY
The behavioral effects of cannabinoids are dependent upon numerous variables
which include species differences, dose, experimental conditions, etc. The
complexity of the cannabinoid behavioral syndrome certainly complicates attempts
to establish biochemical correlates. It is for this reason that attempts are being
made to develop analogs that exhibit selective behavioral effects. The
pharmacological profile of the analogs summarized in table 6 suggests a tentative
classification for the cannabinoids. While there are numerous analogs which
produce the entire spectrum of cannabinoid effects, only those discussed within
this article are grouped in class 1. CBD and many of its analogs appear to be
devoid of cannabinoid effects, but they are capable of producing CNS depression
at large doses (class 2). It is our working hypothesis that the compounds in class
2 may be altering membrane peturbation in a nonspecific fashion. This latter effect
may or may not be related to the psychoactive cannabinoids. Class 3 compounds
are potent CNS depressants that appear to lack other effects that are unique to
cannabinoids. These analogs are particularly interesting in that they may be
altering membrane function in a specific fashion in contrast to nonspecific effects
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exerted by analogs in class 2. Analogs in class 4 appear to exert selective CNS
depression. While the mechanism by which these analogs are producing their
effects may be proven to be different from those postulated, it does appear that a
classification of cannabinoid effects is possible through structural alterations in the
cannabinoid molecule.
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Interactions of Cannabinoids With Membranes.
The Role of Cannabinoid Stereochemistry and
Absolute Configuration and the Orientation of
Delta-9-THC in the Membrane Bilayer
Alexandros Makriyannis, Ph.D.; Ali Banijamali, Ph.D.;
Cornelis Van Der Schyf, Ph.D.; and Harold Jarrell, Ph.D.
INTRODUCTION
Cannabinoid  Membrane  Effects
Many pharmacological actions of the cannabinoids, such as psychotropic effects,
bronchodilatation, increased heart rate, reduced intraocular pressure, analgesia,
alteration in body temperature, and anticonvulsant activity, can be related to
their known effects on a variety of cellular membranes. Indeed, cannabinoids
are known to affect a variety of membrane functions (Martin 1986; Mechoulam
et al. 1985; Hillard et al. 1985, 1986). Among these we can list their effects on
numerous membrane enzymes (e.g., adenylate cyclase; Na+, K+-, Mg2+-, Ca2+-
ATPases; NADH dehydrogenase; LPC acyltransferase; phospholipase A2;
monoamine oxidase; cholesterol esterase; 5'-nucleotidase), brain synaptosomes,
blood platelets, human fibroblasts, neuroblastoma cells, rabbit neutrophils
(Naccache et al. 1982), excitable membranes (Martin 1986), and membrane
receptors (e.g., beta-adrenergic, cholinergic, opioid, dopaminergic) (Bloom 1984;
Bloom and Hillard 1985). The membrane functions affected by the cannabinoids
can be related to a wide variety of membrane-bound proteins. A common
feature with all of these effects is that the cannabinoids do not seem to interact
directly with the protein catalytic sites and do not compete with those ligands
known to interact with these sites.
Cannabiniod Activity Through Interactions with Phospholipids
It is generally accepted that the lipid microenvironment surrounding membrane-
associated enzymes (Sandermann 1978), receptors, or other functional proteins
(Loh and Law 1980) can influence protein function. On this basis, the view was
advanced that cannabinoids may exert their effects by interacting with the lipid
component of the membrane. The following evidence is offered in support of
this view: (I) Cannabinoids are highly lipophilic molecules and partition
favorably in membrane lipids. (2) Cannabinoids have been shown to affect the
thermotropic properties of phospholipids. They thus decrease the phase
transition temperature of pure (Bruggemann and Melchior 1983; Makriyannis et
al. 1987) and brain membrane (Bach and Sela 1981) phospholipids. Also, they
eliminate the discontinuity in the Arrhenious plot for microsomal O-demethylase
(Bach et al. 1977), an effect attributed to a change in the phase transition
properties of the lipids associated with the enzyme. (3) Cannabinoids affect the
"microviscosity" of model and biological membranes as determined by electron
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spin resonance (ESR) (Lawrence and Gill 1975), fluorescence (Hillard et al.
1986), and NMR methods (Makriyannis et al. 1987; Kriwacki 1986). The lipid
hypothesis is bolstered by the fact that some of these studies were carried out
using cannabinoid concentrations considered to be "physiological" (Hillard et al.
1985).
The Role of Drug Geometry in Drug: Phospholipid Interactions
Traditionally, the potency of drugs that are believed to act on the lipid
component of the membrane has been correlated with their lipid solubility and
no consideration was made for variations in their conformational properties or
their absolute configurations. This assumption was shown to be true with the
low molecular weight general anesthetics (Kendig et al. 1973), but does not seem
to hold with the larger membrane-active drugs. It was thus reported that
enantiomeric pairs of barbiturates showed marked differences in potency
(Wahlstrom et al. 1970). This has also been well documented in the case of
anesthetic sterioids where small structural variations in the steroid molecule,
having no effect on its lipid solubility, produce dramatic changes in anesthetic
activity (Atkinson et al. 1965). When tested for their effectiveness in inhibiting
the function of a membrane-bound protein (Makriyannis and Fesik 1980) and for
their abilities to perturb model phospholipid membranes (Makriyannis and Fesik
1983; Makriyannis et al. 1986), the anesthetic steroids showed variations that
paralleled those of their respective potencies. We explained the observed
differences in steroid membrane interactions on the basis of observed
conformational differences between the drug molecules (Fesik and Makriyannis
1985).
Interestingly, an analogous effect was demonstrated by Bloch and coworkers, who
found that small variations in sterol structure influence in a dramatic manner
their effects on model membranes, including solute permeation, microviscosity,
and steroid mobility in the membrane (Lala et al. 1978; Dahl et al. 1980), as well
as the growth rates of microorganisms (Lala et al. 1978).
Analogous evidence is also available for cannabinoids, pointing to the role of
structure and geometry in their interactions with phospholipids. Earlier work
using ESR (Lawrence and Gill 1975) showed that cannabinoid analogs with only
slight structural differences, or having the same structure but differing in
absolute configuration, exhibited relatively large differences in their effects on
model membrane preparations. As reported in a recent publication, fluorescence
polarization was used to study the effects of cannabinoids on synaptosomal
plasma membranes (Hillard et al. 1985). The study found significant changes in
membrane "fluidity" when "physiological" concentrations of cannabinoids were
used. Another study compared the thermotropic properties of model membrane
preparations containing each of the two delta-9-THC enantiomers and found
differences between them (Burstein et al. 1986). We would like here to report on
more detailed work from our laboratories using solid-state 2H-NMR
spectroscopy.
RESULTS AND DISCUSSION
Model Membranes and the Use of Solid-State NMR Techniques
Because of their demonstrable applicability to the natural systems, studies with
model membranes have contributed a great deal toward understanding the
properties of biological membranes. Model membranes have also been used
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successfully to obtain information on drug:membrane interactions. Many of these
studies have made use of fluorescence, E.S.R., and high resolution NMR
techniques. However, the availability of solid-state NMR has opened new
horizons in this field of research. During the past few years, these methods have
led to previously unavailable molecular information on the conformational and
dynamical properties of model and biological membranes (semisolids) (Griffin
1981; Davis 1983). The use of solid-state NMR has also been extended to study
drug:membrane interactions and showed it to be the method of choice (Boulanger
et al. 1981; Makriyannis et al. 1986). The model membranes used for the solid-
state NMR experiments are multilamellar bilayer phospholipid dispersions that
have proven to be excellent models, sharing to a surprisingly large degree many
of the properties of the lipid component in biological membranes (Davis 1983).
The Role of Cannabinoid Conformation and Absolute Configuration During its
Interaction with Membranes as Studied by Solid-State 2H-NMR
In systems undergoing anisotropic motions, as is the case with phospholipid
multilamellar bilayers, the deuterium nucleus gives rise to a "powder spectrum" in
which the doublet with the maximum intensity is the 2H quadrupolar splitting
( ) and equal to:
= (3/4) (e2qQ/h) SCD (Davis 1983)
where e2qQ/h) is the static quadrupole coupling constant which for, paraffinic
C-D bonds, is approximately 170 KHz. SCD is the order parameter which can be
used to describe the amount of motional averaging of the C-D bond vector with
respect to a fixed symmetry axis and has been used as a measure of membrane
"fluidity."
In its liquid crystalline phase, the 2H spectrum of DPPC labeled in a single site
has the powder pattern features observed in the 2H spectra of solids. However,
the quadrupolar splitting is reduced due to motional averaging, including axial
diffusion of the chains and gauche:trans isomerization in the methylene chain
segments.
To compare the effects of cannabinoid analogs on membranes, we used DPPC
model membranes containing 0.15M cholesterol into which 0.15M cannabinoid
was incorporated. From earlier studies with anesthetic steroids (Makriyannis,
unpublished), we have found that model membranes of such composition are
very suitable for discriminating between membrane-acting drug analogs and that
the relative effects of these molecules on the model membrane parallel their
effects on biological membranes.
We compared the effects of (-)-delta-9-THC to those of its inactive (-)-delta-
9,11-THC isomer on the model membrane by obtaining solid-state 2H-NMR
spectra as a function of temperature for each of the two preparations as well as
spectra for the membrane preparation without cannabinoid. We also compared in
a similar manner the effects of the two delta-9-THC enantiomers.
Figure 1 shows representative spectra from the model membrane preparations
with (-)-delta-9-THC, (-)-delta-9,11-THC, and no drug, obtained at two
different temperatures. The spectra are of the liquid crystalline type and allow
us to extract directly values for the residual 2H quadrupolar splittings ( ). As
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expected, the splittings decrease as the temperature is increased, reflecting the
higher ratio of gauche:trans chain conformers in the chain at higher temperatures.
In figure 2, we compare the  values for the above three preparations as a
function of temperature, while figure 3 compares the effects of the two delta-9-
THC enantiomers on the same membrane preparation. As can be seen, the
presence of each of the three cannabinoids in the membrane results in a decrease
in the respective 2H quadrupolar splittings. Also, membrane preparations
containing the pharmacologically active (-)-delta-9-THC analog give 2H spectra
with consistently smaller splittings than those from its inactive or less active
isomers, (-)-delta-9,11-THC or (+)-delta-9-THC. This is evidence that, although
all three cannabinoids increase the ratio of gauche:trans conformers in the
membrane chain, the more active analog produces the larger increase in
gauche:trans methylene ratio and the smaller order parameter (SCD). This, in
turn, may be interpreted to mean that the active (-)-delta-9-THC analog
"perturbs" the model membrane more effectively than its two less active isomers.
The above data show that the interaction of cannabinoids with the phospholipid
component of the membrane is governed by specific stereoelectronic require-
ments. Our results also provide support for the view that at least some of the
cannabinoid effects result from their interactions with the lipid component of the
membrane. The above observations on the stereoselectivity of cannabinoid:
phospholipid interactions are understandable if the defined geometric parameters
of the phospholipid bilayer are considered. These include the natural asymmetry
of the lecithin and cholesterol molecules as well as the conformational
preferences and dynamic properties of the lipid hydrocarbon chains and/or polar
head groups.
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FIGURE 1. Solid-state 2H-NMR spectra due to the 2(7’,7’-C2H) segment of
DPPC obtained using a 90°x - -90° quadrupolar echo sequence at 45.3 MHz
with a 90° pulse width of 2.1-2.4 µs. To obtain each spectrum, 8,000-16,000
ethos were signal averaged. (A) DPPC + 0.15m cholesterol + 0.15M (-)-delta-9-
THC; (B) DPPC + 0.15M cholesterol + 0.15M (-)- delta-9,11-THC; (C) DPPC +
0.15M cholesterol.
FIGURE 2. Temperature dependence of the 2H quadrupolar splittings in the 2H-
NMR spectra of the 2(7’,7’-C2H2) segment DPPC. DPPC + 0.15M
cholesterol + 0.15M (-)-delta-9-THC: ( )DPPC  0.15M cholesterol + 0.15M
(-)-delta-9'11-THC; (  ) DPPC  0.15M cholesterol.
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FIGURE 3. Temperature dependence of the 2H quadrupolar splittings in the 2H-
NMR spectra of the 2(7’, 7’-C2H2) segment of DPPC. ( ) DPPC + 0.15M
cholesterol + 0.15M (-)-delta-9-THC; ( ) DPPC + 0.15M cholesterol + 0.15M
(+)-delta-9-THC.
Since the drug concentrations used in our experiments are much higher than
"pharmacological," the results presented here cannot be viewed as a quantitative
description of the membrane perturbation produced by cannabinoids in vivo.
However, the data give us a qualitative description of the type of conformational
and dynamical changes produced by cannabinoids on the membrane bilayer.
Moreoever, such experiments provide us with a method for comparing the effects
of structurally related cannabinoid analogs on membranes.
The Orientation of (-)-delta-9-THC in DPPC Bilayers
In our effort to understand the geometric parameters involved in the interaction
of cannabinoids with membrane bilayers. we have made use of solid-state 2H-
NMR to study the orientation of (-)-delta-9-THC in the membrane bilayer.
This experiment required the strategic introduction of 2H labels in different
positions of the tricyclic cannabinoid ring system. To that effect, we synthesized
(-)delta-9-THC with specific 2H labels in each of the 2, 4, 8 alpha, 8 beta, 11-
CH3, 10, and 10a positions (Banijamali et al. 1987). The labeled drug molecule
was then introduced in DPPC bilayers. 2H spectra were generally obtained for
membrane preparations containing (-)-delta-9-THC with one 2H label or with up
to three 2H labels if these could be unambiguosly assigned in the solid-state
spectra. Spectra from the 2H-labeled THC in the membrane in the liquid
crystalline phase were axially symmetrical or nearly so and had different
quadrupolar splittings ( ) depending on the position of the 2H label in the
molecule (figure 4). The va ue of these splittings was then used to calculate thel
orientation of (-)-delta-9-THC in DPPC bilayers.
128
FIGURE 4. Below: Representative solid-state 2H-NMR spectrum of 2,4-d2-(-)-
delta-9-THC (.3M) in hydrated DPPC bilayers at 42°C;
(2H2) = 20.8 KHZ. The central doublet ( 
(2H4 ) = 43.0 KHz,
=6.6 KHz) is due to the
phenolic deuteron. Above: Firs& derivative of the same spectrum from which 2H
splittings could be obtained more accurately.
Briefly, the principle of this determination is as follows (Taylor 1981):
Deuterons attached to a rigid structure will give quadrupolar splittings described
by the equation:
= 3/4 e2qQ (3cos2a - 1) [ 3cos2 - 1]
h 2 2
where is the angle between the individual C-2H bond and the rotation axis.
The last term, which is known as the molecular order parameter (Smol), defines
the anisotropic motion of the entire molecule. The angles between the rotation
axis and the C-2H bonds cannot be calculated directly because Smol is not known.
However, Smol is expected to be identical for all 
2H atoms attached to the
cannabinoid ring system in which overall tumbling is expected to dominate the
dynamics of this part of the molecule. Thus, the ratios (R ) between two
quadrupolar splittings for two different deuterium atoms (2Hi and 
2Hj) are equal
to:
R = 3cos
2
a
3cos 2
Our calculations showed that (-)-delta-9-THC orients with its axis of rotation
almost in the plane of the aromatic ring. However, the molecule does not orient
with its long axis parallel to the bilayer chains, as is the case with cholesterol,
but almost orthogonal to the chains. Details of the above calculations will be
given elsewhere.
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The above-described orientation allows the cannabinoid phenolic hydroxy group
to direct itself toward the polar side of the bilayer, indicating that this group
serves as the orienting anchor in the molecule. We refer to this cannabinoid:
bilayer interaction as "amphipathic interaction" in which its primary incentive is
to direct the polar and hydrophobic components of the cannabinoid molecule
toward the respective components in the amphipathic bilayer. This anchoring
effect of the THC phenolic OH on the membrane is intriguing and deserves more
extensive investigation.
Indeed, the requirement of a free OH for activity in THC is well established.
Also, differences in activities have been reported between cannabinoid isomers,
differing only in the presence and/or orientation of hydroxy and keto groups in
the C ring. Since it is reasonable to assume that these hydrogen bonding groups
may also be involved in the orientation of the cannabinoid molecule, one may
speculate that cannabinoid orientation in the membrane may have an important
effect on its biological activity. The drug orientation in the amphipathic
membrane may, thus, play an important (although not unique) role in
determining the nature of the cannabinoid:membrane interaction and its ability to
produce "productive membrane perturbations." We are currently investigating the
above hypothesis.
FIGURE 5. The orientation of (-)-delta-9-THC in DPPC bilayers as determined
from solid-state 2H-NMR data.
We combined our results on the orientation of delta-9-THC in the bilayer with
previously obtained data on the conformation of delta-9-THC (Kriwacki 1986) to
model its interaction with a DPPC bilayer using computer graphics. The
parameters for modeling the phospholipid bilayer were obtained from available
crystallographic data. As can be seen, the THC molecule inserts between the two
fatty acid chains of the bilayer while maintaining its phenolic hydroxy group at
the level of the bilayer interphase. Also, it can be noted that the plane of the C
ring in delta-9-THC deviates from those of the A and B rings. This conforma-
tional property of delta-9-THC may explain its ability to perturb membranes.
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FIGURE 6. Modeling of (-)-delta-9-THC in a DPPC bilayer from experimental
data using a E&S PS 300 system and ChemX graphics software (developed and
distributed by Chemical Design Ltd., Oxford, England).
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The High Affinity Cannabinoid Binding Site
in Brain: Regulation by Guanine Nucleotides
and Isolation of an Endogenous Inhibitor
Jeffrey S. Nye and Solomon H. Snyder, M.D.
INTRODUCTION
The molecular mechanism by which delta-9-tetrahydrocannabinol (delta-9-THC)
produces its characteristic psychotropic effect in man and animals remains a
mystery. The very high potency of cannabinoids and their stereochemical and
structural requirements for eliciting characteristic psychotropic effects suggest
that a neuronal receptor exists for delta-9-THC. Neuronal receptors have been
identified for a wide range of psychotropic agents; these sites have been
characterized by studying the binding of radiolabeled analogues of high potency
drugs.
The biochemical labeling of a drug receptor helps illuminate the drug’s
mechanism of action. The identification of receptor subtypes in different organs
or regions of the brain has helped clarify the pharmacological effects of certain
drugs. Sometimes the site of action of a drug may in fact be the receptor for a
well known neurotransmitter, as was the case for the antipsychotic drugs which
act at dopamine and serotonin receptors. Alternatively, a drug receptor may
physiologically interact with a previously unknown neurotransmitter, as in the
case of opiate receptors and the enkephalins.
DEVELOPMENT AND CHARACTERIZATION OF THE RADIOLIGAND
[3H]5'-TRIMETHYLAMMONIUM-DELTA-8-THC ([3H]TMA)
To identify a receptor for cannabinoids, we developed a cationic analogue of
THC which was water-soluble and biologically active. Because of the extensive
membrane partioning of cannabinoids, studies with 3H-delta-9-THC have not
revealed saturable binding sites. TMA (figure 1) (Seltzman et al. 1985) possesses
a quaternary ammonium moiety at the 5’ position. Pharmacological studies reveal
that modification of the 5’ position does not result in loss of psychotropic activity
(Ohlsson et al. 1979). A tritiated version of TMA was prepared from
5'dimethylammonium delta-8-THC and [3H]CH3I.
Cannabimimetic Activity of TMA
To evaluate the biological activity of TMA, we studied its effects on the field-
stimulated contractions of the guinea pig ileum (Nye et al. 1985, table 1). The
ileum serves as an excellent model of cannabinoid action since its contractions
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FIGURE 1. 5’-Trimethylammonium delta-8-tetrahydrocannabinol (TMA)
are inhibited by cannabinoids in a stereospecific manner which accurately
parallels their psychotropic effects (Rosell et al. 1979). Active cannabinoids
suppress the contractions of the ileum when stimulated by low voltage fields or
serotonin application, but not those elicited by acetylcholine. Contractions are
suppressed by an inhibition of release of acetylcholine from the presynaptic
nerves.
TMA and 5’-dimethylammonium delta-8-THC inhibit contractions of the ileum
with IC50s of 1000 and 900 nM, respectively. TMA also inhibits serotonin-
induced contractions, but not those elicited by acetylcholine. These studies
suggest that TMA is an active cannabinoid. Because of its permanent positive
charge, TMA may not cross the blood-brain barrier and, thus, be inactive when
administered i.v.
Binding of [3H]TMA to Neuronal Membranes
Binding of [3H]TMA to homogenates of membranes from whole rat brain is
saturable (Nye et al. 1985). Typically, we use 75 pM [3H]TMA with 5 to 10 ug
protein of brain membranes. Inhibition of binding by unlabeled TMA reveals a
half-maximal inhibition at 100 nM TMA (figure 2). The dissociation constant
(KD) is 89 nM, calculated from Scatchard analysis of the data. The maximal
number of binding sites is calculated as 1.1 nmol mg protein. The Hill
coefficient is 1.1, indicating a single class of binding sites and the absence of
significant cooperative interactions.
Detailed kinetic analysis of the binding of [3H]TMA to brain membranes
indicates very slow association and dissociation rates (figure 3). The association
rate constant (k1) is 4.5 x 10
9 M-1h-l. Dissociation of radioligand was initiated
with 10 uM unlabeled TMA yielding a dissociation rate constant (k-1) of
0.24 h-1. The dissociation constant (KD) calculated as the quotient of the rate
constants (k-1/k1) is 5.7 x 10
-11 M, which is more than 1000-fold lower than the
KD determined above, calculated from inhibition of equilibrium binding. This
discrepancy may reflect a nonspecific interaction of [3H] TMA with membranes,
resulting in a low free concentraction of TMA.
135
FIGURE 2. [3H]TMA binding to rat cortical membrane homogenates. Triplicate tubes containing [ 3H]TMA
(75 PM) were incubated with crude homogenates (20 ug protein) at 37°C for 3 hr with varying concentrations
of unlabelled TMA. Nonspecific binding in the presence of 10 uM TMA is subtracted and the result is
compared to binding in the absence of unlabelled TMA. Data presented are from a representative experiment
which was repeated four times with results varying less than 15%. Inset: Scatchard analysis of [3H]TMA
binding. Bmax, maximum binding. From Nye et al. 1985. Copyright 1985 by American Society for Pharmacology
and Experimental Therapeutics (Baltimore).
FIGURE 3. Kinetic analysis of [3H]TMA binding. Left: [3H]TMA (100 PM)
was incubated with crude rat brain membrane homogenates at 37°C for varying
periods of time before rapid filtration and washing. Right: [3H]TMA (100 PM)
and crude membrane homogenates were preincubated for 4 hr. Ten micromolar
TMA was added to aliquots of the mixture to initiate dissociation for varying
times before rapid filtration and washing. Fraction specific binding is calculated
as the total binding minus the binding in the presence of 10 uM TMA divided by
the maximal specific binding (at 4 hr). The rate constants are calculated
assuming first-order dissociation (r=.99) and pseudo first-order association
kinetics (r=.96).
Cannabinoid Specificity of [3H]TMA Binding
The binding of [3H]TMA is not inhibited at concentrations less than 1 uM by a
wide range of drugs and compounds spanning numerous drug-receptor classes,
active peptides, and highly hydrophobic compounds (legend to table 1).
However, cannabinoids show high affinity for the [3H]TMA site. Delta-9-THC,
the major naturally occurring psychotropic cannabinoid, inhibits [3H]TMA
binding with an inhibitory constant (Ki) of 27.3±5.0 nM, and delta-8-THC has a
Ki of 32.9±0.8 nM. These concentrations represent the calculated concentration
of compound in the assay volume. Because of extensive nonspecific membrane
partitioning, the actual free concentrations are substantially lower. Similar
concentrations of delta-9-THC are found in the blood of human subjects and
rhesus monkeys after threshold doses (Agurell et al. 1985).
Binding studies of a series of cannabinoid analogues reveal a well-defined
structure-potency relationship for the [3H]TMA site in brain (Nye et al. 1985,
table 1). Taken together, the potencies for all of the cannabinoids at the
[3H]TMA site do not correlate with their potencies observed in the psychotropic
test or in any other known behavioral assay. However, among groups of
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TABLE 1
Comparison of potencies for cannabinoids
aInhibitory constant (Ki) for [
3H]TMA site. Compounds with negligible effects
at 1 uM are: amphetamine, atropine, capsaicin, captopril, carbamazepine, chloral
hydrate, cholesterol, choline, cocaine, cortisone, cyclohexyladenosine, diazepam,
dihydro-ergotamine, doxepin, 17-beta-estradiol, GABA, haloperidol, imipramine,
2-isobutyl-3-methoxypyrazine, lysergic acid diethylamide, mazindol,
meprobamate, mianserin, muscimol, naloxone, norepinephrine, nitrendipine,
nortriptyline, orcinol, ouabain, paraldehyde, pargyline, phencyclidine,
phenobarbitol, phentolamine, phenytoin, phorbol dibutyrate, picrotoxin,
progesterone, resorcinol, SKF525a. strychnine, testosterone, thiothixene,
thyroxine, tyrosine, valproic acid, verapamil, and zopiclone. bPotency of
cannabinoids on guinea-pig ileum. cThreshold for rhesus psychotropic effects
from Mechoulam and Edery (1973) and references therein. Codes are: H, high,
<.1 mg/kg; M, medium, .1-.5 mg/kg; L, low, .5-2 mg/kg; I,inactive, >2 mg/kg.
dDifferent from levo isomer (P<.05). eDifferent from levo isomer (P<.1). fnt-
Not tested. jSee Lee et al. 1983. From Nye et al. 1985. Copyright 1985 by
American Society for Pharmacology and Experimental Therapeutics (Baltimore).
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cannabinoids which are active in eliciting a psychotropic response, the order of
affinity for the [3H]TMA site parallels the order of potency in behavioral studies
and in inhibiting contractions of the ileum. The features of [3H]TMA
pharmacology which parallel behavioral potencies are as follows:
1. The [3H]TMA site shows a stereochemical preference for the natural isomer
of THC. Thus, for both delta-8- and delta-9-THC, the levo stereoisomer is
significantly more potent than the dextro isomer.
2. The pentyl side chain is essential for [3H]TMA binding. Substitution of the
side chain with a carboxylic acid abolishes potency, while the addition of 1’ and
2’ methyl groups enhances affinity for the [3H]TMA site. The order of
inhibitory potencies for side-chain hydroxylated analogues of delta-9-THC
accurately reflects their order of potency in both psychotropic tests and
physiological assays.
3. The phenolic hydroxyl (position 1) must be unobstructed for significant
[3H]TMA binding potency. Thus, desacetyl-levonantradol is 10-fold more potent
than levonantradol (figure 4). This deacetylation occurs in vivo and is essential
for psychotropic activity (McIlhenny et al. 1981). Cannabinol acetate is also
significantly weaker than cannabinol.
4. The addition of a carboxylic acid moiety inactivates delta-9-THC in inhibiting
[3H]TMA binding and in behavioral assays. The addition of a hydrox  to the 11
position of delta-9- or delta-8-THC does not impair affinity for the[3H]TMA
site, whereas 8-hydroxyl derivatives have significantly reduced affinity.
A number of natural cannabinoids and synthetic analogues display significant
affinity for the [3H]TMA site despite their apparent inactivity in numerous tests
for psychotropic efficacy. Thus cannabinol, cannabidiol, cannabigerol,
cannabicyclol and delta-9,11-THC lack psychoactivity but show affinities for the
[3H]TMA site of 34.4, 73.1 8.3, 73.1, and 13.6 nM, respectively. These
discrepancies suggest that [3H]TMA may not be labeling the site of action of
delta-9-THC for producing psychotropic effects.
An alternative possibility suggested by analogy to other drug-receptor systems is
that structural isomers that lack bioactivity may be antagonists. Although the
pharmacological data are incomplete for many of the inactive cannabinoids, a
growing body of evidence indicates that antagonists do exist. The best studied is
cannabidiol, which antagonizes the effects of delta-9-THC in humans, rodents
(Karniol and Carlini 1973; Karniol et al. 1974) and seizure-sensitive animals
(Consroe et al. 1982, this volume). More recently, Martin et al. (this volume)
have demonstrated that delta-9, 11-THC suppresses the psychoactivity of delta-
9-THC in rhesus monkeys. Burstein et al. (this volume) have shown that 9-
catboxy,11-nor-delta-9-THC reduces the catalepsy in mice produced by THC.
Since most measures of the psychotropic effects of cannabinoids in man and
monkey are not quantitative, it is difficult to observe the shifts in dose-response
relationships that result from antagonism. Moreover, several of these compounds
may be weak agonists or partial agonists. This is supported by the observation
that cannabinol in high doses elicits psychotropic effects indistinguishable from
delta-9-THC in humans (Perez-Reyes et al. 1973).
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FIGURE 4. Inhibition of [3H]TMA binding by nantradol isomers. [3H]TMA
(100 pM) was incubated with crude rat brain membranes in the presence of
varying concentrations of nantradol isomers under standard assay conditions.
Nonspecific binding is determined in incubations with 10 uM TMA and is
subtracted from all data.
Localization and Physical Properties of the High Affinity Cannabinoid Site
[3H]TMA binding is found in brain as well as a number of peripheral organs.
The density of binding sites is greatest in brain compared to other organs, and
the highest binding levels occur in the hippocampus. The relative potencies for
several cannabinoids at the [3H]TMA site are similar in all brain regions. Of
peripheral organs, the kidney shows the highest density of sites, while lung and
muscle show the lowest densities.
The [3H]TMA site is an integral membrane component which is fully extracted
by detergents, such as CHAPS and Triton X-100. Molecular sieve chroma-
tography of the [3H]TMA binding site in CHAPS-extracted membranes reveals a
bimodal peak of activity with an Mr of 60,000 daltons. This molecular size
probably includes an undetermined number of bound detergent molecules.
REGULATION OF THE HIGH AFFINITY CANNABINOID SITE BY PURINE
NUCLEOTIDES
We evaluated the effect on [3H]TMA binding of guanine and adenine nucleotides
(figure 5). The specific binding of [3H]TMA is enhanced about 3-fold by the
nonhydrolyzable analogue GTP-gamma-S. This enhancement occurs between 0.1
and 10 micromolar; at higher concentrations the enhancement is abolished, with
small inhibition observed at >200 uM. GTP does not produce an increase in
[3H]TMA binding; instead, it shows a similar inhibition at high concentrations.
GTP is probably hydrolyzed to GDP and GMP by nonspecific hydrolases during
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FIGURE 5. Regulation of [3H]TMA binding by purine nucleotides. [3H]TMA
was incubated with washed crude brain membranes under standard assay
conditions in the presence of added nucleotides. Control binding is defined as the
specific [3H]TMA binding measured in the absence of added nucleotides minus
nonspecific binding (10 uM TMA). Each data point is the average of duplicate
assays and is representative of three experiments.
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the long incubations required for measuring [3H]TMA binding. The non-
hydrolyzable analogue GDP-beta-S produces a similar enhancement of binding,
but at somewhat higher concentrations. The ED200 (concentration that doubles
binding) is about 1 uM for GTP-gamma-S and about 10 uM for GDP-beta-S.
GMP is without either stimulatory or inhibitory effect. These concentrations are
in the relevant range for an effect which is mediated by a GTP binding protein
(Lefkowitz et al. 1983).
Adenine nucleotides fail to display high potency stimulation of specific [3H]TMA
binding. ATP inhibits binding, but only at high concentrations (IC50 = 100 uM)
(figure 5). The nonhydrolyzable analogue of ATP, ADP-imidophosphate (AMP-
PNP), inhibits [3H]TMA binding with an IC50 between 5 and 10 uM. These
concentrations of AMP-PNP are sufficient to inhibit ATP-dependent processes,
such as adenylate cyclase or GDP-phosphorylation. Forskolin, a stimulator of
adenylate cyclase, has no effect on [3H]TMA binding at the concentrations tested.
The enhancement of [3H]TMA binding by nonhydrolyzable GTP and GDP
analogues suggests that the site may be regulated by a guanine nucleotide binding
protein or G-protein. G-proteins are coupled to a large number of
neurotransmitter and hormone receptors, and they regulate a variety of
intracellular processes, including adenylate cyclase and phospholipase C (Stryer
1986). Paradoxically, both GTP and GDP analogues produce an apparent
increase in [3H]TMA binding. In the case of another receptor linked to a G-
protein, the beta-adrenergic receptor, the affinity of agonists is decreased by
GTP analogues leading to a reduction in binding. Antagonists, on the other
hand, are unaffected by GTP analogues (Lefkowitz et al. 1976).
Recent work by Howlett et al. (1986) suggests that cannabinoids act via a G-
protein in the neuroblastoma cell line N18tg2. Psychotropically active
annabinoids inhibit the adenylate cyclase of these cells at submicromolar
concentrations (Howlett and Fleming 1984; Howlett, this volume). Interestingly,
stimulation of adenyl cyclase via a number of different receptors is inhibited by
cannabinoids. Moreover, Howlett et al. (1986) have demonstrated that the
inhibition is reversed by ADP-ribosylation with pertussis toxin, suggesting that
the cannabinoids are acting via the inhibitory G-protein or Gi.
ISOLATION OF AN ENDOGENOUS INHIBITOR OF CANNABINOID
BINDING
The presence of a neuronal receptor for a psychoactive drug implies that some
endogenous neural mechanism is perturbed by that drug. One possible
neurochemical mechanism is the interaction of a neurotransmitter or
neuromodulator and its receptor. Accordingly, we decided to search in brain
extracts for an endogenous inhibitor of [3H]TMA binding.
Extracts of rat brain were prepared according to the method of Bennett et al.
(1978). Such extracts preserve peptides from proteolysis and precipitate most
proteins. These preparations inhibit [3H]TMA binding in a dose-dependent
manner when added to standard assays. Because inhibitory activity was stable to
acid and acetonitrile, we partially purified the active component using a
combination of conventional chromatography and HPLC. The extracts were
loaded on a C18 reverse-phase Sep Pak (Waters), washed with 0.1% trifluoracetic
acid, and eluted with 80% acetonitrile 0.1% aqueous TFA. This material was
chromatographed on a Biogel P10 column (Biorad) and eluted with 10% formic
acid 0.1% 2-mercaptoethanol. The fractions were evaporated and assayed for
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inhibition of [3H]TMA binding (figure 6). A single peak of inhibitory activity is
observed in fractions corresponding to the void volume of the column. HPLC
gel filtration chromatography of the pooled fractions on a TSK column (Biorad)
reveals a single peak of [3H]TMA inhibitory activity corresponding to a
calculated molecular size of 15-20,000 daltons (figure 7).
FIGURE 6. Gel filtration chromatography of the endogenous inhibitor of
[3H]TMA binding. Rat brain extracts. prepared as described in the text, were
loaded onto a Biogel P10 (Biorad) column (1x25 cm) equilibrated in 10% formic
acid/0.1% 2-mercapto-ethanol running at 5 ml/hr. Fractions (0.35 mL) were
evaporated and resuspended in 25 mM TES buffer (pH 6.8) before being added to
standard [3H]TMA binding assays in the presence of 75 pM [3H]TMA. Fractions
26-32 correspond to the void volume of the column. Assays were performed in
singlicate and represent two similar experiments.
Partially purified fractions of the endogenous inhibitor reduce [3H]TMA binding
(figure 8) in a concentration-dependent manner. Although the preparation tested
is only partially purified, it shows an inhibitory potency (IC50) of 1.5-2.0 x 10
-4
g protein/L. Assuming that a 15-20,000 dalton protein accounts for the
inhibitory activity, the maximal molar concentration of the preparation at the
IC50 is 10 nM. When fully purified, the actual IC50 of the endogenous inhibitor
of [3H]TMA binding may therefore be substantially lower than 10 nM. Many
possibilities exist for the role of the endogenous inhibitor of [3H]TMA binding.
It is enticing to speculate that this protein is a neurotransmitter or
neuromodulator whose normal functioning is perturbed by cannabinoids. Thus,
further characterization of the endogenous inhibitor may lead to additional
insights into the effects of cannabinoids upon the brain. Alternatively, the page
endogenous inhibitor may be an intracellular regulatory protein which interacts
with the cannabinoid site to alter certain cellular processes.
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FIGURE 7. Molecular sizing of the endogenous inhibitor of [3H]TMA binding by
high pressure liquid chromatography. Partially purified rat brain extracts (see
text) were loaded onto a Biosil TSK column triplet (TSK-400, TSK 250, and
TSK-125) connected in series. The columns were eluted with 32% acetonitrile
0.1% aqueous trifluoroacetic acid at a flow rate of mL/min. Fractions (0.5
mL) were evaporated, resuspended in 0.1 N HCl, and added to standard
[3H]TMA binding assays. The data presented (upper tracing) are from single
determinations on each fraction. Equivalent quantities of HCl reduced binding to
60% to 70% of maximal levels. The eluate was monitored for absorbance at 280
nm (lower tracing). Bovine serum albumin (a, Mr=66,000), alpha-MSH (b,
Mr=1572), and 2-mercaptoethanol (c, Mr=78) were used as standards to calibrate
the column.
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FIGURE 8. Inhibitory potency of a partially purified preparation of the
endogenous inhibitor of [3H]TMA binding. Dilutions of partially purified
extracts obtained from gel filtration chromatography were added to triplicate
standard [3H]TMA binding assays with crude bruin membranes. Maximal
binding is defined as the total binding minus the binding in the presence of 10 uM
TMA. The abscissa represents the logarithm of the concentration of added protein
in the final volume of the [3H]TMA binding assay. Protein values were
determined from protein assay (BCA, Pierce) of the partially purified endogenous
inhibitor preparation.
MODEL OF CANNABINOID ACTIONS
One of the most perplexing phenomena in studying the cellular actions of
cannabinoids is their profound effects on a host of enzymes, transport
mechanisms, and neurochemical processes (Martin 1986). One possible
explanation for these diverse effects is that cannabinoids modulate the
metabolism of intracellular second messengers, such as cyclic AMP or the
phosphoinositide phospholipids (PIP,). These intracellular mediators in turn
regulate the activity of multiple cellular processes by stimulating the
phosphorylation of proteins, by the release of calcium ion stores, and by other
mechanisms.
A mechanism for the regulation of intracellular second messengers by
cannabinoids is suggested by the finding that the high affinity cannabinoid site
as labelled by [3H]TMA appears to be coupled to a G-protein. Moreover, the
effect of cannabinoids on adenylate cyclase is mediated via Gi (Howlett, this
volume). Since G-proteins are the regulatory proteins which modulate the
activities of adenylate cyclase, phospholipase, and other second messenger-
metabolizing enzymes, an effect by cannabinoids upon these critical proteins
would in turn affect multiple cellular processes. Although the evidence is
incomplete, the hypothesis that all of the cellular actions of cannabinoids are
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mediated via G-proteins offers a unified explanation for the diverse and multiple
effects of cannabinoids in Vitro and in vivo.
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Regulation of Adenylate Cyclase in a Cultured
Neuronal Cell Line by Marijuana Constituents,
Metabolites of Delta-9-tetrahydrocannabinol,
and Synthetic Analogs Having Psychoactivity
Allyn C. Howlett, Ph.D.
The psychoactive properties of cannabinoid drugs have been described in
man and investigated in a variety of animal models. However, in vitro
studies have failed to elucidate the mechanism of cannabinoid action at the
neuronal level. The activities of a number of enzymes have been reported
to be modified by cannabinoid compounds (Martin 1986). However, in many
studies, problems arise in correlating these cellular events with changes in
animal behavior. This may be because the drug concentrations required for
alterations in enzyme activity are greater than would be expected at the
site of action in the brain. In other studies, cannabinoid drugs having little
or no psychoactivity produce a cellular response similar to that of
psychoactive cannabinoid drugs. These difficulties in defining a mechanism
of action for cannabimimetic drugs have been discussed by Martin (1986) in
a recent review on the cellular effects of cannabinoid drugs. Studies in my
laboratory have determined that cannabimimetic drugs inhibit cyclic AMP
accumulation in neuronal cells (Howlett 1984; Howlett and Fleming 1984).
These studies will be described in this chapter. It is proposed that the
cannabimimetic inhibition of adenylate cyclase is a receptor-mediated
cellular response that may be one mechanism of action for these drugs.
A neuroblastoma cell culture system is used for these studies as a model for
neurons. The N18TG2 cell line was cloned from the cultured C1300 tumor
(Augusti-Tocco and Sato 1969; Gilman and Minna 1973; Schubert et al.
1969). This tumor arose spontaneously in the region of the spinal cord of the
A/J mouse (Augusti-Tocco and Sato 1969) and, therefore, may have been
derived from sympathetic ganglial cells. N18TG2 cells have retained a
typical neuronal morphology in culture (Augusti-Tocco and Sato 1969;
Schubert et al. 1969), and they exhibit electrophysiological responses to
neurotransmitters such as acetylcholine (Chalazonitis et al. 1977). These
cells also synthesize the neuromodulator, vasoactive intestinal peptide (VIP)
(Brick et al. 1985). The advantage of using cultured neuroblastoma cells
rather than brain cells for biochemical studies of adenylate cyclase is that
plasma membranes may be isolated from large quantities of cells that are
genetically and phenotypically identical.
A number of neuromodulators interact with receptors that regulate the
synthesis of cyclic AMP in neuronal cells. Cyclic AMP diffuses into the
neuron as the "second messenger" that activates cyclic AMP-dependent
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protein kinase. Protein kinase modifies the activity of key enzymes
involved in such functions as neurotransmitter synthesis or membrane
excitability (Bloom 1975; Daly 1977; Greengard 1976). The regulation of
adenylate cydase by neuromodulator receptors is complex and has been
reviewed by Gilman (1984). According to our current understanding,
stimulatory receptors interact with a regulatory protein complex, Gs, and
inhibitory receptors interact with a homologous complex, Gi (figure 1). Both
regulatory proteins are heterotrimers comprising , , and subunits.
Although the and subunits of Gs and G i are thought to be nearly
identical, the a subunits differ structurally and functionally. Stimulatory
and inhibitory neuromodulator-receptor interactions promote the binding of
GTP onto the and subunits, respectively. This causes dissociation of
the  or f r o m  t h e a n d pro te ins .  The subunit is then free to
activate the catalytic protein of adenylate cyclase. The free ai subunit may
inhibit the catalytic protein directly. However, inhibition of adenylate
cyclase may also occur as the free  proteins form a new equilibrium with
proteins and thereby prevent the interaction of with the catalytic
subunit.
INHIBITION OF ADENYLATE CYCLASE BY CANNABINOID COMPOUNDS
My laboratory provided the first evidence that cannabimimetic drugs
decreased cyclic AMP accumulation in neuronal cells (Howlett 1984).
Tetrahydrocannabinol (THC) and -THC decreased both basal  and
prostacydin- (prostaglandin I2-) stimulated cyclic AMP accumulation in
neuroblastoma cells. Prostanoid-stimulated adenylate cyclase in a
membrane preparation from these cells was inhibited by cannabimimetic
compounds, indicating that this enzyme complex was the target for the
e f f e c t  o f -THC on  ce l lu la r  cyc l ic  AMP concen t ra t ions . The
cannabimimetic drugs caused a decrease in Vmax of the enzyme, with no
alteration in the Km for substrate (Howlett 1985). Adenylate cyclase
inhibition was apparent immediately upon addition of -THC and the
effects of the drug were readily reversible after the membranes were
sedimented and resuspended (Howlett 1985). The inhibition was shown to be
concentration-dependent over a nM range for both -THC and -THC.
The activity of cyclic nudeotide phosphodiesterase, responsible for the
metabolic breakdown of cyclic AMP, was unaltered by these agents (Howlett
1984).
The cannabimimetic inhibition of adenylate cyclase was not observed
universally in all cell types. The response was not observed in either the
soluble adenylate cyclase from rat sperm or the membrane-bound adenylate
cyclase from C6 glioma or S49 lymphoma cells (Howlett et al. 1986). This
cellular selectivity provides evidence for the existence of specific receptors
for the cannabimimetic drugs. If these drugs were influencing enzyme
activity by intercalating into lipid membranes and altering membrane
fluidity, then one would have expected universal inhibition of adenylate
cyclase in all cell types. This was not the case.
The inhibition of adenylate cyclase by -THC in neuroblastoma plasma
membranes was not due to an effect on stimulatory receptor regulation of
the enzyme (Howlett and Fleming 1984). Inhibition by -THC was not
competitive with prostaglandin E1  or prostacyclin. Furthermore, non-
competitive inhibition was also observed when the peptide hormones
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FIGURE 1. Hypothetical  model of the regulation of adenylate cyclase by stimulatory and inhibitory neuromodulators. Rs
and Ri represent one of several pharmacologically distinct receptors for stimulatoy and inhibitory neuromodulators,
respectively, and Hs and Hi indicate occupancy by their respective agonist ligands. The G-protein complexes, Gs and Gi are
denoted as their subunit constituents, and respectively. The catalytic protein is designated C. Details
concerning the interaction of these protein subunits are found in the text.
secretin and VIP stimulated the enzyme. Additional evidence that the
THC was not acting at the level of the receptors that stimulate adenylate
cyclase was provided by the observation that inhibition also occurred when
forskolin was used to activate the enzyme. Forskolin is believed to act
directly at the catalytic subunit (Seamon and Daly 1981).
The cannabimimetic inhibition of adenylate cyclase appeared to resemble
the regulation resulting from inhibitory neuromodulator receptors that act
via Gi (Howlett 1985). The effects of cannabimimetic drugs were related to
the ability of the enzyme to be regulated by divalent cations and guanine
nucleotides. The inhibition was greatest at micromolar Mg2 + or Mn2 +
concentrations and was attenuated by millimolar concentrations of Mn2+.
Half-maximal inhibition of adenylate cyclase was observeo at 800 nM GTP
for both cannabimimetic and muscarinic cholinergic agents. This
concentration is higher than that required for stimulation of the enzyme by
hormones and is typical of the high GTP concentrations required by
inhibitory hormones and neuromodulators in other systems (Cooper 1982).
These observations illustrate the similarities between the enzyme inhibition
by cannabimimetic drugs and by muscarinic cholinergic drugs. It is inferred
that the cannabimimetic drugs must act via regulatory mechanisms similar
to those operating for hormonal inhibition of adenylate cyclase.
Receptor-mediated inhibition of adenylate cyclase in most eukaryotic
systems requires the presence of the guanine nucleotide-binding protein
complex, Gi. Further studies confirmed that cannabimimetic inhibition of
adenylate cyclase also required the presence of Gi (Howlett et al. 1986). Ci
can be functionally inactivated as the result  of an ADP-ribosylation
modification catalyzed by pertussis toxin. Therefore, pertussis toxin can be
used as a tool to identify Gi-mediated events in the cell. Pertussis toxin
treatment of intact N18TG2 cells abolished the cannabimimetic regulation
of cellular cyclic AMP content. The adenylate cyclase response to -THC
was also attenuated in membranes isolated from cells that had been treated
with pertussis toxin. The action of pertussis toxin for in vitro modification
of neuroblastoma Gi requires NAD as substrate for the ADP-ribosylation.
The toxin was able to catalyze the labeling of a neuroblastoma membrane
protein in vitro using (32P)NAD under conditions similar to those by which
attenuation of the cannabimimetic inhibition of adenylate cyclase could be
demonstrated. Protein labeling and the loss of the response to -THC
followed the same dose-response curve for pertussis toxin. This strengthens
the argument that cannabimimetic drugs act via receptors that interact
with the inhibitory GTP-binding protein complex.
THE PHARMACOLOGY OF CANNABIMIMETIC INHIBITION OF
ADENYLATE CYCLASE
Inhibition of adenylate cyclase in N18TG2 cells is known to be regulated by
muscarinic cholinergic, -adrenergic, and -opioid receptors. Thus, it was
possible that -THC may be acting via one of these pharmacological
receptor types. When this was tested, it was found that inhibition by
THC was neither synergistic nor additive with muscarinic cholinergic or
adrenerg ic  agen t s  when  each  was  p resen t  a t  maximal ly  inh ib i to ry
concentrations (Howlett and Fleming 1984). Furthermore, the response to
-THC was not blocked by the antagonists to these receptors, atropine and
yohim bine, respectively.
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The opioid drugs are another pharmacological class of neuromodulatory
compounds that inhibit adenylate cyclase in N18TG2 cells. Because of the
interaction of cannabimimetic and opioid drugs in animal models of
tolerance, the possible involvement of opioid receptors was examined (see
Devane et al. 1986 and references contained therein). -Opioid receptors
were found on neuroblastoma membranes using ( 3 H)-D-ala2 -D-ieu5 -
enkephalin. N o  µ - or -opioid receptors were detected. The -opioid
receptor binding affinity and capacity were unaltered by cannabimimetic
drugs. Opioid drugs as well as -THC and the nantradol series of analgesic
cannabimimetic analogs decreased cyclic AMP accumulation in intact cells
and inhibited adenylate cyclase in membrane preparations. Opioid
antagonists blocked the response to the opioid agonists but not to the
cannabimimetic drugs. The interaction between cannabimimetic drugs and
the opioid agonist etorphine showed no antagonistic, synergistic, or additive
effects at maximal concentrations. These results suggest that the opioid
and cannabimimetic drugs operate via distinct, noninteractive receptors
that can be coupled to the same effector, adenylate cyclase.
Other neuronal cell lines having a -opioid response were also examined
(Devane et al. 1986). The cannabimimetic inhibition of cyclic AMP
accumulation in NC108-15 neuroblastoma x glioma hybrid cells was not as
great as the response in N18TG2 cells. N4TG1 neuroblastoma cells, which
exhibit a prominent inhibition of adenylate cyclase in response to opioid
drugs, did not respond to cannabimimetic drugs under any conditions tested.
Thus, the cannabimimetic response does not correlate with the efficacy of
the -opioid response.
STRUCTURE-ACTIVITY RELATIONSHIPS AMONG THE CANNABINOID
DRUGS
Given that the cannabimimetic response in neuroblastoma cells is mediated
by Gi and does not result from drug interaction with -opioid, muscarinic
cholinergic, or -adrenergic receptors that inhibit adenylate cyclase, the
hypothesis can be proposed that these drugs act via a "cannabinoid"
receptor. The classical means to describe a receptor is to define its
pharmacological spectrum of activity. Th is  was  per fo rmed  us ing
constituents of marijuana extracts and metabolites of these compounds
(Howlett 1987). The concentration of -THC exhibiting half-maximal
inhibition was less than 500 nM (figure 2A). -THC was less active,
cannabinol was only partially active, and cannabidiol was inactive. Other
constituents of marijuana that have no psychoactivity (cannabigerol,
cannabichromene, olivetol) and compounds having a reduced length of the
C3 alkyl side chain were not active as inhibitors of adenylate cyclase (table
1). These inactive compounds did not behave as antagonists to the effects
of -THC.
The nantradol class of cannabinoid analogs were potent inhibitors of
adenylate cyclase (figure 2B). Desacetyllevonantradol was more potent than
nantradol. The nonpsychoactive isomer dextronantradol was a poor inhibitor
of adenylate cyclase.
The metabolities of -THC and -THC hydroxylated at the C11-position
were more potent than the parent drugs (table 1). However, hydroxylation
at the C8-position of the terpenoid ring resulted in loss of activity of
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THC. Compounds hydroxylated along the C3 alkyl side chain were equally
efficacious but less potent than -THC.
These structure-activity relationships are consistent with cannabinoid
pharmacology reported for psychological effects in humans and for
behavioral effects reported in a variety of animal models. Potency
estimates have suggested that the psychological high experience in humans
is greater for - T H C  t h a n  f o r -THC (Hollister 1974; Hollister and
Gillespie 1973). Neither cannabinol nor cannabidiol produced responses in
human subjects at the oral dosages tested (Hollister 1973, 1974). However,
when infused intravenously, cannabinol (but not cannabidiol) produced a
psychological high and cardioacceleration at ten-fold the dose of -THC
(Hollister 1973; Perez-Reyes et al. 1973a). 11-OH-metabolites of -THC
a n d -THC were up to twice as active as the parent compounds in
producing a psychological high (Hollister 1974; Lemberger et al. 1973). The
ability of these compounds to inhibit adenylate cyclase parallel these
responses.
FIGURE 2. Inhibition of adenylate cyclase by cannabinoid and nantradol
compounds. Forskolin was present at 1.0 µM to activate adenylate cyclase.
Other compounds present at the indicated concentmtfons were cannabinol
(CBN), cannabidiol (CBD), levonantradol ( -Nan), dextronantradol (d-Nan),
and desacetyllevonantradol (Da- -Nan).
In animal studies, -THC was less potent than -THC in such tests as dog
ataxia (Martin et al. 1981; Wilson et al. 1976), monkey behavior (Edery and
Crunfeld 1971), mouse hypothermia (Martin et al. 1981), and hot-plate
analgesia (Uliss et al. 1975; Wilson and May 1975) and in genetically THC-
seizure prone rabbits (Consroe and Fish 1981). Cannabidiol (Consroe and
Fish 1981; Edery and Crunfeld 1971; Pertwee 1972; Uliss et al. 1975),
cannabinol (Edery and Grunfeld 1971), and cannabichromene (Edery and
Grunfeld 1971) were inactive in a number of these models. The THC-seizure
prone rabbits responded to cannabinol at high doses (Consroe and Fish 1981).
The 11-OH metabolites of -THC and -THC were more potent than the
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parent compounds in the dog ataxia (Wilson et al. 1976), mouse immobility
(Gill et al. 1973), hot-plate analgesia (Wilson and May 1975), and THC-
seizure prone rabbit models (Consroe and Fish 1981) and in the drug
discrimination studies using rats or pigeons (Jarbe and McMillan 1980).
Animal studies of the hydroxylated metabolites at  the 8-position are
inconsistent; although in each study, 8-OH metabolites are either inactive or
less potent than -THC (Ben-Zvi et al. 1971; Wilson and May 1975; Perez-
Reyes et al. 1973b; Jarbe and McMillan 1980). The data reported here for
inhibition of adenylate cyclase are consistent with this pharmacological
pattern.
TABLE 1
Pharmacological Parameters of Marijuana Constituents and Metabolites
Compound Efficacya Potency
Kinh
-THC
-THC
Cannabinol
Cannabidiol
Cannabichromene
Cannabigerol
Olivetol
-THC
11-OH- -THC
11-OH- -THC
11-OH-cannabinol
8 OH- -THC
8 OH- -THC
8 , 11-diOH- -THC
2´-OH- -THC
3´-OH- -THC
4´-OH- -THC
5´-OH- -THC
Tri Nor- -THC-
carboxylic acid
Penta Nor- -THC-
carboxylic acid
1.0 430
0.9 560
0.5 1400
O b - -
0 - -
0 - -
0 - -
0.6 290
1.0 100
1.0 260
1.0 320
0 - -
0 - -
0 - -
1.0 2800
1.0 840
1.0 1800
1580
0 - -
0 - -
a Relative to -THC equal to 1.
b An efficacy of 0 was assigned to all compounds exhibiting a
lack of inhibition at concentrations up to 50 µM .
The parallels in cannabinoid structure-activity relationships exhibited by the
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neuronal cells compared to the human and animal behaviors is intriguing.
These findings suggest that certain behavioral effects of cannabimimetic
drugs  may be  the  resu l t  o f  an  in te rac t ion  of  these  drugs  wi th  a
pharmacologically distinct receptor associated with neuronal adenylate
cyclase. At least one possible mechanism of action for the cannabimimetic
compounds may involve regulation of cyclic AMP synthesis in populations of
neurons associated with modification of such behaviors.
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Inhibitory and Stimulatory Effects
of Cannabinoids on Eicosanoid
Synthesis
Sumner H. Burstein, Ph.D.
BACKGROUND
Introduction
More than a decade ago, we suggested that some of the actions of
tetrahydrocannabinol (THC) were mediated by changes in
prostaglandin synthesis. This was based on a comparison of the
literature from both fields and the results of pilot experiments
in our laboratory (Burstein and Raz 1972). Much evidence in
support of this hypothesis has since been reported both by us and
by others. At this point, it appears that such a mechanism is
still quite viable and can provide a rational framework for new
experiments aimed at developing a mechanism of action for THC (for
a review, see Martin 1986).
Role of Prostaglandins in the Brain
Arachidonic acid, the precursor of all eicosanoids, is a major
lipid component of brain, and the ability of this organ to
synthesize eicosanoids is well established (Chiu and Richardson
1985). In addition, peripherally administered prostaglandins are
known to produce potent effects on central nervous system (CNS)
function (Curro et al. 1982) and can cross the blood-brain barrier
quite readily (Bito et al. 1976). Moreover, evidence for the
existence of receptors in the brain for several of the
prostaglandins has been reported, although their functional
significance is not clear at present (Malet et al. 1982; Shimizu
et al. 1982).
Of particular interest to this discussion are reports that both
centrally and peripherally injected prostaglandins can produce
behavioral changes in rodents (Poddubiuk 1976; Hollingsworth and
Patrick 1984; Laychock et al. 1980). Sedation and the inhibition
of locomotor activities are prostaglandin-induced responses which
have been known for some time (Gilmore and Shaikh 1972). The
molecular mechanisms accompanying these effects are not well
understood. However, there is some evidence suggesting that
prostaglandins regulate neurotransmitter levels and/or calcium
transport in neuronal tissue (Bergstrom et al. 1973).
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In Vitro Evidence for the Hypothesis
The data reported thus far from our laboratory using a cell
culture model are strongly supportive for a role for prostaglandin
E2 (PGE2) as a mediator of THC action. The structure-activity
relationships (SAR) (Burstein et al. 1983a, 1984a), the develop-
ment of tolerance (Burstein et al. 1985), and the existence of
stereospecificity (Burstein et al. 1986a) give a profile of
activity similar to that for the psychotropic effects of THC in
vivo. The properties of the other primary cannabinoids (CBD,CBN,
etc.) in our model do not show a good correlation with psycho-
activity (Burstein et al. 1983). However, these substances do
have other activities which may be mediated by eicosanoids (Martin
1986). Clearly, any model has its limitations; however, this does
not prevent its utilization as part of a broader approach to
establishing a mechanism.
The experiments we have reported thus far using subcellular
preparations from mouse brain demonstrate that THC can stimulate
lipid turnover by increasing phospholipase activities (Hunter et
al. 1986). We studied phospholipase A2 (PLA2) and phospholipase C
(PLC) activity in synaptosomes, myelin and mitochondrial fractions
using both exogenous and endogenous substrates containing radio-
labelled arachidonate. Submicromolar levels of THC produced
significant increases in PLA2 activity in synaptosomes. Diacyl-
glyceride (DAG) levels were also increased by THC, probably due to
its inhibitory action on diglyceride lipase combined with its
stimulatory action on phosphatidyl inositol (PI) hydrolysis by
PLC.
Hillard and Bloom (1983) have suggested that there may be a role
for prostaglandins in the effects of cannabinoids on adenylate
cyclase activity, which they have observed. They reported that
aspirin, indomethacin, and mepacrine all inhibited THC-induced
stimulation of adenylate cyclase in homogenates of mouse cerebral
cortex. It is well known that PGE2 is an effective stimulator of
cyclase in a variety of systems and that CAMP has an essential
role in catecholamine-mediated neurotransmission.
Using an experimental design very similar to ours, White and
Tansik (1980) reported stimulation of human platelet PLA2 activity
by THC and cannabidiol (CBD). The released arachidonate was
converted primarily into lipoxygenase products. A similar finding
was reported by Laychock et al. (1986) in which rat pancreatic
islet preparations were exposed to THC. Again, when arachidonic
acid levels were increased, it resulted in increased synthesis of
12-HETE which enhanced insulin secretion.
The synthesis of F-type prostaglandins by rat brain synaptosomes
was reported to be inhibited by THC (ID50, 750 µM) (Raffel et al.
1976). The high doses needed for this effect cast some doubt on
its relevance to any in vivo action of THC. In a symposium
report, Howes and Osgood (1976) described a THC-induced inhibition
of PGE1 synthesis in rat striatal synaptosomes with an ID50 of
approximately 0.5 uM.
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In Vivo Evidence for the Hypothesis
Some time ago, Jordan and Castracane (1976) reported that THC
produced a 50% rise in PGE levels in rat uterine venous blood.
The animals were given a dose of 40 mg/kg following estradiol
stimulation, and samples of blood were taken by means of a uterine
vein cannula. They raised the possibility that some of the
actions of THC were due to its ability to increase PGE levels.
Dalterio et al. (1981) found that a complex response was produced
by cannabinoid exposure in mice when pituitary and testicular
levels of PGE and PGF were monitored. Significant increases or
decreases could be observed depending on subtle experimental
conditions. They concluded that, "prostaglandins may mediate some
effects of cannabinoids on male reproductive function in mice."
We have provided evidence for a role for prostaglandins in the
hypotensive action of THC in the dog (Burstein et al. 1982b). A
THC-induced decrease in mean arterial blood pressure could be
profoundly inhibited by the prior administration of aspirin. We
postulated that the hypotensive effect of THC could be mediated by
the release of prostacyclin in the cardiovascular system.
Fairbairn and Pickens (1979, 1980) presented convincing evidence
that the cataleptic response to THC in mice is mediated by PGE2.
Animals treated with any of several prostaglandin synthetase
inhibitors showed a reduced response to THC which could be
restored by intraperitoneal injection of PGE2. Moreover, mice
placed on an essential fatty acid deficient diet showed little
response to THC. However, the administration of arachidonic acid
resulted in a rapid restoration of the cataleptic effect. These
findings raise the possibility that the CNS effects of THC in
humans may be mediated by eicosanoids.
A study in humans was recently reported (Laviolette and Belanger
1986) in which cannabis-induced bronchodilation was measured in a
group of 11 volunteers. A second exposure to marijuana smoke was
monitored in which the subjects were heavily dosed with aspirin
over a 30-hour pretreatment period. No inhibition of broncho-
dilation was observed, prompting the authors to conclude that
eicosanoids were not mediators of this effect of marijuana.
In the next section, we describe recent findings on the in vitro
antagonism of THC by its major metabolite, THC-7-oic acid-
(Burstein et al. 1986b). In subsequent experiments, mice were
given oral doses of this acid (40 mg/kg), and a 50% reduction in
the cataleptic effect of THC (50 mg/kg) was observed by us (see
table 7). The most likely explanation for this result is that the
metabolite blocks the conversion of arachidonic acid into PGE2
based on our in vitro findings. Thus, THC is able to both
stimulate and inhibit prostaglandin production via its metabolite
depending on experimental parameters.
This possibility for dual effects could explain reports where
there is an apparent reduction of prostaglandin synthesis
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following THC exposure. Ayalon et al. (1977) reported a decrease
in rat ovarian PGE content after THC; Green and Podos (1974)
similarly found that the arachidonic-induced rise in rabbit
intraocular pressure was inhibited by intravenous THC.
Hypothalamic "PGE2-like material" in THC-treated rats was reduced
in experiments reported by Coupar and Taylor (1982). The tissue
extracts were monitored by a bioassay procedure using the rat
gastric fundus strip which is not a particular specific assay for
PGE2. The same authors have subsequently reported (1983) that
intestinal "PGE2" is also reduced by THC.
In summary, a number of in vitro studies have demonstrated that
cannabinoids are potent stimulators of eicosanoid synthesis. The
data obtained from our cell culture model suggest that this effect
is due to the action of the cannabinoids on the phospholipases
which control the levels of free arachidonic acid needed for
prostaglandin production. In certain instances, some cannabinoids
may inhibit prostaglandin synthesis, indicating the possibility of
complex interactions. The in vivo support for the "prostaglandin
hypothesis" is less complete at this time. Most convincing are
the reports by Fairbairn and Pickens (1979, 1980) which strongly
suggest that PGE2 is an important mediator in THC-induced
catalepsy in mice. While this may or may not be related to THC
effects on the human psyche, it does demonstrate a role for
prostaglandins in a CNS action of THC.
RECENT FINDINGS
In Vivo Studies
Encouraging data in support of a role for prostaglandins in the
actions of THC were obtained by us some time ago (Burstein et al.
1982b). In collaboration with members of the Pharmacology
Department, we were able to demonstrate inhibition of THC-induced
hypotension in dogs by the prior administration of aspirin. Such
an effect is consistent with a mechanism in which THC stimulates
prostacyclin synthesis in the cardiovascular system. Prostacyclin
is a potent vasodilator and could well mediate the observed
hypotensive effect of THC.
Evidence for a role for prostaglandins in the CNS actions of THC
has been more difficult to obtain. Recently (Hunter et al.,
unpublished data), we have shown a 29% rise in mouse brain
prostaglandins (table 1) following oral administration of -THC
(50 mg/kg). Prior administration of probenecid (120 mg/kg) was
necessary, presumably to slow the rapid clearance of PGE2 from the
brain; however, this had no effect on arachidonate metabolism
(table 2). We also utilized a double isotope labelling procedure
to reduce the difficulties in the analysis of the brain extracts
(table 3). This approach reduced the variability of results
caused by losses during the extraction and chromatographic
separations.
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TABLE 1
Effect of -Tetrahydrocannabinol on [14C]-Arachidonate
Metabolism in the Mouse Braina
Metabolite Controlb Treatedb (%) P(n=4)
Phospholipids 47.2 ± 5.8 39.3 ± 9.1 - 17 > .05
Prostaglandins 23.7 ± 13 30.5 ± 3.8 + 29 < .Ol
Arachidonate 10.3 ± 2.9 10.5 ± 2.1 + 1.7 > .05
Diglycerides 9.90 ± 3.9 12.8 ± 3.3 + 29 > .05
Triglycerides 8.00 ± 4.3 6.10 ± 3.6 - 24 > .05
a Values are expressed as percentage of total radioactivity
recovered from tlc ± S.D. P was determined by the Student's t
test.
b -Tetrahydrocannabinol (50 mg/kg) administered orally in sesame
oil to the treated group. Control and treated groups received
probenecid (120 mg/kg) i.p.
TABLE 2
Effect of Probenecid (120 mg/kg) on [14C]-Arachidonate
Metabolism in the Mouse Braina
Metabolite Control Probenecid Treated P(n=8)
Phospholipids 44.0 ± 12 46.4 ± 6.6 > .05
Prostaglandins 18.9 ± 6.9 18.8 ± 5.5 > .05
Diglycerides 15.8 ± 4.6 14.8 ± 3.0 > .05
Triglycerides 8.5 ± 2.4 8.0 ± 2.9 > .05
a As in table 1.
Cell Culture Experiments
Our initial observations on the stimulatory effect of cannabinoids
on prostaglandin synthesis were made using cells in culture
(Burstein and Hunter 1978). More recently, we have described this
effect in some detail and attempted to develop it into an in vitro
model for the CNS actions of THC (Burstein et al. 1982a). Using
such model systems, we plan to investigate the biochemical basis
for the effects of THC on arachidonate turnover and metabolism.
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TABLE 3
Effect of -Tetrahydrocannabinol on [14C/3H]Arachidonate
Metabolism in the Mouse Brain
Metabolite Isotope Ratioa
Controlb Treatedb
(%) P(n=4)
"Phospholipids"
PGF2
TXB2
PGE2
HETEs
PGA2 and HETEs
Arachidonate
Neutral lipids
0.52 ± 0.15 0.69 ± 0.04
1.19 ± 0.22 1.16 ± 0.05
1.23 ± 0.33 1.32 ± 0.09
0.99 ± 0.21 1.24 ± 0.18
0.35 ± 0.37 0.38 ± 0.18
1.26 ± 0.20 1.58 ± 0.34
1.24 ± 0.21 1.08 ± 0.23
0.70 ± 0.35 1.02 ± 0.36
+ 34
-2.5
+ 7.5
+ 25
+ 7.2
+ 25
- 13
+ 46
< 0.0005
> 0.05
> 0.05
< 0.05
> 0.05
> 0.05
> 0.05
> 0.05
a Values are given as the ratios of the percentage of total
radioactivity recovered from tlc for each isotope ± S.D.
b As in table 1.
For a variety of reasons, we have primarily utilized the WI-38
human lung fibroblast cell line for our studies. This cell line
is the most THC-sensitive of those we have tested, which included
mouse neuroblastoma cells, mouse glioma cells, human skin
fibroblasts, and HeLa cells. Moreover, it produces predominantly
PGE2 in response to a variety of agonists, including the
cannabinoids. We have also demonstrated that mouse peritoneal
macrophages are a suitable cell type for studying cannabinoid
effects on arachidonate metabolism by lipoxygenases (Burstein et
al. 1984a).
Dose-response relationships were reported for both primary canna-
binoids and several metabolites of -THC in which we measured the
release of free arachidonic acid and the levels of PGE2 in WI-38
cells (Burstein et al. 1983). Responses were obtained starting at
around 0.8 µM and a good correlation was found between PGE2
synthesis and arachidonate release, suggesting that, as expected,
the two events are related. Of particular interest was the
finding that, within the THC series, a good SAR could be seen when
PGE2 levels were compared with literature reports on the
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subjective "high" in humans and in the monkey behavioral assay. A
similar SAR was demonstrated with mouse peritoneal cells showing
that this was not a special feature of WI-38 fibroblasts (Burstein
et al. 1984a).
A wide range of agents were shown to be effective in blocking the
stimulatory actions of THC in cell culture, including phospho-
lipase inhibitors (such as mepacrine and dexamethasone) and
cyclooxygenase inhibitors (such as aspirin, indomethacin, and
naproxen). Lysolecithin acyltransferase inhibitors, such as
p-hydroxymercuribenzoate, were shown to greatly augment the
stimulatory effects of THC, presumably by preventing released
arachidonate from being incorporated into phospholipids that would
render it unavailable for conversion to eicosanoids (Hunter et al.
1984).
Tolerance to the stimulatory action of THC could also be readily
observed in our model system (Burstein et al. 1985). Three
successive 30-minute exposures with 24-hour intervals in THC-free
media reduced the response to control levels. The effect could
also be seen when arachidonate release was monitored, and it was
reversed by allowing a 5-day recovery period.
We have recently examined the stereospecificity of these effects
again using WI-38 cells as the model Burstein et al. 1986a).
Three pairs of enantiomers ( -THC, -THC, and -dimethylheptyl-
THC) were studied and all three showed statistically significant
twofold to threefold greater potency for the (-) natural isomer in
stimulating PGE2 synthesis. Interestingly, we did not observe a
significant effect when arachidonate release was measured. A
possible explanation is that PGE2 is derived from a single
stereoselective lipid pool; the free arachidonate we measured was
released from several pools, some of which were not
stereoselective.
As an offshoot of our research, we tested the possibility of using
the lipid mobilizing properties of the cannabinoids to provide
symptomatic relief for certain of the lipid storage diseases, such
as Niemann-Pick. Cells derived from Niemann-Pick patients when
treated with cannabinoids showed a favorable decrease in
sphingomyelin content (Burstein et al. 1984b). Cannabidiol (which
is nonpsychoactive) was particularly effective, thus raising the
possibility of its use in managing patients with such problems.
Brain Subcellular Experiments
Synaptosomes, myelin, and mitochondria were prepared from whole
mouse brain, and cannabinoid effects on their lipases were studied
(Hunter et al. 1986). PLA2 activity was increased in the presence
of THC and its metabolites and the effect exhibited structural
specificity (table 4). Synaptosomal PLC-mediated hydrolysis of
phosphatidyl inositol (PI) was also stimulated by THC (table 5),
giving rise to increased levels of DAG. This is of interest since
DAG has a potent effect on C-kinase activity which has been linked
to neurotransmitter action. In addition, THC inhibited DAG lipase
activity, which could amplify the PLC effect.
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Metabolite Studies
As part of our long-standing general interest in the metabolites
of THC, we tested several of the available examples for inter-
actions with THC in our model system. The simplicity of the model
allowed us to examine a number of metabolites over a range of
doses wi th relative ease (table 6). It became immediately
apparent that the carboxyl-containing metabolites, in particular,
-THC-7-oic acid, were antagonists to the stimulatory action of
THC on PGE2 synthesis (Burstein et al. 1986a).
A kinetic analysis of the inhibition suggested that it was
noncompetitive. The structure of -THC-7-oic-acid is similar to
many of the nonsteroidal antiinflammatory agents, prompting us to
test it for cyclooxygenase inhibition. The metabolite showed
potent inhibitory action in several different preparations with
cyclooxygenase activity. Moreover, it had no effect on the
release of arachidonate from labelled WI-38 cells, showing that it
has a specific action in antagonizing the effect of THC.
An obvious question was whether this antagonism would manifest
itself in vivo. The cataleptic response to THC in mice has been
suggested to involve prostaglandins as mediators. We established
the procedure as described by Pertwee (1972) in our laboratory and
treated mice with the 7-oic acid (40 mg/kg) orally followed by
-THC (50 mg/kg) orally (Burstein et al., unpublished data). The
cataleptic effect was inhibited by at least 50% by this procedure,
showing that the metabolite can greatly affect this particular CNS
action of THC (table 7).
SUMMARY
Experimental support for a role for prostaglandins in the actions
of THC has been greatly expanded by data from our laboratory
during the last 5 years. The majority of the data has been
obtained using a cell culture model. However, important findings
have also come from in vivo experiments as well as subcellular
preparation studies. We have shown that aspirin can inhibit the
hypotensive action of THC in dogs, which is consistent with a
mechanism in which THC stimulates prostaglandin synthesis in the
cardiovascular system. In vivo treatment of mice with THC was
followed by a significant in the level of PGE2 in whole brain
extracts, suggesting a role for this eicosanoid in the CNS actions
of THC.
We have also shown that our cell culture model displays several of
the characteristics of THC action in vivo. These include
tolerance, stereospecificity, and an SAR which resembles that for
THC and its metabolites in humans and in the rhesus monkey. These
findings would seem to justify the use of this model for further
experiments aimed at elucidating the biochemical events connected
with THC action.
Lipid metabolism in brain preparations such as synaptosomes have
been found by us to be responsive to THC, which generates such
potent mediators as arachidonate and DAG by stimulating the
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TABLE 4
Effects of Cannabihoids on Arachidonic Acid Formation From
[1-14C] Arachidonylphosphatidylcholine by Synaptosomes
Cannabinoid µM Arachidonic Acid Change (%)
(dpm ± SD)
Vehicle - 302 ± 14 -
-THC 0.32 379 ± 40 25.4
-THC 0.8 370 ± 20
-THC
22.4
1.6 353 ± 15
-THC
16.7
3.2 368 ± 43
-THC
21.9
8.0 423 ± 35 40.1
-THC 16.0 397 ± 38 31.3
7-oxo- -THC 1.6 357 ±
7-oxo- -THC
32 18.3
3.2 303 ± 16
7-oxo- -THC
0.3a
8.0
16.0
371 ± 11
7-oxo- -THC
22.8
351 ± 20 16.1
7-OH- -THC
7-OH- -THC
8.0 464 ± 16 53.8
16.0 503 a 26 66.5
-THC-7-oic acid 8.0 279 ± 15 -7.8
-THC-7-oic acid 16.0 364 ± 24 20.4
6 -OH- -THC ± 15
6 -OH- -THC
8.0 284 -5.9
16.0 360 ± 31 19.0
6 -OH- -THC 8.0 298 ± 15 -1.3a
6 -OH- -THC 16.0 308 ± 17 2. 1a
Synaptosomes (0.22 mg protein) were incubated with [1-14C]arachi-
donylphosphatidylcholine (35,000 dpm) in 1 ml of 5 mM-CaCl2:0.05 M
Tris-HCl buffer (pH 7.4) for 45 min. Cannabinoids were added in
10 µ1 ethanol. Arachidonic acid levels were obtained by hexane
extraction of the incubate. Values represent mean (dpm) ± SD of
triplicate samples. All values were significantly different from
the vehicle, p < 0.0005 by Student's t test. a Not significant.
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TABLE 5
Synaptosomal Hydrolysis of [1- 14C]Arachidonylphosphatidylinositol
Cannabinoid µM Product Formation
Diacylglyceride (%) Arachidonic acid (%)
Control 10.9 ± 9 (4) 2.5 ± 0.4 (4)
-THC 1.6 25.2 ± 2.3 (3)a 2.5 ± 0.6 (3)d
-THC 8 30.4 ± 1.8 (3)b 3.2 ± 0.8 (3)d
7-COOH- THC 8 18.2 ± 2.4 (3)c 2.2 ± 0.1 (3)c
Synaptosomes (0.1 mg protein per ml) were suspended in 5 mM CaCl2:
S.T.E.M. buffer (pH 7.4) and incubated for 30 min with
[1-14C]arachidonylphosphatidylinositol (25,000 dpm) and either
cannabinoid or vehicle (10 µl). The values are the percentage
mean (dpm) ± SD of the number of determinations given in
a
arentheses. Values were significantly different from control:
p < 0.005; b p < 0.0005; c p < 0.01; d Not significant.
appropriate lipases. This showed that the brain responds in a
manner analogous to other tissues with regard to lipid
mobilization.
A surprising and potentially important discovery was made using
the cell culture model we have developed. The major metabolite of
-THC, -THC-7-oic acid, was found to antagonize the stimulatory
action of THC by inhibiting a specific step in the synthesis of
prostaglandins. We were also able to demonstrate antagonism by
this metabolite in vivo using THC-induced catalepsy in the mouse
as the biological parameter. We propose, based on these
observations, that tissue levels of this metabolite will have a
profound influence on THC responses. Future pharmacokinetic
studies should consider this possibility since the acid has been
shown to be present in amounts comparable and even exceeding those
of THC itself. In passing, it is worth noting that THC exhibits
potent antiinflammatory activity in animal models (Sophia et al.
1973a, 1973b) which can now be readily explained by a metabolite
that inhibits prostaglandin synthesis. Finally, all of these
facts are most consistent with a mechanism of action in which THC
stimulates the production of prostaglandins and other
eicosanoids.
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TABLE 6
Interactions of -THC with Its Metabolites on PGE2
Synthesis in Fibroblasts*
Metabolite
6 -OH- -THC (3.2 µM)
6 -OH- -THC (8.0 µM)
1"-OH- -THC (3.2 µM)
1"-OH- -THC (8.0 µM)
1"-oic Acid (16 µM)
2"-oic Acid (16 µM)
3"-oic Acid (16 µM)
7-oic Acid (8 µM)
7-oic Acid (16 µM)
-THC Concentration (µM)
0.32 0.80 1.6 3.2
0.93 0.93 1.76 0.99
1.15 0.93 1.26 0.89
1.31 1.44 0.93 1.07
2.16 1.89 1.46 1.45
0.96 0.93 1.43 1.56
0.83 0.49 0.51 0.74
1.43 1.14 1.20 0.87
- 0.28 0.28 0.27
- < 0.15 0.13 0.11
* The metabolite was added to the cells 30 min prior to the
addition of -THC at the indicated concentrations. The values
shown are the ratios of PGE2 levels in treated over control cells;
the controls consisted of cells to which vehicle (10 µl ethanol)
had been added in place of a metabolite. PGE2 was measured by
RIA. Duplicate determinations were done on three individual
monolayers.
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TABLE 7
The Inhibition of -THC Induced Catalepsy in Mice
by -THC-7-oic Acid
Control Treated Pretreated
Experiment 1 0.05 ± 0.05 (4) 0.28 ± 0.02 (4) 0.11 ± 0.04 (5)
Experiment 2 0.09 ± 0.04 (3) 0.26 ± 0.03 (3) 0.19 ± 0.10 (5)
Experiment 3 0.08 ± 0.03 (4) 0.42 ± 0.01 (4) 0.19 ± 0.10 (4)
Mean 0.07 ± 0.02 0.32 ± O.O1* 0.16 ± 0.05*
Female, CD-1 mice (Charles River) weighing 20 to 25 grams were
given -THC (50 mg/kg) in sesame oil (10 µl) orally. One hour
later the cataleptic effect was measured using the procedure
described by Pertwee (1972). The "control" groups received only
sesame oil and the "pretreated" groups were given -THC-7-oic
acid (40 mg/kg) in oil (50 µl) 1 hour prior to the administration
of -THC. The values are expressed as the means of the fraction
of time the mice remained immobile ± S.D. Values in parentheses
indicate the number of mice in each group. Asterisks denote a p
value of < 0.01 as determined bv a one-wav analvsis of variance
(F = 26.4, DF = 2,33) and a post hoc Newman-Keuls test.
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Pharmacokinetics and Disposition
of Cannabinoids
C. Nora Chiang, Ph.D., and Rao S. Rapaka, Ph.D.
INTRODUCTION
Cannabis was used for fiber or medicinal purposes for centuries
(Camp 1936). Recently, it has been widely used for recreational
purposes, due largely to its euphoric effect. Cannabis contains
hundreds of compounds. Among them, a class of compounds unique to
cannabis has been identified as cannabinoids, which have been
associated with cannabis activities. So far, over 60 naturally
occurring cannabinoids have been identified in cannabis (Turner et
al. 1980). In addition, a large number of cannablnoids have been
synthesized for structure-activity studies and for the development
of therapeutic drugs. Due both to concerns about health hazards
related to the social use of marljuana and to the potential use of
cannabinoids for therapeutic purposes, extensive research on their
chemistry, pharmacokinetics and disposition, pharmacology, cellular
effects, and therapeutic effects has been carried out and recently
reviewed (Razdan 1986; Agurell et al. 1986; Dewey 1986; Martin 1986;
Hollister 1986).
As information on the pharmacokinetics and disposition of
cannabinoids is important for understanding their use and abuse,
this chapter summarizes current understanding of the pharmaco-
kinetics and disposition of these substances. The cannabinoids to
be discussed include delta-9-tetrahydrocannablnol (THC), the major
psychoactive component In cannabis; cannabinol (CBN) and cannabidiol
(CBD), which are usually abundant in plants that are rich in THC;
and nabilone, a synthetic cannabinoid approved for therapeutic use.
The major focus will be on THC, as it is the most widely used
cannabinoid and has been the subject of extensive research. In
addition to pharmacokinetics, regulatory requirements for the
approval of drugs by the United States Food and Drug Administration
(FDA) will also be reviewed briefly.
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PHARMACOKINETICS AND DISPOSITION
TETRAHYDROCANNABINOL
Delta-9-tetrahydrocannabinol, the major psychoactive component of
marijuana, has been shown to have a broad range of cellular,
biological, and behavioral effects (Martin 1986; Dewey 1986). It
was recently approved for therapeutic use in the treatment of nausea
and emesis caused by cancer chemotherapy (Hollister 1986). The
health hazards from the social use of marijuana are a major
concern. In particular, marijuana use has been associated with
decrements in behavior and cognitive performance. For example, safe
operation of motor vehicles or machinery at the workplace when a
person is under the influence of THC is a major concern. There is
an urgent need for the interpretation of a certain concentration of
THC in urine or blood as related to the pharmacological effects,
such as performance impairment. So far, data from controlled
clinical studies indicate that there is a correlation for both the
"high" effect and the performance impairment with plasma THC
concentrations (Chiang and Barnett 1984; Barnett et al. 1985) when a
pharmacokinetlc and a pharmacodynamic analysis are performed on a
series of plasma samples. However, the prediction of the extent of
high effect or impairment from a single plasma level of THC cannot
be established (Hollister et al. 1981) because of the complex nature
of the pharmacokinetics and pharmacodynamics of THC (Agurell et al.
1986; Mason and McBay 1985). Further research is still needed in
these areas.
Pharmacokinetic Parameters
Half-Life. Following an intravenous dose of THC, plasma levels of
THC decline very rapidly over the first few minutes and then decline
at slower rates. A four-exponential equation with a four-
compartment model, proposed by Hunt and Jones (1980), indicates that
there are at least four different composites of tissues into which
THC is distributed with different rates of permeation and different
tissue binding strengths. The averages of the associated
disposition half-lives are 1 minute, 4 minutes, 1 hour, and 19
hours. The half-lives of 1 minute, 4 minutes, and 1 hour are
attributable to the rapid distribution of THC into different tissues
as well as to the rapid metabolism of THC. At approximately 6 hours
after an intravenous dose, a psuedoequilibrium is reached between
plasma and tissues.
After the pseudoequilibrium is reached, THC is then slowly
eliminated. This slow elimination is primarily due to the slow
return of THC from sequestered tissues to blood. The terminal
half-life of THC is approximately 1 day. Hunt and Jones (1980)
suggested a terminal half-life of 19 hours: Ohlsson et al. (1982),
of greater than 20 hours; and Wall et al. (1983), of 25 to 36
hours. There are no significant differences in plasma profiles for
chronic and infrequent users or in half-lives in moderate users
before and after a 2-week exposure of THC (Ohlsson et al. 1982; Hunt
and Jones 1980). The difference between the earlier reported
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terminal half-life of 28 hours for chronic marijuana users and 57 
hours for naive smokers, in studies of Lemberger et al. (1970,
1971a), could be due to relatively nonspecific analytical methods
used for their pioneering studies.
Volume of distribution. The volume of distribution of THC is
estimated to be 10 1/kg (Hunt and Jones 1980: Wall et al. 1983).
which is over 200 time; the plasma volume. This large volume of
distribution is commonly seen for lipophilic drugs, where the
majority of the drug in the body is in tissues and only a small
fraction is in the blood. In blood, THC is preferentially
distributed in plasma and only about 10% in the red blood cells
(Garrett and Hunt 1974; Widman et al. 1974).
Clearance. The average plasma clearance is about 605-980 ml/min
(Hunt and Jones 1980; Ohlsson et al. 1982) and estimated blood
clearance of 1.0 to 1.6 l/min is close to the hepatic blood flow.
This suggests that the rate of metabolism of THC is clearly
dependent on hepatic blood flow to the liver, and enzyme
induction/inhibition appears to have little effect on the metabolic
clearance of THC (Hunt and Jones 1980). Because of the high
metabolic clearance, part of the drug absorbed from the
gastrointestinal tract is metabolized in the liver before it enters
the systemic circulation. As a result, the bioavailability of THC
is low and is in the range of 10% to 20% (Wall et al. 1983).
Distribution
In blood, THC is extensively bound, approximately 97% to 99%, to
plasma proteins and only limited amounts of THC (about 10%) are
present in red blood cells (Garrett and Hunt 1974; Widman et al.
1974).
Because THC is a highly lipophilic compound, it is readily
distributed into tissues from blood circulation. THC concentrations
in brain reach a maximum, about three to six times higher than in
plasma, within 30 minutes (the first sampling time after drug
administration) after a single intravenous dose of THC in mice
(Harvey et al. 1984). THC brain concentrations roughly parallel the
plasma concentrations. This suggests that there is no barrier for
the partition of THC into brain and that an equilibrium between the
brain and plasma is quickly reached.
Earlier studies in animals using labeled THC demonstrated that
tissue levels of THC (in most cases, of THC and metabolites) were
higher in fat, liver, heart, and lung than in brain and blood
(Ryrfeldt et al. 1973; Kreuz and Axelrod 1973; Leighty 1973; Siemens
et al. 1979). A recent study in rabbits, using a more specific
GC-MS method for the assay of unchanged THC, also suggests that much
higher concentrations of THC are found in fat and heart than in
brain (Leuschner et al. 1986). THC concentrations in fat are about
1,000 times those in plasma, while in brain they are only about 3 to
10 times those in plasma. This is consistent with the fact that THC
is a very lipophilic compound and, therefore, accumulates in fatty
tissues. The relatively low THC levels in brain, in contrast to
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what would be expected from the partition coefficient, are primarily
due to the fact that the brain is well perfused and the blood flow
moves THC in and out of the brain very rapidly.
Animal studies indicate that THC passes through the placenta and
affects fetal development (Lee and Chiang 1985). THC levels in
fetal tissues and blood are shown to be lower than in maternal
tissues for dogs and sheep (Martin et al. 1977; Abrams et al.
1985). In humans, THC is also found in cord blood, and the cord
blood levels are three to six times lower than in maternal blood
(Blackard and Tennes 1984). However, its effects on the fetus are
not yet fully understood. THC is also secreted in milk at a higher
concentration than in plasma, which may be attributed to the high
lipid content in milk (Perez-Reyes 1982).
Metabolism
Metabolism is the major route for the elimination of THC from the
body; only negligible amounts of this substance are excreted as
unchanged THC. So far, approximately 80 metabolites of THC have
been reported from studies in humans, animals, and in vitro liver
preparations (Agurell et al. 1986). In humans, over 20 metabolites
have been identified in urine and feces (Halldin et al. 1982a,
1982b; Widman et al. 1985; Wall and Perez-Reyes 1981). Still, a
significant number of the metabolites, in both urine and feces, have
not been identified.
The metabolism of THC in humans involves allylic oxidation,
epoxldatlon, aliphatlc oxidation, decarboxylation, and conjugation
(Burstein 1985; Harvey 1984; Wldman et al. 1985). Allylic oxidation
at C-8 and C-11 and aliphatic oxidation at the side chain result in
the formation of hydroxylated metabolites. The mono- and di-hydroxy
metabolites are further oxidized to form acid and hydroxy-acid.
Allylic oxidation at C-11 position is the major metabolic pathway,
and the resultant metabolite 11-OH-THC is identified as a
predominant metabolite from in vitro studies using human liver
preparations. This metabolite is also found in significant amounts
in feces (Halldin et al. 1982c; Wall and Perez-reyes 1981).
11-Nor-THC-9-COOH, produced from the oxidation of 11-OH-THC, is a
major metabolite identified in plasma, urine, and feces (Widman et
al. 1985; Wall and Perez-Reyes 1981; Wall et al. 1983). The side
chain is also easily degraded to form decarboxylated metabolites,
and 4',5'-bisnor-THC-11,3'-dioic acid is the second most abundant
metabolite found in urine.
Conjugation with glucuronide acid may occur to THC and to
hydroxylated and carboxylated metabolites. Glucuronic acid
conjugates of 11-nor-THC-9-COOH and THC have been identified in
human urine (Halldin et al. 1982a, 1982b; Widman et al. 1985; Wall
and Perez-Reyes 1981). Epoxide of THC (11-OH-epoxyhexahydro-
cannabinol) is found in trace amounts in the liver preparation
(Halldin et al. 1982c).
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Pharmacological activities of metabolites have been studied in
humans. The major metabolite 11-nor-THC-9-COOH is found to be
inactive, while some hydroxylated metabolites are found to be
pharmacologically active (Perez-Reyes et al. 1973; Perez-Reyes
1985). 11-OH-THC, another major metabolite, produces
pharmacological activity similar to THC and follows similar
disposition (Lemberger et al. 1972; 1973; Perez-Reyes et al. 1972;
Perez-Reyes 1985). 8-Beta-OH-THC is less potent and 8-alpha-OH-THC
is essentially inactive in producing THC-like activity (Perez-Reyes
1985).
The activity of side-chain hydroxylated metabolltes has not been
studied well in humans. Pharmacological tests in dogs and mice
indicate that 3'-OH-THC has a pharmacological profile similar to
that of THC and is about 2 to 3 times more potent than THC, while
the dlhydroxy metabolite 3',11-dihydroxy-THC is less potent than THC
(Martin et al. 1984).
Excretion
About 80% to 90% of the dose of THC is excreted as metabolites
within 5 days, 65% in feces and 20% in urine. Only negligible
amounts of THC were recovered as unchanged drug (Hunt and Jones
1980; Wall et al. 1983). Since a significant portion of the
metabolites is excreted in the feces, enterohepatic recirculation
(which may also be a contributing factor for the slow elimination of
a drug) of THC metabolites in humans is also possible. Studies in
dogs indicate that 10% to 15% of the dose of THC is
enterohepatically recirculated (Garrett and Hunt 1977).
Among the metabolltes, 11-nor-9-THC-COOH is a major metabolite
identified in both urine and feces (Wall and Perez-Reyes 1981;
Widman et al. 1985). Metabolites in the urine consist of primary
acidic compounds; while the metabolites in feces consist of both
acidic and neutral compounds. In urine, a total of 20 metabolites
of THC, 2 as glucuronic acid conjugates and 18 as nonconjugated
acids, have been identified. All of the other nonconjugated acidic
metabolltes identified in urine, except for 11-nor-9-THC-COOH, have
their side chains further oxidized or degraded to form various
hydroxylated or carboxylated metabolites (Widman et al. 1985). In
contrast to urine, neutral metabolites appear in significant amounts
in feces: the amount of 11-OH-THC is about the same as that of
11-nor-THC-9-COOH; and 8,11-dihydroxy, 8-alpha-OH, and 8-beta-OH
metabolites are also found in significant amounts. However,
one-third of the metabolites in feces are less well-defined acids
(Wall and Perez-Reyes 1981). Glucuronic acid conjugates of THC and
11-nor-THC-9-COOH are found in urine (Widman et al. 1985). In
general, the glucuronic acid conjugates are labile in the basic
conditions and, hence, it is likely that most of the acidic
metabolites identified could also be partly present in the original
urine or feces as glucuronic acid conjugates which are later readily
hydrolyzed during the experimental procedures.
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Absorption
THC from various routes of administration is absorbed quite
differently. Smoking marijuana cigarettes is the most common route
for the self-administration of THC in the United States. In cancer
treatment, THC capsules are ingested orally for the antiemetic
effect. Parenteral injectables of THC are used primarily in
research. As THC is practically insoluble in water (Garrett and
Hunt 1974), organic vehicles or surfactants are generally employed
to make parenteral solutions of THC. Commonly used vehicles for the
intravenous administration of THC in humans are alcohol and albumin
solution. For use in animals, many other vehicles--such as
propyleneglycol, polyvinylpyrrolidone, Tween-80, and Emulohor--have
been used for the parenteral preparations. The bioavail
pharmacokinetics of THC from the different preparations
variable. As a result, the time profiles and the magni
pharmacological effects are also different.
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Smokinq. During the smoking process, part of the dose i
pyrolysis and from side stream smoke. In an in vitro s
(Davis et al. 1984) when cigarettes were consumed as a single puff
to minimize side stream smoke, about 30% of THC was degraded during
smoking. This suggests that the maximum amounts of THC absorbed
from smoking will not exceed 70% of the THC content of cigarettes.
When puff volume and puff duration of a typical marijuana smoker
were simulated, about 16% to 19% of the THC in the cigarettes was
recovered in the smoke condensate (Davis et al. 1984).
THC is readily absorbed from the lungs or respiratory tract into the
systemic circulation. Peak plasma concentrations are rapidly
reached, and the plasma profile is very similar to that of an
intravenous dose (Ohlsson et al. 1982; 1985; Chiang and Barnett
1984). The bioavailability of THC from this route of administration
is quite variable (Barnett et al. 1982; Lindgren et al. 1981;
Ohlsson, et al. 1980; 1982; 1985; Perez-Reyes et al. 1982), as it is
affected not only by the burning characteristics of the cigarettes,
but also by the depth of inhalation, puff duration, and other
factors. Experienced smokers seem to inhale marijuana more
efficiently than nonexperienced ones. The THC bioavailabllity from
actual smoking of a 1% to 2% marijuana cigarette is 16 to 40% for
heavy users and 13% to 14% for light users (Ohlsson et al. 1982).
When cigarettes of different potencies are used, smokers may tend to
titrate the amount of THC inhaled. In one study, subjects were
instructed to smoke cigarettes containing 1.3%, 2.0%, and 2.5% of
THC in their usual fashion (Perez-Reyes et al. 1982). Plasma THC
levels increased with THC potencies, indicating that higher amounts
of THC were absorbed from high potency cigarettes. However, the
actual fractions of THC inhaled were relatively less for high
potency cigarettes. This self-adjustment of THC intake became more
apparent in a study using marijuana cigarettes of 1% and 3.8% THC.
The actual amount of THC inhaled from a 3.8% cigarette was about 1.8
times of that from a 1% cigarette. That indicates that the
fraction of THC inhaled from a 3.8% cigarette was only about half of
that estimated for a 1% cigarette (Perez-Reyes 1985).
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Oral Administration. The THC oral dosage form that is currently
available in the market is a soft gelatin capsule containing THC in
sesame oil. The absorption of this dosage form is slow, the peak
THC levels are reached at about 2 hours, and the bioavailabillty is
in the range of 10% to 20% (Wall et al. 1983). This low
bioavailabillty of THC is primarily due to the "first-pass effect."
In other words, a large fraction of THC is metabolized to
metabolites in the liver before it reaches the systemic circulation,
thus resulting in a small fraction of the administered dose of THC
getting into the systemic blood. Consequently, the active
metabolites appear in significant amounts in the systemic blood and
therefore may contribute significantly to the effects of THC (Wall
et al. 1983; Hunt and Jones 1980).
Parenteral administration. After an intravenous dose, THC is
distributed instantly in the systemic circulation. Since THC is
highly bound to plasma protein, a vehicle made from plasma protein
(and premixed with THC) may compete with tissue uptake of THC. A
study by Fehr and Kalant (1974) suggested that tissue distribution
could be partly retarded when THC is administered in a vehicle made
from plasma protein as compared with a vehicle made from
polyethylene glycol.
Generally, intramuscular injectables of THC are used in animal
studies. These injetables are commonly made in Tween-80 and in
Emulphor. Studies in monkeys, using radioimmunoassay methods,
suggest that the systemic absorption of THC from the Emulphor
preparation is greater than from Tween-80 preparation (Perlin et al.
1985). Although peak levels attained for these two preparations are
similar, times required to reach peak levels are different: 30
minutes for Tween 80 and about 2.5 hours for Emulphor.
Other routes of administration. THC is absorbed from the ophthalmic
route of administration. Studies in rabbits indicate the absorption
of THC in light mineral oil is slow, and peak levels are reached in
about 1 hour and maintained for approximately 4 to 8 hours. The
bioavailablllty is quite variable, ranging from 6% to 40%. (Chiang
et al. 1983).
Rectal route of administration of THC has been evaluated for several
suppository formulations using Carbowax, Witepsol, sesame oil, cocoa
butter, and Cetomacrogol in monkeys (Perlin et al. 1985). No drug
is detected in plasma, possibly due to the high lipophiliclty of
THC, which might prevent the partitioning of THC out of the vehicles.
Kinetics of the THC Metabolites
THC is rapidly and extensively metabolized. After in intravenous
dose of THC. metabolites appear immediately in plasma, and peak
levels are reached in about 15 to 30 minutes (Hunt and Jones 1980;
Wall et al. 1983). The concentrations of metabolites reach levels
equal to that of THC in about 20 minutes and, at 1 hour, the
metabollte levels increase to about 5 to 10 times that of THC. A
major portion of metabolites in plasma are polar and acidic
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compounds; neutral metabolites (mostly hydroxy metabolites) account
only for about 10% of total metabolites. A significant fraction of
metabolites in plasma has yet to be identified.
Consistent with the first pass-effect, ratios of concentrations of
metabolites to THC in plasma for an oral dose are much higher than
those for an intravenous dose (Wall et al. 1983). For example, the
concentration levels of 11-nor-THC-9-COOH (a major metabolite that
is devoid of THC activity) in plasma are about 2 to 3 times higher
than that of THC after an intravenous dose and about 6 to 10 times
after an oral dose. Plasma levels of the active metabolite
11-OH-THC are about 10% to 15% of THC levels for an intravenous dose
and about 50% of THC levels for an oral dose. Also found in plasma
are 8-alpha-OH, 8-beta-OH, and 8,11-di-OH metabolites. The levels
of active metabolites 11-OH-THC and 8-beta-OH-THC from an
intravenous dose or smoked dose may not contribute significantly to
THC effects, but they could contribute significantly to THC effects
from an oral dose.
Metabolites are also highly bound to plasma protein (88% to 99%).
The terminal plasma half-life of metabolites from THC administration
is approximately 50 hours, which is longer than that of THC. This
slower elimination rate of THC metabolites is not due to the slower
elimination rate of the metabolites, but rather to their slower
rates of formation, which, in turn, depends on the slower return of
THC from sequestered tissues to form metabolites (Hunt and Jones
1980).
NABILONE
Nabilone, a synthetic cannabinoid, is currently used as an
antiemetic (Herman et al. 1979; Hollister 1986). Following an
intravenous dose of nabilone, plasma levels sharply decline due to
extensive tissue distribution and metabolism. The plasma half-life
is reported to be about 2 hours. Metabolites have not been well
identified for nabilone; however, it is suggested that the long
duration of its action may be due to the active metabolites.
Similarly to THC, 65% of dose of nabilone is excreted in feces and
about 20% in urine within 4 days. Urinary metabolites are primarily
polar, acidic metabolites. The half-life of total metabolites in
plasma is about 35 hours. The oral absorption of nabilone
preparation made from coprecipitation with polyvinylpyrrolidone is
complete and the peak plasma levels are reached in 1 hour (Rubin et
al. 1977).
CANNABIDIOL
Cannabidiol, one of the major cannabinoids found in cannabis, is
shown to be devoid of any psychotomimetic activity in humans
(Perez-Reyes et al. 1973; Perez-Reyes 1985), but it possesses
significant anticonvulsant activity (Martin 1986). Plasma profiles
of CBD following an intravenous dose are quite similar to those of
THC. Plasma levels decline rapidly shortly after intravenous dose
and decline at slower rates later. Similar to THC, plasma
clearances of CBD are 960 to 1560 ml/min and terminal plasma
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half-life averages 24 hours (range 18 to 33 hours). Volume of
distribution for CBD is estimated to be 30 l/kg (Ohlsson et al.
1986).
CBD, like THC, is extensively metabolized (Burstein 1985).
Hydroxylation is a major metabolic pathway and occurs primarily at
11 position. The 11-OH metabolite is further oxidized to form
dlhydroxy and carboxy metabolites. 9-carboxy-CBD is a major
metabollte identified in plasma. Similar to THC, the majority of
the administered dose of CBD is excreted in feces and a relatively
small fraction is excreted in urine (about 16% of the dose in urine
and 33% in feces over 72 hours). Unlike THC, unchanged CBD is
excreted in large portion in the feces (Wall et al. 1976).
After smoking, CBD is quickly absorbed into the systemic
circulation. The bloavailabilities of CBD averaged 31% (range, 11%
to 45%) (Ohlsson et al. 1986). Coadministration of CBD with THC may
alter THC's effects (Hollister and Gillespie 1975; Karniol et al.
1974); it has minimal or no effects on plasma levels of THC,
however, suggesting that there are no apparent pharmacokinetic
interactions of CBD with THC (Agurell et al. 1981; Hunt et al.
1981).
CANNABINOL
Cannabinol is a major cannabinoid found in cannabis and has about
one-tenth the activity of THC in humans (Perez-Reyes et al. 1973;
Perez-Reyes 1985). Similar to THC, plasma levels of CBN following
an intravenous dose decline rapidly shortly after the dose and then
decline at slower rates (Ohlsson et al. 1984). CBN is also
extensively metabolized (Burstein 1985). 9-COOH-CBN is a major
ity of the dose of CBN is
fraction is found in
ine and 35% in feces over
for CBN are mono-OH-CBN,
).
metabolite identified in plasma. The major
excreted in feces, while a relatively small
urine: About 8% of the dose is found in ur
72 hours. Major metabolites found in feces
9-COOH-CBN, and dl-OH-CBN (Wall et al. 1976
CBN is also quickly absorbed from smoking.
CBN average 41% (range, 8% to 77%) (Ohlsson
The bioavailabilities of
et al. 1984, 1985). It
is likely that a very limited pharmacokinetic interaction exits
between CBN and THC, because the coadmlnistration of CBN with THC
results in plasma concentrations of THC slightly higher than, but
not statistically significant from, THC concentrations obtained from
THC administered alone (Agurell et al. 1981).
MEDICINAL ASPECTS OF CANNABIS
Several ancient civilizations used cannabis and related products for
the "treatment" of a number of disease conditions, and the
therapeutic claims were very extensive. As systematic
investigation, isolation, and identification of the active
ingredients proceeded and these ingredients were pharmacologically
investigated, most of the earlier claims were not substantiated.
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During the early sixties, Goni and Mechoulam (1964) identified
delta-9-THC as the major active component of cannabis. Following
their research, several other active ingredients were identified.
Later, a number of analogs of delta-9-THC, cannabidiol and several
closely related compounds, were synthesized and evaluated for
therapy. Some examples of these synthetic compounds are nabilone,
nabitan, levonantradol, and BRL 4664. Nabilone is currently
available in Canada and Switzerland for the treatment of emetic
effects of cisplatin in cancer chemotherapy. In the United States,
the only two newly approved drugs to date for treatment of
drug-induced emesis are delta-9-THC and nabilone.
Although pharmacological evaluations of several hundred analogs for
various therapeutic purposes are not highly encouraging,
considerable research is being carried out. Some of the therapeutic
aspects that are considered for cannabinoids are:
Antiemetic effects in cancer chemotherapy
Reduction of intraocular pressure in glaucoma
Anticonvulsant effects; and
Miscellaneous minor uses--as an antiasthmatic, analgetic, and
appetite stimulant, and for the treatment of insommia, hypertension,
and anxiety.
It is expected that in the near future at least some synthetic
analogs that are devoid of "cannabimimetic" (psychotropic) effects
may be approved in the United States for therapeutic purposes.
Hence, this is an opportune time to present the regulatory aspects
of drug approval by the Food and Drug Administration.
REGULATORY ASPECTS OF DRUG APPROVAL
In order to understand the extensive procedures involved for FDA
approval, a brief account of the FDA regulatory aspects will be
helpful. Federal regulatory legislation started with the passage of
the 1848 Import Drug Act. This was a result of finding that the
quinine used by American troops in Mexico was adulterated. In 1906,
the original Food and Drug Act was passed, which specified standards
for purity, strength, and quality. In 1938, the Federal Food, Drug
and Cosmetic Act was enacted. This legislation required clearance
for safety of new drugs prior to distribution. Later, following the
thalidomide tragedy in Europe in 1962, the Kefauver-Harris
amendments were passed. These amendments require that, in addition
to the safety of the drugs, their effectiveness must be
demonstrated. For final approval of a drug by FDA for commercial
distribution, the manufacturer must go through the IND and NDA
stages.
INVESTIGATIONAL NEW DRUG (IND)
In order for a researcher or a commercial firm to establish the
safety and efficacy of a compound, a "Notice of Claimed
Investigational Exemption for a New Drug" (an IND) must be filed.
The IND contains information on (1) all the components; (2) quanti-
tative composition; (3) methods of preparation; (4) analytical
methodology to assure identity, strength, and quality; (5) results
of preclinical investigations; (6) a detailed clinical protocol of
phase I, II, and III studies; and (7) other related information.
After the sponsor or the applicant is confident from the animal and
human trials that the product is safe and effective, an NDA may be
filed.
NEW DRUG APPLICATIONS (NDA)
In 1985 the Food and Drug Administration published a comprehensive
revision of the Code of Federal Regulations relating to the
procedure for NDA submission and approval (Federal Register, Vol.
50, No. 36, p. 7542). The NDA contains information on each of the
following disciplines: chemistry, clinical medicine, pharmacology,
statistics, biopharmaceutics, and microbiology. The chemistry
section should include:
1. Drug Substance--Names, formulas, physical stability,
manufacturers, methods of manufacture, process controls,
specifications, and analytical methods.
2. Drug Product--components, composition, specifications and
analytical methods for components, manufacturers, methods of
manufacture, packaging procedures, and in-process controls,
specifications and analytical methods for drug product
container--closure system, and stability.
All the material supplied is reviewed by FDA, and only after
approval may the drug be sold in interstate commerce. For
additional information, see Hoiberg and Rapaka (1986).
CONCLUSION
At present, research on the medicinal chemistry of cannabinoids is
being extensively carried out. It is hoped that, in the not too
distant future, this research will lead to the introduction of
useful new therapeutic drugs to alleviate human suffering.
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Drug Abuse in India: Progress
in Research
B. N. Dhawan, M.D.
INTRODUCTION
Intensive studies on drug abuse in India have been undertaken during the last
two decades, but surveys on the use of cannabis and opium have been
undertaken for about 100 years. One of the earliest and most exhaustive studies
on drug dependence was conducted on the abuse of cannabis by the Indian Hemp
Commission (published in 1894). Chopra and Chopra (1935) undertook a detailed
survey of the opium habit in the country. In recent years, there have been
changing trends in usage of drugs, and age-old culturally circumscribed barriers
are being thrown aside.
It is proposed to include work done after 1970 only in the present review due to
constraints of space, etc. These studies can be broadly classified in three major
categories: 1) Epidemiological surveys; 2) Adverse effects of drug abuse; and
3) Experimental studies to investigate mechanisms involved in drug abuse,
particularly in the case of cannabis and methaqualone. Some other miscellaneous
problems have also been investigated.
EPIDEMIOLOGICAL STUDIES
The epidemiological surveys undertaken during this period differ widely in their
sample size, parts of the country covered, type of population, etc. The studies
can be classified in three major groups, depending upon the type of population
surveyed: 1) Rural population; 2) Urban population; and 3) Select categories, like
students, psychiatric patients, etc.
Chopra (1971) has analysed the factors motivating persons to drug abuse and has
identified certain "beneficial" factors which promote drug abuse. The abuse in
most cases starts with such objectives as facilitation of social interaction,
enhancement of sensual pleasures, mystical or religious experience, and quasi-
medical use (cannabis leaves are used to sharpen appetite, to relieve muscle and
joint pains, etc.). Modern adolescents often use cannabis as part of a purely
exploratory activity without any religious overtones.
Rural Population
These surveys have collected data on the variety of drugs being abused as well as
the type of community structures, etc. According to an ICMR report (Drug
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Addiction - An Overview) published in 1977, 40% of the rural population
consumed tobacco. The major agents of abuse were alcohol (25.6%). opium
(18.9%), barbiturates (6.2%). and cannabis (2.2%). The rather excessive use of
barbiturates was surprising. The females had a much lower incidence than the
males with all the agents. Several reports of various sample sizes have been
published during the last few years. Their results have been summarised in table
1. In all of these surveys, the incidence has been much lower in the females. In
an earlier survey of rural adolescents of Punjab, Mohan et al. (1978a) had
interviewed 281 male subjects. The incidence of alcohol usage was 32.9% and
another 0.8% were using opium, cannabis, or other agents. The abuse incidence
was higher in illiterate youth. The overall percentage of abusers varied between
15% and 40%. Nandi et al. (1982) have brought out the difference in incidence
between restrictive (where society has a strong disapproval) and permissive
communities. Further, in the restrictive communities, the abuse was almost
totally confined to the psychopaths (antisocial behaviour, from police records) as
opposed to a more uniform distribution in the permissive societies. Mohan et al.
(1980) point out that more than 50% of alcohol abusers start drinking before the
age of 25 years.
TABLE 1
Incidence of Drug Abuse in Rural Communities of India
Investigator Year Sample
size
Incidence
of abuse
No. %
Lal and Singh
Sethi and Trivedi
Mohan et al.
Varma et al.
Nandi et al.
a. Restrictive
community
b. Nonrestrictive
community
1978 443 124 29.3
1979 2,010 427 21.2
1980 3,600 1,309 36.4
1980 1,031 409 39.7
1982 5,423 834 15.4
2,804 45 1.6
2,619 789 30.1
Urban Population
Less data are available about the incidence of drug abuse in the general urban
population, though specific subgroups, like students, have been more extensively
studied. Thacore et al. (1971) investigated the incidence of drug abuse in 2,696
members of 497 families in Lucknow. The survey revealed an incidence of 18.55
per 1,000 population, most of which were cases of alcohol abuse. A significantly
higher incidence was observed in the poor population, in unitary or small
families, and in males; the majority of abusers fell in the age group of 26 to 45
years. Similar findings from other investigators have been reviewed by Sethi
et al. (1984). Among sociodemographic correlates, the incidence is highest in
semi-rural areas, followed by rural and urban areas in decreasing order. It is
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also common in industrial areas. A study team of the Planning Commission made
a nationwide survey of the alcohol consumption habits and the results have been
summarised in the ICMR report of 1977. It analysed the budgets of 21,197
working class families of 50 different centres. Between 10% and 24% of all
working class families were given to drinking. The incidence was lowest among
factory workers (9.6%) and highest among mine workers (23%). The incidence
was higher in the northwestern part of the country and in those urban centres
where there was a greater trend toward "pseudo-westernisation."
Drug Abuse in Students
A comprehensive survey of incidence of drug abuse among students in various
parts of the country was undertaken by the Department of Social Welfare,
Government of India, in 1976. Their results indicate that pain killers, tobacco,
and alcohol had the highest incidence, followed by cannabis. The relative
incidence as well as the total incidence varied and was higher in bigger cities like
Bombay, Delhi, and Madras. Cannabis had the highest proportion of users at
Varanasi, partly reflecting its widespread use and social acceptance in that region
of the country. Mohan and his colleagues have undertaken a systematic study of
drug abuse in school and college students. Their results, published in a series of
papers, have been summarised in table 2. The data on tobacco have not been
TABLE 2
Incidence of Drug Abuse in University and College Students at Delhi
Agents % Users
School Pre-University* University
Colleges
University
Alcohol 27.9 51.2 24.1 23.5
Amphetamines 4.9 19.1 2.0 3.6
Cannabis 9.8 18.1 4.4 8.4
Barbiturates 3.1 21.7 0.6 3.4
Opium 1.3 11.8 2.0 2.7
Tranquillisers 6.7 17.4 3.2 7.8
LSD - 12.6 - 2.6
Others - 15.3 3.5 12.1
Sample Size 225 117 882 502
Authors Mohan et al. Varma and
1978 Dang 1978
*Data from Chandigarh (ages 13-20 yr)
Mohan and Mohan et al.
Arora 1976 1977
included in this and subsequent tables. The table also includes data on pre-
university students from Chandigarh, where the incidence is much higher. A
similar study of school children from other parts of the country will be useful.
A comparison of findings in students of different age groups indicates only
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marginal changes after the habit has been acquired at a young age. The
increased use of tranquillisers and other agents as well as exposure to LSD may
be related to the residential character of the university wherein a large number
of students stay in the university hostels. Mohan et al. (1978 ) have found a
significantly higher incidence of drug use among students residing in a hostel. A
major change appears to be a much higher percentage of students becoming
regular users as they move from the school to the university (table 3), as well as
introduction to harder stuff like barbiturates, tranquillisers, etc. There is also a
marked increase in regular use of alcohol among college students. It is possible
that many of these students come from families where other family members also
use alcohol and, as they grow up, it becomes permissible for them also to drink.
Such data, however, are not available. Mohan et al. (1977) have provided
comparative data on the two sexes. A summary of their results in table 4 clearly
indicates that the incidence of both occasional and regular use is much higher in
the male students. As a matter of fact, there was hardly any regular use of drugs
in the female students.
TABLE 3
Frequency of Abuse in Students
Agents % Frequency of Abuse
School Pre-University* University
Colleges
University
O R O R O R O R
Alcohol 24 3.5 37.2 14.0 3.6 20.5 20.1 3.4
Amphetamines 4.9 - 17.3 1.9 1.8 2.0 2.8 0.8
Cannabis 8 1.8 16.3 1.8 3.8 0.6 6.4 2.0
Barbiturates 3.1 - 17.4 4.3 0.6 - 3.0 0.4
Opium 1.3 - 8.1 3.7 1.4 0.7 2.7 -
Tranquillisers 6.7 - 13.1 4.3 2.6 0.6 7.0 0.8
Others - - 23.8 5.0 3.5 - 13.1 2.4
O = Occasional, R = Regular.
*Data from Chandigarh (ages 13-20 yr)
Varma et al. (1977) investigated the incidence of abuse of five specific drugs in
408 college students in Chandigarh. Their results have been summarised in table
5 and the incidence (18.87%) is higher than the rates obtained by Mohan and his
colleagues at Delhi or by Thacore et al. (1971) at Lucknow. One of the reasons
for this could be their differing definition of drug abuse. Varma et al. (1977) and
(1980) have defined it as even occasional intake without medical prescription.
The percentage of regular users is low even in this study. In this study also, the
percentage in female students was much lower.
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TABLE 4
Sex-wise Distribution of Drug Usage in University Students*
Agents Male students % Female students %
Occasional Regular Occasional Regular
Alcohol 28.9 6.6 10.6
Amphetamines 4.7 1.6 0.8
Cannabis 11.3 3.9 1.2
Barbiturates 5.1 0.8 0.8
Opium 4.7 0.8
LSD 4.3 0.4 0.4
Tranquillisers 9.8 1.6 4.1
Others 13.3 2.3 7.3 0.4
*Sample size was 256 male and 246 female students.
TABLE 5
Incidence of Abuse to Specific Agents in Students in Chandigarh
Agents % Students’ use
Never Occasional Regular
Amphetamines 91.9 5.4 2.7
Barbiturates 96.3 3.7 0
Cannabis 95.1 4.4 0.5
LSD 99.3 0.7 0
Mandrax* 90.9 8.1 1.0
*Mandrax is a combination of methaqualone and diphenhydramine;
its production has now been banned in India.
Agarwal et al. (1980) have analysed the interrelationship between drug abuse,
anomie, alienation, and authoritarianism in 197 postgraduate students at
Chandigarh. Anomie can be defined as deregulation or normlessness; alienation
indicates distance between mind and reality leading to loss of identity and
depersonalization; while authoritarianism represents antidemocratic and fascist
social attitudes. Their results indicate a negative correlation between anomie and
authoritarianism and drug use, particularly in the younger age group, in those
with an urban background and high parental education, and in female students.
A positive correlation under similar conditions was observed between alienation
and drug use. The psychosocial correlates in adolescents have also been
investigated by Mohan and Thomas (1977). Mohan et al. (1978a) have found a
highly significant correlation between the father’s income, education, and place
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of residence as well as the adolescent’s course of study and the drug abuse in
both sexes.
Medical Students and Interns
At least three detailed studies on prevalence and pattern of drug abuse in medical
students have been published in recent years following the survey by Agarwal et
al. in 1975. Singh (1979) has investigated 672 undergraduate students in Punjab,
and 576 students have been studied by Sethi and Manchanda (1977) at Lucknow.
In both studies, the ratio of male to female students involved in drug abuse was
6:1, conforming to the pattern obtained in other studies. Agarwal and Pande
have recently (1982) undertaken a similar study in 270 medical students at
Gorakhpur. The ratio of prevalence in males and females was 3:1. The relative
abuse of different agents in the three studies has been summarised in table 6.
TABLE 6
Incidence of Drug Abuse in Medical Students
Agents % Students’ abusing
Sethi and Manchanda Singh Agarwal and Pande
(1977) (1979) (1982)
Alcohol
Amphetamines
Barbiturates
Cannabis
Nonbarbiturate
sedatives
Tranquillisers
14.2 12.2 11.85
7.6 4.8
0.7 1.5
5.6 4.0 14.45
2.8 3.9 9.25
17.7 12.0 14.81
A rather surprising finding is the high incidence of use of tranquillisers, which
may in part be related to their availability in the hospital. In the sample of
Agarwal and Pande, the greater use of cannabis is related to its widespread use in
that part of the country. The relative frequency of use of various agents has not
been described in Agarwal and Pande, but the data from the other centres appear
to be comparable (table 7).
There have been two recent surveys concerning drug abuse in interns and
resident doctors in medical college. The survey at Jammu (Choudhary et al.
1980) covered 105 doctors, while that at Madras (Ponnudurai et al. 1984) covered
116 interns. In both surveys, the incidence was about sixfold lower in females.
The data in table 8 indicate the marked increase in drug abuse by interns in
comparison with the figures reported for medical students (table 6), particularly
in the case of alcohol and tranquillisers. Choudhary et al. (1980) have reported
that similar results were obtained by Joshi and Bharadwaj in a survey in
194
TABLE 7
Frequency of Drug Abuse in Medical Students
Agents % Frequency of use
Never Occasional Frequent Regular
A B A B A B A B
Alcohol
Ampheta-
mines
Barbiturates
Cannabis
Nonbarbitu-
rate sedatives
Tranquillisers
87.8 85.8 2.4 23.5 0.6 0.7 3.1 -
95.2 92.4 2.5 1.6 2.2 3.3 - 2.7
98.5 99.3 1.0 - 0.5 - - 0.7
96.0 94.4 3.4 5.0 0.6 0.6
96. 1 97.2 3.3 2.8 0.4 - 0.2 -
90.0 82.3 5.4 15.8 4.3 1.0 0.3 0.7
A: Data of Singh (1979), 672 students
B: Data of Sethi and Manchanda (1977), 576 students
Rajasthan in 1978. The increase is largely among those taking it occasionally and
is much less marked in regular users (see tables 9 and 7). The possible reasons
appear to be availability of tranquillisers in the hospital and financial
independence from their parents due to their stipends. To this also must be
added the long hours of work and stress and the urge to get temporary respite
from all this.
TABLE 8
Incidence of Drug Abuse among Interns and House Officers
Agents % Ever used
Choudhary et al. 1980 Ponnudurai et al. 1984
Alcohol 55.2 53.5
Amphetamines 12.6 7.8
Cannabis 16.7 18.1
Hallucinogens - 7.8
Pain killers 12.0 -
Tranquillisers 36.5 14.7
Others 17.2 -
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TABLE 9
Frequency of Drug Abuse in Interns and House Officers
(Choudhary et al. 1980)
Agents % Frequency of use
Never Occasional Frequent Regular
Alcohol 44.8 44.8 4.2 6.3
Amphetamines 87.6 10.5 1.0 1.0
Analgesics 87.5 5.2 2.1 5.2
Cannabis 83.4 15.6 - 1.0
Tranquillisers 63.5 34.4 - 2.1
Psychiatric Patients
Even though there is no uniform pre-addictive personality, individuals with
personality problems are more likely to look for relief with drugs; therefore,
chronic users may have a higher proportion of insecure personality. There have
been global efforts to establish any possible relationship between drug abuse and
psychiatric disorders. One approach has been to find out the prevalence of drug
abuse in patients coming to psychiatric hospitals. Some interesting observations
have been made in the country during the last few years. Trivedi and Sethi
(1978) investigated 1,000 consecutive newly registered male psychiatric outpatient
cases for drug abuse to find any possible correlation with psychiatric illness. The
pattern of drug abuse in their sample has been summarised in table 10. They
reported an overall incidence of 16.4%. There was a slightly higher incidence
(22.8%) of drug abuse in patients suffering from affective disorders in
comparison to those suffering from schizophrenia (16.5%) or neurosis (15.4%).
The incidence in other diseases was much lower (12.4%). There appeared to be a
possible correlation between abuse of alcohol and cannabis with affective
disorders and neurosis, but further studies are necessary to establish a definitive
relationship and to offer an explanation. Venkoba Rao et al. (1978) have
analysed cases of drug addiction seen in a psychiatric hospital over a 5-year
period. They obtained a sample of 178 cases from 10,023 patients (1.8%)
attending the outpatient clinic and only three of these were female. The relative
distribution in various drug categories has been given in table 10. A majority of
these patients (53.4%) came for the treatment of drug dependence, 39% were
suffering from schizophrenia, and the remaining few had associated affective
disorders or neuroses. More than a third of these cases had a family history of
psychiatric morbidity. Ray and Chandrashekhar (1982) have examined 1,984
consecutive admissions to male psychiatric wards at the National Institute of
Mental Health and Neuro Science, Bangalore, for evidence of alcoholism by
administering to them the Michigan Alcoholism Screening Test (MAST). During
the period, 6.1% of all admissions to that hospital were due to alcohol-related
problems. The results indicated that 19% of the patients were alcoholic and
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TABLE 10
Incidence of Drug Abuse in Psychiatric Patients
Agents % Incidence
Sethi and Trivedi
1979
Venkoba Rao et al.
1978
Alcohol
Amphetamines
Barbiturates
Cannabis ± alcohol
Opium
Tranquillisers
Multiple
9.3 24.2
1.1 -
0.6 2.2
- 29.2
0.3 3.4
2.1 -
- 11.1
Patient population Outpatient cases Addicted cases
Sample size 1,000 178
another 22% were social drinkers. The remaining patients had not been exposed
to alcohol. The alcoholics had more first-degree relatives afflicted with
alcoholism, sociopathy, and depression.
OTHER CLINICAL STUDIES
There has been considerable interest in abuse of cannabis and methaqualone.
Chopra et al. (1942) were the earliest investigators to draw attention to a possible
relationship between cannabis use, mental diseases, and crime. The problem of
cannabis abuse has been reviewed recently by Sethi et al. (1984). They have also
evaluated 50 pure chronic cannabis users for their physical, mental, cognitive,
and socioeconomic function and compared the results with a matched control
group. On clinical evaluation, most (64%) of the subjects had no psychiatric
problem; indeed, they had significantly low anxiety scores in comparison to
controls on Taylor’s Manifest Anxiety Scale. The other tests also failed to reveal
any impairment. Their earlier study (Sethi et al. 1981) also had failed to detect
any particular identifiable personality trait in chronic cannabis users. Clinical
study of volunteers on the effect of chronic cannabis use did not reveal any
serious harmful effects even though some subjects reported withdrawal effects
(Singh et al. 1981a). Similarly, no differences were observed in cognitive
functions between chronic users of cannabis and nonusers (Ray et al. 1979). The
results indicate that cannabis does not appear to be as injurious in the Indian
setting as has been suggested by reports from Western countries.
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There are, however, a few reports which indicate that chronic use of cannabis
may not be as harmless as made out by studies on the cognitive functions. There
have been reports of psychoses in chronic cannabis users. In a well-controlled
study, Thacore and Shukla (1974) compared cases of cannabis psychoses with
those of paranoid schizophrenia. Cannabis psychoses were characterised by more
bizarre behaviour, more violence and panic, but an absence of schizophrenic
thought disorders. These cases cleared more rapidly with hospitalisation and
relapsed when drug was resumed. Chopra and Smith (1974) reported that cases
of cannabis psychoses were predominantly instances of toxic delirium, but those
who had schizoid features became overtly schizophrenic during the period of
intoxication. Uppal et al. (1981) have observed a significant decrease in
antipyrine elimination half-life compared to control subjects. It was more
marked than observed even in cigarette smokers (Uppal et al. 1980). A similar
decrease in theophylline clearance has been reported from Western countries
(Jusko et al. 1978).
Thacore et al. (1971) undertook a detailed study of addiction to methaqualone.
The clinical tolerance developed in 4 to 6 months and the withdrawal symptoms
included depression, sleep disturbances, anxiety, and restlessness in addition to an
intense craving for the drug. In most cases, they were first prescribed the drug
by a physician for some ailment. Mahal and Nayar (1978) reported 15 cases of
petrol dependence from Bangalore. All of these were young boys in the second
decade of life, most of them from unsettled families. They suffered from
perceptual distortion and hallucination, in some cases of a wish-fulfilling quality
and having some resemblance with LSD-psychosis. There was no evidence of
tolerance or report of withdrawal symptoms, but there was intense psychological
craving following deprivation.
There seems to have been little effort at innovative treatment of drug addiction
even though institutional care is available at many places. Earlier work in this
area has been reviewed by Wig and Varma (1977). Gangadharan et al. (1982)
investigated the use of clonidine in management of cases of opiate dependence
(morphine or pethidine). In their studies, clonidine controlled the nonpurposive
withdrawal symptoms effectively within 2 to 3 days following abrupt opiate
withdrawal, but the purposive symptoms took 8 to 10 days to be adequately
controlled. The patients could be discharged earlier from the hospital. The drug
merits further studies. Bagadia et al. (1982) have evaluated the usefulness of
disulfiram in management of chronic alcoholics in the Indian settings. They have
concluded that older patients and those brought by relatives or friends did better
and, except for psychotic episodes in 3 out of 75 patients, other side effects were
of mild nature.
Shukla (1980) has investigated the sociocultural aspects of abuse of drugs in male
adults in a rural community, including the use of alcoholic drinks and drugs as a
sociocultural phenomenon. Only 27% of the respondents in the village surveyed
by him were nonusers and about 32% were habitual users of alcohol or cannabis;
the use of opium was rare. This had gone on for generations without posing any
sociocultural crisis or any increase in number of addicts in the village. The use
was more frequent in unskilled labourers, and regular use was more common in
nonfamilial households or in children whose fathers used drugs. Hasan (1975)
investigated social aspects of use of cannabis and concluded that there was no
evidence of increase in dosage or of physical dependence. In most cases, persons
in that rural community used it on occasions of festivity and ceremonial
functions.
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ANIMAL STUDIES
The major interest in recent years has centered around methaqualone, which was
discovered in India (Gujral et al. 1955, 1956), and cannabis, which has a
widespread use.
Methaqualone
Khanna et al. (1971) have investigated development of tolerance to methaqualone
in rats following once daily oral administration. Maximum reduction of hypnotic
response was obtained in 6 days. There was a cross-tolerance between
phenobarbitone and methaqualone. It appears that induction of microsomal
enzymes in the liver play a role in development of tolerance, since normal
hypnotic response has been restored by SKF 525-A, an inhibitor of liver
microsomal enzyme system. These studies have been subsequently extended by
Kohli et al, (1974). Tolerance was discernible during the first week to
hypothermia and reduction in spontaneous motor activity. Withdrawal resulted in
increased susceptibility to audiogenic seizures, hyperactivity, and precipitious
decrease in body weight. Nath et al. (1980) compared the dependence liability of
methaqualone alone and when used in combination with diphenhydramine (a
combination which is widely abused). Their results indicate a more severe
degree of physical dependence to the combination than to methaqualone alone.
Cannabis
Singh and Das (1977) undertook a detailed study on tolerance to the resin
extracted from Cannabis indica in rats. The resin contained 17% delta-9-
tetrahydrocannabinol (THC) and was administered in a dose of 50 to 200 mg/kg.
The animals developed tolerance to hypothermic, analgesic, and anticonvulsant
activities very rapidly. The potentiating effect on barbiturate hypnosis was also
concomitantly reduced. Tolerance did not develop to either increased or
decreased locomotor activity or to hyperthermia in tolerant rats.
The disappearance of tolerance on stoppage of cannabis was very slow.
Tolerance to hypothermic activity was the first to disappear and that to analgesic
activity was the last. Daily administration of cannabis did not affect rate of
learning or rate of extinction of learned behaviour. This is in agreement with
the clinical results reviewed earlier. Singh et al. (1981) have reported similar
tolerance to petroleum ether extract of flowering tops of Cannabis indica. On
withdrawal, treated animals showed increased sensitivity to audiogenic seizures.
Dixit et al. (1974) found a reduction in the size of testis and a regression of
Leydig cells following chronic administration of cannabis extract in mice.
Investigations have also been directed toward biochemical changes following
chronic administration of cannabis and its constituents. Singh et al. (1980)
allowed rats to inhale marijuana fumes daily for a period of up to 90 days.
Exposure for up to 15 days decreased brain acetylcholine levels but increased the
catecholamine and serotonin levels. After a prolonged administration, the effects
were found to be reversed and associated with a decrease in body weight due to
a decrease in food intake. Ghosh and his colleagues have studied the effects of
acute and chronic administration of cannabis and THC on subcellular
components. Chronic treatment with cannabis or THC was devoid of effect on
dopamine and norepinephrine turnover (Poddar and Ghosh 1976b) and on the
metabolism of other biogenic amines (Poddar et al. 1975). Acute treatment
resulted in either increased mitochondrial (Na+K+)- and Mg++ ATPase or a
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decrease in Na+K+ ATPase activity in synaptosomal preparation. The effect
disappeared following chronic treatment (Poddar and Ghosh 1976a). Similarly,
acute treatment led to a marked increase in sialoglyco-proteins and ganglioside
content in both microsomal and synaptosomal fractions, but the effects were not
observed after chronic treatment (Sarkar and Ghosh 1976). Sarkar and Ghosh
(1975) also investigated the effect of THC on lipid constituents of subcellular
fractions in rat brain. Their results have been summarised in table 11. In
contrast to other biochemical parameters, the effect on several lipid components
remained unaltered following chronic administration. It has been suggested that
chronic administration of THC stimulates its own metabolism, leading to its
conversion to hydroxylated polar metabolites which may not interact strongly
with membrane components. This can explain some but not all of the
differences between the effects of acute and chronic administration.
TABLE 11
Effect of Delta-9-Tetrahydrocannabinol on Lipid Constituents of Rat Brain
Subcellular Fractions
Lipid component Subcellular fraction
Mitochondria Microsome Synaptosomes Myelin
A B A B A B A B
1. Total lipids
2. Total cerebroside
3. Total cholesterol
4. Total phospholipids
i Phosphatidylcholine
ii Phosphatidylethanol
iii Phosphatidylserine
iv Sphingomyelin
A = Acute treatment, B = Chronic treatment, - = Decrease, + = Increase,
O = No change.
CONCLUDING REMARKS
The problem of drug abuse in India has taken a different shape and presented
different dimensions than in most of its neighbouring countries. Opium abuse
has not become a major problem due to a well-defined government policy which
has controlled cultivation of opium since 1895. Also, there has been no ban or
control on cannabis. The use of alcohol has undergone a period of rigid controls,
but the laws are more relaxed now. Due to closed borders with Pakistan, the
heroin traffic from Afghanistan has not posed a major problem until very
recently. This situation has also determined the research activity on drug abuse
in the country.
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Recent studies suggest a change in the traditional pattern of drug usage in two
main directions (Mohan et al. 1978 ). One of these is a movement away from
nonusage of drugs as a cultural norm, even in restrictive societies, beginning at
an earlier age, particularly with respect to alcohol and tobacco. Second, and a
somewhat redeeming feature, is that the social strata involved in such deviation is
the small affluent upper socioeconomic group and the pattern has not undergone
a major change in the rural areas. Such a change had been predicted (Nayar
1972) since the concerned group of urban population tends to confuse
modernisation with westernisation and tends to adopt symbols rather than
substances of Western societies. Fortunately, this does not appear to have
assumed subculture or counterculture overtones or a symbolic protest value
against accepted social norms as has happened in many Western countries.
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The Medicinal Chemistry of
Cannabinoids: An Overview
Alexandros Makriyannis, Ph.D., and Rao S. Rapaka, Ph.D.
Since the early 194Os, when Roger Adams synthesized the first
cannabinoid analogs and subjected them to pharmacological testing,
cannabinoid research has maintained a sustained progress involving
the synthesis of a large number of analogs with a varied degree of
resemblance to the natural analogs. At the same time, the
pharmacological properties of the principal cannabis constituents
were studied in detail, while less extensive studies were reported
on their synthetic analogs. A good effort was also made to study
biochemical effects of cannabinoids on a variety of biochemical
preparations and the use or potential use of those compounds as
therapeutic agents.
Over four decades later and after the successful synthesis and
testing of several hundred analogs a number of important questions
related to the function of cannabinoids still remain unanswered.
Nevertheless, we have made progress in defining correlations between
structure and function while recognizing that such correlations
should be made in the context of the biological function being
measured. It has also become clear that differences between the
species tested are an important consideration. More recently
testing of the cannabinoids on discrete biochemical systems has
allowed us to better dissect the molecular events involved in the
"cannabinoid effect." Parallel to such tests, we should note that
increased sophistication in behavioral testing has allowed for more
accurate structure-function correlations.
Still, the specific details involved in the cannabinoid molecular
mechanism of action are far from clear. The "receptor" versus
"membrane" site of action arguments have not been resolved, and
there are indications that each of the two hypotheses can provide
partial answers, while no unifying theory has yet been articulated.
The recent informative review by Martin (1986) does a very good job
of outlining these different points of view. The present overview
is not intended to be all inclusive, nor does it seek to define all
the unanswered questions related to cannabinoid research. Instead,
it seeks to highlight some of the important developments in this
interesting multidisciplinary field of research, drawing to a large
extent from the presentations made during the recent NIDA technical
review on structure-activity relationships of cannabinoids.
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STRUCTURE-FUNCTION CORRELATIONS
Structure-function correlations in cannabinoids have recently
been reviewed in great detail by Razdan (Razdan 1986, Razdan,
this volume; Mechoulam et al., this volume). From the emerging
picture, we can identify the key structural features required
for activity. These should also provide us with insights about
the molecular mechanism of cannabinoid activity.
Phenollc Hydroxyl
First, the presence of a free phenolic group is an absolute
requirement for cannabinoid activity. Phenolic esters of
delta-9-tetrahydrocannabinol (THC) are active in vivo,
presumably after hydrolysis, and are inactive in in vitro
preparations. However, the phenolic ethers are totally
inactive. The role of the phenolic group during its interaction
with the active site could be either as hydrogen bonding donor
or a hydrogen bond acceptor through its lone pair of electrons.
The latter hypothesis has been elaborated by Regglo (this
volume) who points out that the orientation of the phenolic lone
pair is the key molecular determinant and that only the free
phenolic group has the opportunity to align in the proper
"active orientation" while substituted phenols are unable to do
so because of steric considerations. The ability of the
phenolic OH to act as a hydrogen donor with one or more of the
polar membrane sites (either at the phospholipid or the protein
component) has been investigated by Makriyannis and colleagues
and is discussed later in this review.
The role of hydroxyl substitution in cannabinoid molecules
becomes more intriguing in the case of analogs having an
additional one or two hydroxyl groups in the C ring. Several of
these analogs have been synthesized, and their structure-
functions correlations can be clearly visualized. Certainly,
the OH orientations must have an important molecular role during
the cannabinoid interaction with the site(s) of action. Because
of the large differences in activity between individual analogs,
the di- and trihydroxy cannabinoids may prove to be very good
tools for probing the molecular requirements of the drug-active
site interactions.
Ring C Geometry
An important molecular determinant is the geometry of the C
ring. It is now being recognized that compounds where the C
ring is totally coplanar with the aromatic ring, as in the case
of delta 9- and 11-THC and cannabinol, result in inactive
compounds. A certain deviation from this coplanarity between
rings A and C appears to be one off the crucial molecular
requirements (Razdan, this volume; Mechoulam et al., this
volume; Makriyannls et al., this volume). This may be related
to specific geometric requirements for interaction with a
specific "receptor protein." On the other hand, this
"out-of-plane" conformation may be required for the molecule to
produce perturbations at the level of the phosphollpid bilayer
(Makriyannis et al., this volume).
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Side Chain in Ring A
The role of this molecular fracture is a crucial one, pointing
to some requirement for hydrophobic interactions with the
membrane components. However, these hydrophobic interactions
still allow for the presence of some polar groups such as that
of a phenolic ether oxygen or a hydroxy substituent in certain
positions of the chain. The length of the chain is critical,
with the n-heptyl group being optimal. Also, methyl
substituents (e.g., 1,1- or 1.2-dimethyl) enhance activity not
only by interfering with the drug metabolism but apparently by a
direct effect at the site(s) of action as well.
Absolute Configuration
Although it was early recognized that tetrahydrocannabinol
enantiomers differ in potency, accurate values for enantiomeric
potency ratios were not available. This, to a large extent, was
due to the fact that the enantiomeric starting materials were
not of high enough purity. This situation has been remedied
through careful purification of these compounds. More recently,
starting materials possessing high optical purity have become
available commercially.
Recent work by Mechoulam et al. (this volume) involving the
11-hydroxy-delta-8-THC enantiomers showed a potency difference
of two to three orders of magnitude between the enantiomers.
This difference is much higher than anything reported earlier
and does not appear to be solely due to metabolic factors. In
all likelihood, it is to a large extent due to the abilities of
individual cannabinoids for productive interaction with their
site(s) of action.
Nonclassical Cannabinoids
The term "nonclassical cannabinoids" includes a group of
compounds that were developed by Melvin and Johnson (this
volume). These resemble the tetrahydrocannabinols but do not
incorporate the pyran ring. These analogs, developed as
potential analgesics, possess pharmacolgical profiles resembling
those of the classical cannabinoids. First among these analogs
possessing pharmacological activity is a hydroxyphenyl
cyclohexanol with a 1.1-dimethylheptyl side chain. It
represents the simplest of the cannabinoid structures and
incorporates the required phenolic group and an appropriate side
chain. The presence of a secondary hydroxy group on the
cyclohexane ring enhances activity; as with the "classical
cannabinoids," its orientation is crucial in determining
activity. This compound also shows a modest enantiomeric
potency ratio. The nonclassical blcyclic structure introduces a
hydroxypropyl group on the cyclohexanol ring that results in
dramatic increases both in potency and in enantlomeric potency
ratio. The highest enantiomeric potency ratio is obtained when
the hydroxypropyl group is incorporated into a six-membered ring
to yield the corresponding hydroxymethyl decalin tricyclic
analog.
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Melvin and Johnson (this volume) synthesized a relatively large
number of such analogs and examined the structural and
stereochemical correlates with activity in detail. Based on
their studies, they formulated a structure for the hypothetical
receptor site. The correlations made here do not necessarily
advance our knowledge about the nature of the cannabinoid site
of action. However, they do provide very interesting molecular
templates, beyond the classical cannabinold structure, which may
serve as important tools in the search for the cannabinoid
active sites.
MOLECULAR MECHANISMS OF CANNABINOID ACTIVITY
The idea of a specific receptor through which cannabinoids
produce some of their effects has traditionally received
favorable attention (Mechoulam et al., this volume; Mechoulam et
al 1985; Martin 1986; Martin et al., this volume). Recently,
evidence for a cannabinoid receptor has been advanced from two
laboratories. In one case, the water soluble nonhydrolyzable
cannabinoid trimethylammonlum delta-8-tetrahydrocannabinol (TMA)
was used by Snyder and his coworkers as a radiolabeled ligand to
test for the presence of "cannabinoid receptors" (Martin et al.,
this volume; Nye and Snyder, this volume). Indeed, the compound
showed some specific binding to rat brain membranes.
Furthermore, delta-9-THC and other cannablnoids competed
successfully with TMA for its binding site. Snyder and
coworkers also demonstrated some enantiomeric selectivity among
the THC antipodes and lack of binding for other non-cannabinoid
structures. There was no good correlation between cannabinoid
"affinity" for the TMA binding receptor and for the abilities of
the cannabinoiids to displace TMA from its binding site.
One shortcoming of the above approach rests with TMA's most
attractive feature, namely its water solubility. Although, this
molecule maintains the key cannabinoid structural features, it
introduces a permanently charged bulky group in the molecule.
This alters one of the key characteristics of the cannabinoid
structure, i.e., its overall hydrophobic properties, especially
at the level of the side chain. The other data favoring a
specific protein site for cannabinoid activity by Howlett (this
volume) comes from experiments with murine neuroblastoma cells
showing that cannabinoids decrease cyclic AMP production. This
response can be attributed to the inhibition of adenylate
cyclase activity. Since adenylate cyclase is regulated by a
number of receptors through the intermediacy of the ubiquitous G
protein, the data suggest that cannabinoids may act either at
the receptor or the G-protein level. After having shown that
cannabinoids do not act at the receptor protein level, Howlett
suggests that the G protein is, indeed, their site of action.
The results from this biochemical system are encouraging because
there are good correlations between adenylate cyclase inhibition
and cannabinoid potency. This hypothesis for the site of action
of cannabinoids is yet to be proved through direct binding
experiments.
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A different type of evidence pointing to a role played by
membrane lipids in cannabinoid activity comes from the
laboratories of Makriyannis and coworkers (this volume). Using
model membranes, and with the help of solid state nuclear
magnetic resonance and other biophysical techniques, they showed
differences in the manner in which cannabinoid enantiomers and
cannabinoid isomers having different potencies interact with
model membranes. Such data refute the general notion that
cannabinoid phospholipid interactions are "nonspecific" and
totally dependent on the drug's oil/water partitioning
properties. Makriyannis also showed that cannabinoid analogs
orient in the membrane in such a manner that the phenolic
hydroxy group serves as the anchor at the membrane bilayer
polar/nonpolar interphase and has an important role in
determining the geometry of the cannabinoid-membrane amphipathic
interaction. The above studies are also congruent with a
hypothesis involving more specific cannabinoid-lipid
interactions which would, in turn, affect the function(s) of the
neighboring proteins. Although one may expect some common
general features in the interaction of cannabinoids with
membranes, one also expects differences in the molecular details
of these interactions depending on the nature and composition of
the membrane. Such differences may explain the observed
variations in cannabinoid selectivity with different membrane
preparations.
Additional evidence for cannabinoid action at the membrane level
comes from the laboratories of Burstein (this volume). Using a
cell culture model to test cannabinoid activity, Burstein showed
that cannabinoids have marked stimulatory action on eicosanoid
synthesis and that the cannabinoid interaction does not occur at
the level of the protein catalytic site. Also, the model system
shows a fair degree of correlation between structure and
activity relationships, tolerance, and stereospecificity for the
cannabinoids tested. These effects of cannabinoids on the
eicosanoid biochemical systems may be related to their CNS
activity. Indeed, delta-9-THC when administered orally was
found to increase PGE2 content in the mouse brain and also
increased phospholipase activity in brain synaptosomes. A more
recent interesting finding from the same laboratories is that
the 9-carboxylic acid metabolite of delta-9-THC inhibits
delta-9-THC effects on eicosanoid synthesis, apparently through
its action on prostaglandin synthetase. This metabolite may
thus prove useful as a nonsteroidal antiinflammatory agent.
CANNABINOID PHARMACOLOGY, TOXICOLOGY, AND PHYSIOLOGY
Based on extensive pharmacological evidence, Martin et al. (this
volume) pointed out that the cannabinoid behavioral syndrome
represents a composite rather than a single event. To dissect
these different effects, which he classifies in two general
categories as membrane- and receptor-related effects, he used a
variety of behavioral test systems. These include spontaneous
activity, rectal temperature and analgesia in the mouse, static
ataxia in the dog, and drug discrimination and conditioned
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behavior in monkeys. This approach is very useful and should
contribute towards putting the correlations between cannabinoid
structure and function on more solid ground. In the same vein,
detailed studies by Karler and Turkanis (this volume) have
served to point out the dramatic differences in cannabinoid
activity among different species. These studies are important
because they help to show the possible discrepancies when
correlations are made between cannabinoid structure and function
using pharmacological data from difference species. Also, from
the laboratories of Karler and Turkanis (this volume),
toxicological and electrophysiological data demonstrate the wide
diversity of action between different cannabinoids. Again,
correlations between cannabinoid structure and function should
be made judiciously, taking into account the details of
pharmacodynamics, toxicology, and electrophysiological testing.
Last but not least, the use of cannabinoids as anticonvulsants
is an important therapeutic application. In this regard,
Consroe and Mechoulam (this volume) have made good contributions
towards elucidating the correlations between cannabinold
structure and anticonvulsant properties. The testing is done
with epilepsy-prone rats, and the compounds are tested for their
abilities to prevent audiogenlc seizures (AGS) and to cause
rotorod neurotoxicity (ROT). From these studies, it is clear
that the anticonvulsant SAR for cannabinoids does not overlap
with the corresponding correlations for psychotropic or
analgesic activity. This observation holds a good deal of
promise for the use of cannabinoid analogs as anticonvulsants.
Excellent research is being carried out all over the world on
the SAR of cannabinoids. This research has resulted in the
development of several compounds of therapeutic use and, more
importantly, provided tools for further research on cannabinoid
biochemistry and pharmacology. It is not unrealistic to hope
that in the near future some additional compounds of potential
therapeutic value will be developed.
REFERENCES
Martin, B.R. Cellular effects of cannabinoids. Pharmacological
Reviews 38:45-74, 1986.
Mechoulam. R .; Srebnik. M.; and Burstein. S. Cannabinoid
chemistry; biochemistry and therapeutic applications: An
overview. In: Harvey, D.J., ed. Marihuana '84. Proceedings
of the Oxford Symposium on Cannabis. Oxford: IRL Press,
1985. pp. 1-12.
Razdan, R.K. Chemistry and structure-activity relationships of
cannabinoids: An overview. In: Agurell, S .; Dewey, W.L.:
and Willete, R.E.. eds. The Cannabinoids: Chemical,
Pharmacologic, and Therapeutic Aspects. Orlando: Academic
Press, 1985. pp. 63-78.
Razdan, R.K. Structure-activity relationships in cannabinoids.
Pharmacological Reviews. 38:75-149, 1986.
209
AUTHORS
Alexandros Makrlyannis, Ph.D.
School of Pharmacy and
Institute of Materials Science
University of Connecticut
Storrs, CT 06268
Rao S. Rapaka, Ph.D.
Research Technology Branch
Division of Preclinical Research
National Institute on Drug Abuse
Room 10A-13, 5600 Fishers Lane
Rockville, MD 20857
210
While limited supplies last, single copies of the monographs may be
obtained free of charge from the National Clearinghouse for Alcohol
and Drug Information (NCADI). Please contact NCADI also for
information about availability of coming issues and other
publications of the National Institute on Drug Abuse relevant to
drug abuse research.
Additional copies may be purchased from the U.S. Government Printing
Office (GPO) and/or the National Technical Information Service
(NTIS) as indicated. NTIS prices are for paper copy. Microfiche
copies, at $6.50, are also available from NTIS. Prices from either
source are subject to change.
Addresses are:
NCADI
National Clearinghouse for Alcohol and Drug Information
P.O. Box 2345
Rockville, Maryland 20852
GPO
Superintendent of Documents
U.S. Government Printing Office
Washington, D.C. 20402
NTIS
National Technical Information
Service
U.S. Department of Commerce
Springfield, Virginia 22161
For information on availability of NIDA Research Monographs 1-21,
1975-1978, write to NIDA Office for Research Communications, Room
10A-54, 5600 Fishers Lane, Rockville, MD 20857.
22 QUASAR: QUANTITATIVE STRUCTURE ACTIVITY RELATIONSHIPS OF
ANALGESICS, NARCOTIC ANTAGONISTS, AND HALLUCINOGENS. Gene Barnett.
Ph.D.; Milan Trsic, Ph.D .; and Robert Willette, Ph.D.; eds.
GPO out of stock NCADI out of stock
NTIS PB #292 265/AS $36.95
23 CIGARETTE SMOKING AS A DEPENDENCE PROCESS. Norman A. Krasnegor,
Ph.D., ed. NCADI out of stock
GPO Stock #017-024-00895-8 $6 NTIS PB #297 721/AS $24.95
24 SYNTHETIC ESTIMATES FOR SMALL AREAS: STATISTICAL WORKSHOP PAPERS
AND DISCUSSION. Jos. Steinberg, ed. NCADI out of stock
GPO out of stock NTIS PB #299 009/AS $24.95
211
25 BEHAVIORAL ANALYSIS AND TREATMENT OF SUBSTANCE ABUSE. Norman A.
Krasnegor, Ph.D., ed. NCADI out of stock
GPO out of stock NTIS PB #8O-112428 $24.95
26 THE BEHAVIORAL ASPECTS OF SMOKING. Norman A. Krasnegor, Ph.D.,
ed. (Reprint from 1979 Surgeon General's Report on Smoking and
Health.)
GPO out of stock NTIS PB #80-118755 $18.95
27 PROBLEMS OF DRUG DEPENDENCE, 1979: PROCEEDINGS OF THE 41ST
ANNUAL SCIENTIFIC MEETING, THE COMMITTEE ON PROBLEMS OF DRUG
DEPENDENCE, INC. L.S. Harris. Ph.D., ed. NCADI out of stock
GPO Stock #017-024-00981-4 $9 NTIS PB #8O-175482 $42.95
28 NARCOTIC ANTAGONISTS: NALTREXONE PHARMACOCHEMISTRY AND
SUSTAINED-RELEASE PREPARATIONS. Robert Willette, Ph.D., and
Gene Barnett, Ph.D., eds. NCADI out of stock
GPO out of stock NTIS PB #81-238875 $24.95
29 DRUG ABUSE DEATHS IN NINE CITIES: A SURVEY REPORT. Louis A.
Gottschalk, M.D., et al. NCADI out of stock
GPO out of stock NTIS PB #80-178882 $18.95
30 THEORIES ON DRUG ABUSE: SELECTED CONTEMPORARY PERSPECTIVES. Dan
J. Lettieri, Ph.D.; Mollie Sayers; and Helen W. Pearson, eds.
NCADI out of stock
GPO Stock #017-024-00997-1 $10 Not available from NTIS
31 MARIJUANA RESEARCH FINDINGS: 1980. Robert C. Petersen, Ph.D.,
ed.
GPO out of stock NTIS PB #80-215171 $24.95
32 GC/MS ASSAYS FOR ABUSED DRUGS IN BODY FLUIDS. Rodger L. Foltz,
Ph.D .; Allison F. Fentiman, Jr., Ph.D.; and Ruth B. Foltz.
GPO out of stock NTIS PB #81-133746 $24.95
33 BENZODIAZEPINES: A REVIEW OF RESEARCH RESULTS, 1980. Stephen I.
Szara, M.D., D.Sc., and Jacqueline P. Ludford, M.S., eds.
GPO Stock #017-024-01108-8 $5 NTIS PB #82-139106 $18.95
34 PROBLEMS OF DRUG DEPENDENCE, 1980: PROCEEDINGS OF THE 42ND
ANNUAL SCIENTIFIC MEETING, THE COMMITTEE ON PROBLEMS OF DRUG
DEPENDENCE, INC. Louis S. Harris, Ph.D., ed. NCADI out of stock
GPO Stock #017-024-01061-8 $8 NTIS PB #81-194847 $36.95
35 DEMOGRAPHIC TRENDS AND DRUG ABUSE, 1980-1995. Louise G.
Richards, Ph.D., ed. NCADI out of stock
GPO out of stock NTIS PB #82-103417 $18.95
36 NEW APPROACHES TO TREATMENT OF CHRONIC PAIN: A REVIEW OF
MULTIDISCIPLINARY PAIN CLINICS AND PAIN CENTERS. Lorenz K.Y.
Ng, M.D., ed.
GPO out of stock NTIS PB #81-240913 $24.95
212
37 BEHAVIORAL PHARMACOLOGY OF HUMAN DRUG DEPENDENCE. Travis
Thompson, Ph.D., and Chris E. Johanson, Ph.D., eds.
NCADI out of stock
GPO Stock #017-024-01109-6 $7 NTIS PB #82-136961 $30.95
38 DRUG ABUSE AND THE AMERICAN ADOLESCENT. Dan J. Lettieri, Ph.D.,
and Jacqueline P. Ludford, M.S., eds. A RAUS Review Report.
GPO Stock #017-024-01107-O $4.50 NCADI out of stock
NTIS PB #82-148198 $18.95
39 YOUNG MEN AND DRUGS IN MANHATTAN: A CAUSAL ANALYSIS.
Richard R. Clayton, Ph.D., and Harwin L. Voss, Ph.D.
GPO Stock #017-024-01097-9 $5.50 NCADI out of stock
NTIS PB #82-147372 $24.95
40 ADOLESCENT MARIJUANA ABUSERS AND THEIR FAMILIES. Herbert
Hendin, M.D., Ann Pollinger, Ph.D., Richard Ulman, Ph.D., and
Arthur Carr, Ph.D. NCADI out of stock
GPO out of stock NTIS PB #82-133117 $18.95
41 PROBLEMS OF DRUG DEPENDENCE, 1981: PROCEEDINGS OF THE 43RD
ANNUAL SCIENTIFIC MEETING, THE COMMITTEE ON PROBLEMS OF DRUG
DEPENDENCE, INC. Louis S. Harris, Ph.D., ed. NCADI out of stock
Not available from GPO NTIS PB #82-190760 $42.95
42 THE ANALYSIS OF CANNABINOIDS IN BIOLOGICAL FLUIDS. Richard L.
Hawks, Ph.D., ed.
GPO Stock #017-024-01151-7 $5 NTIS PB #83-136044 $18.95
43 PROBLEMS OF DRUG DEPENDENCE, 1982: PROCEEDINGS OF THE 44TH
ANNUAL SCIENTIFIC MEETING, THE COMMITTEE ON PROBLEMS OF DRUG
DEPENDENCE, INC. Louis S. Harris, Ph.D., ed. NCADI out of stock
GPO out of stock NTIS PB #83-252-692/AS $42.95
44 MARIJUANA EFFECTS ON THE ENDOCRINE AND REPRODUCTIVE SYSTEMS.
Monique C. Braude, Ph.D., and Jacqueline P. Ludford, M.S., eds. A
RAUS Review Report. NCADI out of stock
GPO Stock #017-024-01202-5 $4 NTIS PB #85-150563/AS $18.95
45 CONTEMPORARY RESEARCH IN PAIN AND ANALGESIA, 1983. Roger M.
Brown, Ph.D .; Theodore M. Pinkert, M.D., J.D.; and Jacqueline P.
Ludford, M.S., eds. A RAUS Review Report. NCADI out of stock
GPO Stock #017-024-01191-6 $2.75 NTIS PB #84-184670/AS $13.95
46 BEHAVIORAL INTERVENTION TECHNIQUES IN DRUG ABUSE TREATMENT. John
Grabowski, Ph.D .; Maxine L. Stitzer, Ph.D., and Jack E.
Henningfield, Ph.D., eds.
GPO Stock #017-024-01192-4 $4.25 NTIS PB #84-184688/AS $18.95
47 PREVENTING ADOLESCENT DRUG ABUSE: INTERVENTION STRATEGIES.
Thomas J. Glynn, Ph.D .; Carl G. Leukefeld, D.S.W.; and
Jacqueline P. Ludford, M.S., eds. A RAUS Review Report.
GPO Stock #017-024-01180-1 $5.50 NTIS PB #85-159663/AS $24.95
213
48 MEASUREMENT IN THE ANALYSIS AND TREATMENT OF SMOKING BEHAVIOR.
John Grabowski, Ph.D., and Catherine S. Bell, M.S., eds.
GPO Stock #017-024-01181-9 $4.50 NCADI out of stock
NTIS PB 84-145-184 $18.95
49 PROBLEMS OF DRUG DEPENDENCE, 1983: PROCEEDINGS OF THE 45TH
ANNUAL SCIENTIFIC MEETING, THE COMMITTEE ON PROBLEMS OF DRUG
DEPENDENCE, INC. Louis S. Harris, Ph.D., ed. NCADI out of stock
GPO Stock #017-024-01198-3 $12 NTIS PB 85-151553/AS $36.95
50 COCAINE: PHARMACOLOGY, EFFECTS, AND TREATMENT OF ABUSE. John
Grabowski, Ph.D., ed.
GPO Stock #017-024-01214-9 $4.50 NTIS PB 85-150381/AS $18.95
51 DRUG ABUSE TREATMENT EVALUATION: STRATEGIES, PROGRESS, AND
PROSPECTS. Frank M. Tims, Ph.D., ed.
GPO Stock #017-024-01218-1 $4.50 NTIS PB 85-150365/AS $18.95
52 TESTING DRUGS FOR PHYSICAL DEPENDENCE POTENTIAL AND ABUSE
LIABILITY. Joseph V. Brady, Ph.D., and Scott E. Lukas, Ph.D., eds.
GPO Stock #017-024-0204-1 $4.25 NTIS PB 85-150373/AS $18.95
53 PHARMACOLOGICAL ADJUNCTS IN SMOKING CESSATION. John Grabowski,
Ph.D., and Sharon M. Hall, Ph.D., eds.
GPO Stock #017-024-01266-1 $3.50 NCADI out of stock
54 MECHANISMS OF TOLERANCE AND DEPENDENCE. Charles Wm. Sharp,
Ph.D., ed. NCADI out of stock
GPO Stock #017-024-01213-1 $8.50
55 PROBLEMS OF DRUG DEPENDENCE, 1984. PROCEEDINGS OF THE 46TH
ANNUAL SCIENTIFIC MEETING, THE COMMITTEE ON PROBLEMS OF DRUG
DEPENDENCE, INC. Louis S. Harris, Ph.D., ed. NCADI out of stock
GPO Stock #017-024-01242-4 $9.50
56 ETIOLOGY OF DRUG ABUSE: IMPLICATIONS FOR PREVENTION. Coryl LaRue
Jones, Ph.D., and Robert J. Battjes, D.S.W., eds.
GPO Stock #017-024-01250-5 $6.50
57 SELF-REPORT METHODS OF ESTIMATING DRUG USE: MEETING CURRENT
CHALLENGES TO VALIDITY. Beatrice A. Rouse, Ph.D., Nicholas J.
Kozel, M.S., and Louise G. Richards, Ph.D., eds.
GPO Stock #017-024-01246-7 $4.25
58 PROGRESS IN THE DEVELOPMENT OF COST-EFFECTIVE TREATMENT FOR DRUG
ABUSERS. Rebecca S. Ashery, D.S.W., ed.
GPO Stock #017-024-01247-5 $4.25
59 CURRENT RESEARCH ON THE CONSEQUENCES OF MATERNAL DRUG ABUSE.
Theodore M. Pinkert, M.D., J.D., ed.
GPO Stock #017-024-01249-1 $2.50
60 PRENATAL DRUG EXPOSURE: KINETICS AND DYNAMICS. C. Nora Chiang,
Ph.D., and Charles C. Lee, Ph.D., eds.
GPO Stock #017-024-01257-2 $3.50
214
61 COCAINE USE IN AMERICA: EPIOEMIOLOGIC AND CLINICAL PERSPECTIVES.
Nicholas J. Kozel, M.S., and Edgar H. Adams, M.S., eds.
GPO Stock #017-024-01258-1 $5
62 NEUROSCIENCE METHODS IN DRUG ABUSE RESEARCH. Roger M. Brown,
Ph.D., and David P. Friedman, Ph.D., eds.
GPO Stock #017-024-01260-2 $3.50
63 PREVENTION RESEARCH: DETERRING DRUG ABUSE AMONG CHILDREN AND
ADOLESCENTS. Catherine S. Bell, M.S., and Robert Battjes,
D.S.W., eds.
GPO Stock #017-024-01263-7 $5.50
64 PHENCYCLIDINE: AN UPDATE. Doris H. Clouet, Ph.D., ed.
GPO Stock #017-024-01281-5 $6.50
65 WOMEN AND DRUGS: A NEW ERA FOR RESEARCH. Barbara A. Ray, Ph.D.,
and Monique C. Braude, Ph.D., eds.
GPO Stock #017-024-01283-1 $3.25
66 GENETIC AND BIOLOGICAL MARKERS IN DRUG ABUSE AND ALCOHOLISM.
Monique C. Braude, Ph.D., and Helen M. Chao, Ph.D. eds.
GPO Stock #017-024-01291-2 $3.50 NCADI out of stock
67 PROBLEMS OF DRUG DEPENDENCE, 1985. PROCEEDINGS OF THE 47TH
ANNUAL SCIENTIFIC MEETING, THE COMMITTEE ON PROBLEMS OF DRUG
DEPENDENCE, INC. Louis S. Harris, Ph.D., ed. NCADI out of stock
GPO Stock #017-024-01292-1 $18
68 STRATEGIES FOR RESEARCH ON THE INTERACTIONS OF DRUGS OF ABUSE.
Monique C. Braude, Ph.D., and Harold M. Ginzburg, M.D.,J.D.,M.P.H.,
eds.
GPO Stock #017-024-01296-3 $6.50 NCADI out of stock
69 OPIOID PEPTIDES: MEDICINAL CHEMISTRY. Rao S. Rapaka, Ph.D.;
Gene Barnett, Ph.D .; and Richard L. Hawks, Ph.D., eds.
GPO Stock #017-024-1297-1 $11
70 OPIOIO PEPTIDES: MOLECULAR PHARMACOLOGY, BIOSYNTHESIS, AND
ANALYSIS. Rao S. Rapaka, Ph.D., and Richard L. Hawks, Ph.D., eds.
GPO Stock #017-024-1298-O $12
71 OPIATE RECEPTOR SUBTYPES AND BRAIN FUNCTION. Roger M. Brown,
Ph.D.; Doris H. Clouet, Ph.D .; and David P. Friedman, Ph.D., eds.
GPO Stock #017-024-01303-O $6
72 RELAPSE AND RECOVERY IN DRUG ABUSE. Frank M. Tims, Ph.D., and
Carl G. Leukefeld, D.S.W., eds.
GPO Stock #017-024-01302-1 $6
73 URINE TESTING FOR DRUGS OF ABUSE. Richard L. Hawks, Ph.D., and
C. Nora Chiang, Ph.D., eds.
GPO Stock #017-024-1313-7 $3.75
215
74 NEUROBIOLOGY OF BEHAVIORAL CONTROL IN DRUG ABUSE. Stephen I.
Szara. M.D., D.Sc., ed.
GPO Stock #017-024-1314-5 $3.75
75 PROGRESS IN OPIOIO RESEARCH. PROCEEDINGS OF THE 1986 INTER-
NATIONAL NARCOTICS RESEARCH CONFERENCE. John W. Holaday, Ph.D.;
Ping-Yee Law, Ph.D .; and Albert Herz, M.D., eds.
GPO Stock #017-024-01315-3 $21
76 PROBLEMS OF DRUG DEPENDENCE, 1986. PROCEEDINGS OF THE 48TH
ANNUAL SCIENTIFIC MEETING, THE COMMITTEE ON PROBLEMS OF DRUG
DEPENDENCE, INC. Louis S. Harris, Ph.D., ed.
GPO Stock #017-024-1316-1 $16
IN PRESS
77 ADOLESCENT DRUG ABUSE: ANALYSES OF TREATMENT RESEARCH.
Elizabeth R. Rahdert, Ph.D. and John Grabowski, Ph.D., eds.
78 THE ROLE OF NEUROPLASTICITY IN THE RESPONSE TO DRUGS
David P. Friedman, Ph.D., and Doris H. Clouet, Ph.D., eds.
216
U.S. GOVERNMENT  PRINTING OFFICE: 1990 – 2 7 6 - 2 0 7 / 2 0 8 6 5
DHHS Publication No. (ADM)90-1534
Alcohol, Drug Abuse, and Mental Health Administration
Printed 1987, Reprinted 1990
